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iAbstract
LIM domain containing protein 1 (LIMD1) is a tumour suppressor located at
3p21.3, a region that harbours multiple tumour suppressor genes and is
commonly subject to homozygous deletions and loss of heterozygosity in many
cancers. The mechanism of LIMD1 tumour suppressive activities are not fully
elucidated, however to date it has been shown to bind to the retinoblastoma
protein (pRb) and repress E2F driven transcription as well as being a critical
component of miRNA mediated gene silencing. Recent work has also identified
/,0'DVDSRVVLEOHQHJDWLYHUHJXODWRURIK\SR[LDLQGXFLEOHIDFWRUĮ+,)ĮDQG
the hypoxic response. In lung cancer, LIMD1 protein expression is down
regulated in up to 79% of tumours when compared to normal tissue with gene
deletion and loss of heterozygosity accounting for 32 and 12% respectively,
leaving 30% of tumours with unexplained mechanism of LIMD1 protein loss.
In an aim to identify other possible mechanisms of LIMD1 loss, scrutinisation of
the LIMD1 promoter identified a CpG Island in the 5 promoter region, within
which a small region was found to be critical for transcriptional activation. This
region was methylated in the non-LIMD1 expressing MDA-MB435 cell line, but
became hypomethylated and LIMD1 expressed following treatment with the DNA
methylation inhibitor 5-Aza-2-deoxycytidine. In primary lung tumours, analysis
of genomic DNA also identified increased methylation of this region as well as a
reduction in LIMD1 mRNA levels when compared to matched normal lung tissue.
Furthermore, in silico analysis identified a conserved binding motif for the Ets
transcription factor PU.1. Experimentally PU.1 was verified as binding to the
LIMD1 promoter with siRNA mediated depletion of PU.1 significantly reducing
endogenous LIMD1 protein levels, thus identifying two possible novel
mechanisms of LIMD1 silencing. Transcription of LIMD1OLNHWKDWRIRWKHU+,)Į
regulatory proteins, was enhanced when cells were exposed to hypoxia (1% O2),
IDFLOLWDWHG E\ +,)Į ELQGLQJ D K\SR[LF UHVSRQVLYH HOHPHQW +5( ZLWKLQ WKH
promoter. At the molecular level, in vivo LIMD1 forms an endogenous complex
with proline hydroxylase 2 (PHD2) and the von Hippel-Lindau (VHL) protein, with
/,0' ORVV GHFUHDVLQJ WKH HIILFLHQF\ RI +,)Į GHJUDGDWLRQ DQG LPSHGLQJ WKH
resultant cellular adaptation to chronic hypoxia.
In summary these studies identified epigenetic silencing of LIMD1 as a possible
explanation for LIMD1 protein loss in transformed cells. Furthermore, LIMD1
WUDQVFULSWLRQZDVLGHQWLILHGDVEHLQJDFWLYDWHGE\38DQGHQKDQFHGE\+,)Į
DQGDUHYLVHG/,0'LQWHJUDWHGPRGHORI+,)ĮUHJXODWLRQLVSURSRVHG
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Chapter 1 Introduction
Chapter 1: Introduction
2
1.1 Thesis Overview
This thesis focuses on advancing our knowledge and understanding of the
physiological control and intracellular role of the tumour suppressor protein LIM
domain containing 1 (LIMD1). In vivo, loss of LIMD1 protein expression has been
demonstrated in a variety of cancers; however, the reasons for this loss could
not be fully explained by genetic alterations. Furthermore, the precise
mechanism of control of LIMD1 expression at a transcriptional level was
unknown, and whether disruption of this regulation could contribute to loss of
protein expression. Also, mechanistically, little is known about how LIMD1 exerts
its tumour suppressive effects.
To address these questions, each results chapter presents experimental findings
that address three areas of distinct LIMD1 biology; epigenetic silencing of LIMD1,
transcriptional control of LIMD1 and the role of LIMD1 in regulating the hypoxic
response.
The first two results chapters focus upon transcriptional regulation of LIMD1 and
correlate these findings with loss of LIMD1 protein expression in cancer. In the
first results chapter, investigations centre on the LIMD1 promoter, where LIMD1
expressing and non-expressing cell lines along with a cohort of human lung
tumour and matched normal tissue are used to investigate epigenetic silencing
of LIMD1. Following identification of a region critical for transcription within the
LIMD1 promoter, the second results chapter focuses upon this region and
identifies the transcription factor PU.1 as a major transcriptional activator of
LIMD1 gene transcription. In the final results chapter, following analysis of
transcription factor binding motifs, a functional hypoxic response element within
the LIMD1 promoter is identified and validated. This is then integrated with
investigations into the molecular role that LIMD1 has in regulation of the hypoxic
response post transcriptionally, and the possible discovery of a negative
regulatory feedback loop for hypoxic regulation is presented.
Therefore the background to these distinct, yet often overlapping areas of
biochemistry will be introduced.
Chapter 1: Introduction
3
1.2 Genetic and Epigenetic Alterations are the Underlying Cause
of Cancer
All multicellular organisms are somatically mosaic, which is defined as multiple
populations of cells with distinct genotypic expression in one individual, whose
developmental lineages trace back to a single fertilised egg. (De, 2011). The
differences in genotypic expression within the same individual are due to a
combination of factors, including erroneous DNA replication or repair
mechanisms, transposable elements, translocations, recombinations,
chromosomal loss or gains, epigenetic alterations, carcinogens, UV light and
nicotine (De, 2011).
When a mutation is introduced into genomic DNA, there can be different
consequences depending upon the genetic location. Mutations that do not affect
the expression or product of either a protein coding or non-protein coding (e.g.
microRNAs, non-coding RNAs) gene, or is part of the true junk DNA (i.e. is not
associated with either a coding or non-coding gene or type of RNA) will not exert
any detrimental effects on the cell and go unperturbed. However, a mutation
that does affect gene expression or the protein/RNA product could have
damaging consequences, and the larger the mutation (e.g. chromosomal
translocations, amplifications, deletions or loss of heterozygosity) the greater the
chance of one or more genes being affected.
Proto-oncogenes are genes that stimulate proliferation, and include both protein
coding genes and non translated RNAs. A mutation within one allele of a proto-
oncogene, which results in a positive activating phenotype, can cause it to
become oncogenic and contribute to cellular transformation. Therefore these
mutations tend to be dominant. Conversely, mutations within tumour suppressor
genes that have a negative effect on their expression or activity are recessive as
long as there is still one functional allele (Wijnhoven et al., 2001), a hypothesis
originally put forward by Knudson (Knudson, Jr., 1971) It is therefore mutations
of this class within (proto) oncogenes and tumour suppressors that can lead to
de-regulated cellular proliferation and ultimately cancerous transformation.
Chromosomal deletions have been described as a common occurrence in a
variety of tumours since the early 20th century, with all 23 chromosomes
exhibiting chromosomal abnormalities in solid tumours/neoplasms and
haematological malignancies (Mitelman et al., 1997). One of the most common
universal chromosomal alterations in human solid tumours occurs on the short
arm of chromosome 3; within 3p, homozygous deletions and loss of
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heterozygosity are characterised early events in lung, breast, head and neck,
gastrointestinal, cervical and kidney cancers (Zabarovsky et al., 2002; Hesson et
al., 2007), with losses occurring in up to 100% of small cell lung cancers (SCLC)
(Angeloni, 2007).
1.3 Chromosome 3 Deletions in Cancer
Loss of heterozygosity and cytogenetic analysis has shown the chromosomal
region of 3p21-22 to be the most frequently deleted in all lung tumours (Kok et
al., 1994; Murata et al., 1994; Zabarovsky et al., 2002). This was identified
through the use of elimination assays. Human chromosome 3- A9 mouse
fibrosarcoma microcell hybrids were inoculated into severely combined
immunodeficient (SCID) mice and any resultant tumours which grew in the SCID
mice were examined for chromosome 3 deletions, which would implicate the
presence of tumour suppressive genes. These investigations identified regions of
3p (but not 3q) that were frequently eliminated in the resultant tumours, most
specifically 3p21.3-p22 (Kholodnyuk et al., 2002; Imreh et al., 1997). This
frequently deleted region was named the chromosome 3 commonly eliminated
region (C3CER1; also sometimes referred to as CER). A transcriptional map
compiled by Kiss et al following elimination tests and PAC sequencing
characterised C3CER1 as spanning ~1.4Mb and containing 19 genes and 3
pseudogenes (Kiss et al., 2002) (Figure 1.1). Kost-Alimova et al more recently
updated the transcriptional map of C3CER1 to span ~2.4Mb (from Mb 43.32-
45.74) and contain 32 genes (Kost-Alimova and Imreh, 2007).
Loss of heterozygosity analysis of C3CER1 in 576 tumours revealed deletions in
70-94% of nine tumour types investigated (breast, gastric, colorectal, lung,
endometrial, ovarian, testicular, renal and thyroid) with soft tissue sarcomas
exhibiting lower deletions of 40%. These C3CER1 deletions were greater than
that of other commonly eliminated regions of chromosome 3 (3p14.2 and
3p25.3) (Petursdottir et al., 2004).
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Figure 1.1: Gene map of the chromosome 3 commonly eliminated region 1
(C3CER1). C3CER1 spans 1.4Mb within 3p21.3 and contains a total of 19 genes,
including 7 chemokine receptors. Chromosomal deletions and LOH of this region have
been reported in up to 94% of solid tumours (Kost-Alimova and Imreh, 2007).
As C3CER1 deletions are frequently found in cancers, this is highly indicative that
these genes may possess tumour suppressive functions, as their loss is found
within with a transformed/tumour cell. The genes that are in close proximity to
LIMD1 within 3p21.3 have been shown to possess one or more tumour
suppressive functions. LTF has been reported to be down-regulated in
nasopharyngeal (NP) carcinomas, and when re-expressed causes a blockage of
cell cycle progression and resultant cell growth inhibition (Zhang et al., 2011a).
Furthermore, LTF expression blocks infection of the carcinogenic Epstein-Barr
virus in primary B lymphocytes and NP epithelial cells, thus demonstrating
another tumour suppressive action (Zheng et al., 2012). LZTFL1 has little
published function; however it has been demonstrated to be down-regulated in
gastric cancers, with over-expression inhibiting anchorage independent growth
and tumour cell survival, possibly through promoting the stabilisation of E-
cadherin mediated cell junctions and regulation of ciliary trafficking of signalling
proteins (Wei et al., 2010; Seo et al., 2011). TMEM7 is down-regulated in
Gene Symbol Name
KIAA0028 mitochondrial tRNA synthetase
LIMD1 LIM domain containing 1
SAC1 suppressor of actin 1
XT3 orphan transporter
LZTFL1 leucine zipper transcription factor like 1
CCR9 CC chemokine receptor 9
FYC01 FYVE and coiled coil domain containing 1
STRL33 G protein coupled receptor
CCXCR1 chemokine XC receptor 1
CCR1 CC chemokine receptor 1
CCR3 CC chemokine receptor 3
CCR2 CC chemokine receptor 2
CCR5 CC chemokine receptor 5
CCRL2 CC chemokine receptor like 2
LTF lactotransferrin
TMEM7 transmembrane protein 7
LRRC2 leucine rich repeat containing 2
LUZP3 leucine zipper protein 3
TDGF1 teratocarcinoma derived growth factor 1
45.78Mb
44.15Mb
C3CER1
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hepatocellular carcinomas, and like with the other C3CER1 genes described,
ectopic expression reduced tumour cell growth and reduced tumour formation in
nude mice (Zhou et al., 2007).
As will be further described later for the published expression profiles and
molecular functions of LIMD1, there is clear molecular evidence that it also is a
tumour suppressor protein. For instance, LIMD1 inhibits transcription of E2F
responsive genes, both dependently and independently of the well characterised
pRb tumour suppressor protein (Sharp et al., 2004). This subsequently results in
inhibition of cell cycle progression, a classical feature of a tumour suppressor.
Furthermore, as LIMD1 is able to do this independently of pRb, this alone
attributes it to being a tumour suppressor protein. The tumour suppressive
functions of LIMD1 are further demonstrated through Limd1 gene knockout
mice, which exhibit increased size and numbers of lung tumours, as well as
decreased survival rates compared to control Limd1 expressing mice (Sharp et
al., 2008). Furthermore, as a critical component of miRNA mediated gene
silencing (James et al., 2010), a process which is well characterised as being de-
regulated in cancer and disease (Naoghare et al., 2011), it could be postulated
that LIMD1 loss, like that of other miRNA pathway proteins such as AGO2 and
Dicer, would contribute to the transforming properties of de-regulated miRNA
silencing.
Chapter 1: Introduction
7
1.4 LIM Domain Containing Proteins
The protein LIM domain was initially identified within the MEC-3 protein from C.
elegans as a protein that contained a characterised DNA binding homeodomain
along with a novel cys-his domain (Way and Chalfie, 1988). The first homology
of this domain was identified following identification and cloning of the rat gene
Isl1 (Karlsson et al., 1990) and the C. elegans gene lin-11 (Freyd et al., 1990).
As such the domain was named a LIM domain after these three proteins (lin-11,
Isl1 and MEC3). The LIM domain within lin-11 was initially reported as being a
metallodomain being able to bind both iron and zinc (Li et al., 1991), however
this was superseded by Michelsen et al who confirmed LIM domains are double
zinc fingers, tetrahedrally binding two zinc ions (Michelsen et al., 1993). The first
solution structure of a LIM domain within the protein CRP1 was published in
1994 (Perez-Alvarado et al., 1994).
A LIM domain has the broad consensus sequence C(X)2C(X)16-
23H/C(X)2/4C/H/E(X)2C(X)2C(X)14-21C/H(X)2/1/3(C/H/D)X, with 8 conserved
cysteine and histidine residues co-ordinating 2 zinc ions (Figure 1.2) (Kadrmas
and Beckerle, 2004). Initially it was presumed that LIM domains would solely
participate in DNA binding; the first identified LIM domain containing protein
MEC-3 contained a homeodomain, which participates in DNA binding and other
characterised transcription factors interact with DNA through zinc finger motifs,
for example the GATA family of transcription factors. However, this has since
been superseded by the identification of non DNA binding LIM proteins (Scott et
al., 1989; Kadrmas and Beckerle, 2004).
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Figure 1.2: Schematic representation of a protein LIM domain. A protein LIM
domain has the consensus C(X)2C(X)16-23H/C(X)2/4C/H/E(X)2C(X)2C(X)14-
21C/H(X)2/1/3(C/H/D)X. 8 conserved cysteine and histidine residues co-ordinate 2 zinc ions
to form a double zinc finger that is subsequently able to facilitate protein-protein
interactions.
LIM domain containing proteins can be characterised into 4 groups (Kadrmas and
Beckerle, 2004; Dawid et al., 1998). Group 1 contains LIM homeodomain and
nuclear LIM-domain only proteins, group 2 contains proteins that are almost
solely comprised of LIM domains and can shuttle between the cytoplasm and
nucleus, group 3 contains proteins with C-terminal LIM domains and other
protein-protein binding domains, and group 4 which contain LIM domains along
with a catalytic kinase or mono-oxygenase domain. LIMD1 belongs to the Zyxin
family of LIM domain containing proteins, which belongs to Group 3.
1.5 The Zyxin Family of LIM Domain Containing Proteins
The zyxin family of LIM domain containing proteins is comprised of Zyxin, Trip6,
LPP, LIMD1, Ajuba, WTIP and migfilin (Figure 1.3A). Phylogenetically, the family
can be sub-divided into the Ajuba sub-family (LIMD1, Ajuba and WTIP) and the
Zyxin sub-family (Zyxin, Trip6, LPP and migfilin) (Figure 1.3B), and this
correlates with their differing functional roles; the Zyxin family are primarily
located at sites of cell adhesion and participate in cytoskeletal arrangements,
whereas the Ajuba family are identified as being located more in cytoplasmic
vesicles and more recently to participate in microRNA (miRNA) mediated gene
silencing (James et al., 2010) and negative regulation of the hypoxic response
(Foxler et al 2012, Nature Cell Biology, in press 2012).
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Figure 1.3: The Zyxin family of LIM proteins. (A) Schematic diagram of the Zyxin
family of proteins, composed of LIMD1, Ajuba, WTIP, LPP, Trip6, Zyxin and Migfillin, all of
which commonly share three tandem C-terminal LIM domains. (B) The Zyxin family can
then be phylogenetically sub-divided into the Zyxin (orange) and Ajuba (green)
subfamilies, which are shown along with their mouse homologues and gi (GenBank)
identification numbers that link to the proteins amino acid and nucleotide sequence.
B
A
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1.6 LIMD1
1.6.1 Identification of LIMD1
Using an elimination test assay in severe combined immunodeficiency (SCID)
mice, the human chromosomal 3p21.3 region was identified as being frequently
deleted during malignant growth and as such was named the chromosome 3
commonly eliminated region 1 (C3CER1) (Kholodnyuk et al., 1997). Utilising a
one megabase PAC contig that covered C3CER1 (Yang et al., 1999), LIMD1 was
first characterised (along with its mouse homologue) in 1999 (Kiss et al., 1999)
and was named LIMD1 following a BLAST search which revealed high homology
with other LIM containing proteins (LIM Domain containing 1).
Since the identification of LIMD1 in 1999, which occurred prior to completion of
sequencing of the human genome, changes in expression in lung, breast and
head and neck carcinomas have been identified. However, relatively little is
known about the mechanism of action and function of LIMD1 within the cell, and
how loss of LIMD1 may promote cellular transformation.
1.6.2 LIMD1 in Lung Cancer
In normal lung tissue LIMD1 is expressed in bronchiolar epithelia, distal alveolar
epithelia, alveolar endothelia, inflammatory and stromal cells (Sharp et al.,
2008). Tissue microarray data from 185 human lung tumours identified 80% of
tumours to have reduced LIMD1 expression compared to a normal control, which
supported a previous smaller study where 83% of human lung cancer cell lines
had reduced LIMD1 expression (Sharp et al., 2004; Sharp et al., 2008).
The tumour suppressive properties of LIMD1 expression in lung tumours have
been validated in vivo. Limd1-/- mice develop both a higher number of lung
tumours, and greater volume tumours when exposed to the chemical lung
carcinogen urethane when compared to wild type mice (Sharp et al., 2008). K-
Ras is a proto-oncogene that is activated and mutated (to become oncogenic) in
up to 25% of all human cancers, the effect of which is increased downstream cell
signalling, proliferation and cancerous transformation (Monticone et al., 2008;
Tuveson et al., 2004). When LIMD1-/- mice were bred with oncogenic K-RasG12D
expressing mice, Limd1 null mice developed more and larger volume of tumours
when compared to wild type controls. After 12 months K-RasG12D/Limd1-/- mice
exhibited a 90% mortality rate, K-RasG12D/Limd1+/+ mice only showed a 30%
mortality rate further indicating Limd1 as a critical tumour suppressor, with loss
contributing to lung cancer development in mice (Sharp et al., 2008).
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There is no evidence that LIMD1 undergoes any base pair mutations in lung
cancers. The LIMD1 gene contains 8 exons, and sequencing of these along with
the intron-exon boundaries in 188 adenocarcinomas did not identify any genetic
alterations. However, analysis of 357 matched normal and tumour
adenocarcinomas identified 32% of tumours had LIMD1 gene deletion, which is
comparable to other genes in the C3CER1 cluster. The percentage deletion is
greater than that for other TSGs implicated in lung cancer including p53 (22%),
RB1 (8%) and RASSF1A (21%) (Sharp et al., 2008) (Figure 1.4). A further 12%
of tumours analysed exhibited loss of heterozygosity (LOH) at the LIMD1 gene
locus (Sharp et al., 2008).
Figure 1.4: Gene deletion of LIMD1 and surrounding 3p21.3 genes in human lung
cancer. Sequencing data from the NHGRI tumour sequencing project lung
adenocarcinoma data set of cancer and matched normal tissue was scrutinised and the
percentage gene deletion for the indicated C3CER1 genes is displayed in the above
histogram. LIMD1 gene deletion (32%) is comparable to that of the other C3CER1 genes.
Taken from (Sharp et al., 2008).
1.6.3 LIMD1 in Breast Cancer
In normal breast tissue LIMD1 is highly expressed in the epithelia of terminal
duct lobular units but not in surrounding breast stroma or foam cells. Using a
Tissue Microarray (TMA), corresponding to 495 different cases of primary
invasive breast carcinomas, 98.8% of tumourous cores tested had LIMD1
expression. However clinicopathological data correlated decreased patient
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prognosis/survival with decreased LIMD1 staining; absent or weak staining had a
mortality rate of 15.7%, this decreased to 5.3% with strong staining (Spendlove
et al., 2008).
There is an indication that LIMD1 mRNA levels are altered in breast tumours;
LIMD1 mRNA has been shown to be both decreased by up to 66% and increased
by up to 260% in sporadic breast tumours when compared to a pool of cell line
RNA (Huggins and Andrulis, 2008). However, as the control standard was a pool
of cell line RNA from a range of tissue types, no definitive conclusions can be
drawn about the LIMD1 mRNA levels in breast cancer as for this tumour samples
need to be compared to matched normal breast tissue from the same patient.
E-cadherin is a transmembrane protein that forms homodimers with E-cadherin
proteins on adjacent cells to form cell-cell contacts. Loss of E-cadherin
expression facilitates the progression from adenoma to invasive carcinoma, and
is associated with malignant epithelial metastases (Batlle et al., 2000;
:LMQKRYHQ HW DO  (FDGKHULQ ELQGV WR ǃFDWHQLQ LQWUDFHOOXDUO\ DQG LV
thought to sequester it from binding to T-cell factor (TCF) and forming an active
transcription factor complex to transduce Wnt signalling pathways; loss of E-
FDGKHULQ OHDGV WR DQ LQFUHDVH LQ ǃFDWHQLQ7&) VLJQDOOLQJ DQG LQFUHDVHG
metastatic potential, whereas over-expression of E-cadherin leads to cell growth
arrest (Gottardi et al., 2001). LIMD1 and co-family member Ajuba repress E-
cadherin transcription through association with the Slug/Snail transcriptional
repressor complex, and as such loss of LIMD1 in breast cancer could contribute
to increased invasiveness (Ayyanathan et al., 2007).
1.6.4 LIMD1 in Head and Neck Squamous Cell Carcinomas
Head and neck squamous cell carcinoma is the collective term for cancers of the
upper aerodigestive tract, including nasal, oral, pharynx and larynx cancers.
These cancers account for up to 40% of all malignancies in the Indian
subcontinent and 5% in the Western countries. The stark difference in incidence
can be explained in part due to the environmental risk factors of tobacco, betel
quid, alcohol and the human papillomavirus, which are more prevalent in the
Indian subcontinent (Hogg et al., 2002; Ghosh et al., 2008). Genetic deletions of
9p (70-80% of HNSCC cases), 3p (60-70%), 17p (50-70%), 11q (30%) and 13q
(30%) are well characterised events in HNSCC (Perez-Ordonez et al., 2006).
Within 3p, a number of smaller regions of common loss including 3p14, 21, 22,
24 and 26 have been identified as early events present in dysplastic lesions
(Masayesva et al., 2004; Garnis et al., 2003; Perez-Ordonez et al., 2006).
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Ghosh et al identified 3 regions of 3p21.3 as having high incidences of gene
deletions, which they referred to as D1, D2 and D3 (Figure 1.5). These regions
showed deletions of 33-43%, 44-49% and 26-38% respectively (Ghosh et al.,
2008), with the LIMD1 locus found within D1 (Figure 1.5). Microsatellite-based
deletion mapping unveiled that in mild dysplastic lesions, D1 and D3 were highly
deleted and the percentage deletion remained relatively unchanged during
tumour progression, whereas deletion of D2 increased, implicating loss of genes
in D1 and D3 contribute to dysplastic lesion development, whereas those in D2
to carcinoma development.
Figure 1.5: Occurance of 3p21.3 genetic alterations in head and neck squamous
cell carcinomas and early dysplastic lesions. The indicated regions D1, D2 and D3
are chromosomal areas identified as areas of high genetic deletions (loss of
heterozygosity and homozygous gene deletions). LIMD1 resides within D1. Adapted from
(Ghosh et al., 2008).
The LIMD1 promoter was highly methylated in both mild dysplastic and HNSCC
cases (59-69%), with other genes at the same locus, LTF, CACNA2D2 and
RASSF1A, exhibiting lower levels of methylation of 49-52%, 42-44% and 17-
21% respectively. However in corresponding normal tissue, there was also
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promoter methylation of LIMD1, LTF and CACNA2D2 showing an incidence of
10%, 5% and 6% respectively. This could be an indication that epigenetic
silencing through promoter methylation (discussed later) could be an initial or
early event in carcinogenesis. Deletion and methylation of LIMD1 (50%) did not
significantly change through progression from mild dysplasia to carcinoma,
contrary to LTF, CDC25A and CACNA2D2, which all significantly increased. This
again implied LIMD1 is involved with initiation of transformation, rather than
tumour progression in HNSCC.
LIMD1 mRNA is reduced in HNSCC by a mean of 53.2% in tumour compared to
matched normal tissue; for reference in the same study the highest reduction
was seen with LTF (67.6%), and the lowest of only 0.58% for SCOTIN and these
can be significantly correlated to the presence of any genetic alterations of either
the gene or promoter (Ghosh et al., 2008).
A screen of exons 1 and 5 of LIMD1 in 83 primary head and neck lesions
revealed 40% contained at least one of six novel mutations within exon 1 (two of
which caused amino acid substitutions, two which didnt and a further two
caused a frame shift mutation due to a single base deletion) or at the intron 4-
exon 5 splice junction (Ghosh et al., 2010). Mutation of LIMD1 however was less
frequent in dysplastic lesions than in Stage I and II or III and IV tumours,
further indicating methylation and genetic deletions are early events in
tumourigenesis. Furthermore, LIMD1 mRNA expression was decreased more
significantly than pRB mRNA expression in tumour samples when normalised to
their matched normal tissue (Ghosh et al., 2010).
1.6.5 LIMD1 is involved in multiple Intracellular Signalling Pathways
1.6.6 LIMD1 interacts with pRb and is a Repressor of E2F Driven
Transcription
In 1971 Alfred Knudson first hypothesised that retinoblastomas in children were
caused by two mutational events, one that was either inherited or sporadic,
followed by an additional sporadic event (Knudson, Jr., 1971). The esterase D
enzyme had previously been mapped to the chromosomal region 13q14, and a
reduction in enzyme activity of about half was observed in some patients who
had suffered from a retinoblastoma, and this reduction in activity correlated with
loss of one allele due to chromosomal deletions (Sparkes and Sparkes, 1983). A
proportion of retinoblastoma sufferers were found to have chromosomal
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deletions at the same broad genetic locus 13q14, which implicated this region as
containing a gene or genes responsible for retinoblastoma growth (Sparkes et
al., 1983). Identification of a patient who had 50% esterase D activity, no
chromosomal deletion at the broad 13q14 region but still suffered from a
retinoblastoma (Benedict et al., 1983) along with further finer chromosomal
mapping, identification of reduced mRNA and chromosomal alterations in
retinoblastomas identified a retinoblastoma susceptibility (RB) gene at 13q14.2
(Lee et al., 1987).
pRB binds to the E2F family of transcription factors, which regulate the
transcription of multiple genes needed for progression through the G1 and S
phase of the cell cycle and for DNA metabolism. Upon binding, pRB turns E2F
from a positive regulator of transcription to a negative regulator, thus acting as a
negative regulator of cell cycle progression (Grana et al., 1998; Harrington et
al., 1998).
LIMD1 binds to pRB (Sharp et al., 2004), identified initially through a yeast two-
hybrid screen and confirmed by in vivo co-immunoprecipitation of endogenous
LIMD1 with exogenous pRB. pRBs role in repressing E2F driven transcription is
well characterised, and LIMD1 was found to augment the same in a
concentration dependent manner. LIMD1 also repressed E2F driven transcription
in the absence of Rb, and introduction of LIMD1 into the non-LIMD1 expressing
MDA-MB435 cell line caused the reduced expression of 85% of E2F responsive
genes, implicating a likely role of LIMD1 as a general tumour suppressor.
Introduction of LIMD1 into MDA-MB435 cells inhibited proliferation, and ectopic
expression in transformed A549 and HEK293 cell lines decreased colony
formation by 80%. Injection of A549 cells transduced with lentiviral-HA-LIMD1
into tail veins of nude mice gave a significant reduction in lung metastases
incidence compared to lentiviral-HA-vector only (Sharp et al., 2004). This was
the first published study to identify a possible tumour suppressive function of
LIMD1.
1.6.7 LIMD1 is a Critical Component of miRNA Silencing
MicroRNAs (miRNA) are short ~22nt non coding RNA molecules that are
responsible for the post-transcriptional silencing of many genes involved in
normal cellular differentiation, development and proliferation, with miRNA
expression frequently deregulated in a variety of cancers, briefly reviewed in
(Deng et al., 2008). The first miRNA to be discovered was in C. elegans in 1993,
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a short lin-4 transcript that did not code for a protein but was complementary to
a sequence in the 3 untranslated region (UTR) of lin-4 mRNA (Lee et al., 1993).
miRNA silencing is a major form of post-transcriptional gene silencing.
Most miRNA genes are transcribed by RNA polymerase II and like most mRNAs
contain a 5 7-methyl guanylate cap and a 3 poly(A) tail (Lee et al., 2004). This
primary transcript is known as a pri-miRNA and may be several kb in length and
contain one or more stem loop structures (Figure 1.6A). miRNA transcripts can
also originate from the introns of mRNAs following splicing, with as many as
40% of miRNAs originating this way (Davis and Hata, 2010) (Figure 1.6C). The
nuclear protein DGCR8 then recognises the region between the single stranded
RNA loop and double stranded RNA stem and guides the RNase III enzyme
Drosha to cleave the RNA approximately 11 base pairs from the single strand-
double strand RNA junction (Denli et al., 2004; Han et al., 2004) to create a 60-
70 nucleotide hair pin RNA with a 3 2 nucleotide overhang, known as a
precursor miRNA (pre-miRNA) (Lee et al., 2003)(Figure 1.6B). The pre-miRNA is
then exported out of the nucleus into the cytoplasm by Exportin 5 and the
cofactor Ran-GTP (Yi et al., 2003) (Figure 1.6D). In the cytoplasm, the RNase III
enzyme Dicer, along with TAR RNA binding protein (TRBP) and protein kinase R
activating protein (PACT) bind to the pre-miRNA in a RNA induced silencing
complex (RISC) loading complex (RLC) and cleaves it into a mature double
strand miRNA, again with a 3 two nucleotide overhang (Zhang et al., 2004a)
(Figure 1.6E). The RLC is then loaded into RISC, with TRBP and the mature
miRNA binding to AGO2 (Chendrimada et al., 2005) (Figure 1.6F). The less
thermodynamically stable strand of the double strand RNA, the guide strand, is
unwound and presented for mRNA target recognition by one of a family of
Argonaute proteins, and the more stable strand, the passenger strand, is
degraded (Figure 1.6G). Binding of the miRNA to its target mRNA (usually in the
3 UTR) then results in translational repression and/or degradation of the mRNA
(Filipowicz et al., 2008).
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Figure 1.6: The miRNA biogenesis pathway. (A) miRNA genes are transcribed from
miRNA coding genes within the genomic DNA by RNA polymerase II to produce pri-miRNA
transcripts containing one or more stem-loop structures. (B) The stem-loops are
recognised and cleaved by a Drosha-DGCR8 complex to form a pre-miRNA. (C) Splicing of
introns from mRNA can also produce pre-miRNA transcripts. (D) The pre-miRNA is
shuttled out of the nucleus by Exportin5/Ran-GTP into the cytoplasm where (E) it is
further cleaved by Dicer in the RNA induced silencing (RISC) loading complex (RLC) to
form a mature double stranded miRNA. (F) This is then loaded into an argonaute protein
in the RISC, where it is unwound by an argonaute protein to yield a single stranded
miRNA that is (G) capable of binding a target mRNA causing translational repression and
or cleavage. Adapted from (Filipowicz et al., 2008).
(A)
(B)
(C)
(D)
(E)
(F)
(G)
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When a target mRNA is recognised and bound into the RISC complex, it is
translationally repressed either through being degraded or stored in GW182/P-
bodies. P-bodies were first characterised as being cytoplasmic foci containing the
mRNA decapping enzyme DCP2 and the 5-3 endonuclease XRN1 as well as
other 5-3 mRNA decay associated proteins including LSM and RCK, and more
recently also GW182 (Cougot et al., 2004; Eystathioy et al., 2002). P-bodies are
sites of mRNA storage and or degradation, however they are a consequence of
RNA induced silencing rather than being a requirement for this pathway;
depletion of the RNA silencing machinery, including AGO2, Dicer, Drosha and
GW182 or inhibition of early steps of degradation like deadenylation causes a
decrease in number of P-bodies, whereas inhibition of XRN1 progression along
mRNAs causes an increase in size and number of P-bodies. Furthermore miRNA
mediated silencing also occurs in the absence of microscopically visible P-bodies
(Eulalio et al., 2007; Eulalio et al., 2008).
LIMD1 colocalizes with and co-immunoprecipitates the P-body and RNAi
associated proteins RCK, DCP2 and AGO2. Endogenous depletion of LIMD1 by
siRNA causes a decrease in miRNA, but not siRNA, mediated silencing, with over-
expression increasing silencing potency. This has been demonstrated using both
a luciferase reporter with a synthetic let-7a miRNA site in its 3 UTR, and a
luciferase fused to the full length endogenous 3 UTR of the HMGA2 (high
mobility group AT hook 2) gene (James et al., 2010). With respect to HMGA2
repression, inhibition of let-7 in a LIMD1 depleted background did not give any
further increases in HMGA2 protein expression, demonstrating that LIMD1
activity was probably not independent from the let-7 pathway. Furthermore
LIMD1 depletion did not affect HMGA2 mRNA levels demonstrating the increase
in HMGA2 protein following LIMD1 loss was due to release of the mRNA from
translational repression.
1.6.8 LIMD1 is a Regulator of Osteoblast and Osteoclast Function
Bone remodelling is part of normal bone homeostasis with bone formation and
bone resorption in equilibrium. These two processes are carried out by
osteoblast and osteoclast cells respectively, with any disturbances or
deregulation leading to diseases such as osteoporosis and Paget disease of the
bone (Cundy and Bolland, 2008; Raisz, 2005).
Osteoclasts are generated from bone marrow derived macrophages (BMDM)
(Figure 1.7). Following stimulation by macrophage colony stimulating factor (M-
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CSF), preosteoclasts are formed, which further divide and then fuse following
VWLPXODWLRQ E\ UHFHSWRU DFWLYDWRU RI 1)Ŧ% OLJDQG 5$1./ WR IRUP D IXVHG
polykaryon. Further RANK-L stimulation then results in a mature activated
multinucleated osteoclast (Boyle et al., 2003; Eriksen, 2010). Osteoclast
differentiation is negatively regulated by the RANK antagonist OPG, which
competes for binding to RANK-L, thus inhibiting it from binding to RANK and
promoting osteoclast development (Boyle et al., 2003; Raisz, 2005; Eriksen,
2010).
Figure 1.7: Schematic diagram of osteoclast differentiation from hematopoietic
stem cells. Osteoclasts are originally derived from hematopoietic stem cells. Monocytes
differentiate into bone marrow precursor cells, which upon stimulation by M-CSF further
differentiate into pre-osteoclasts. Further stimulation by M-CSF and RANK-L facilitates
formation of multi-nucleated fused polykaryons, which ultimately form activated
osteoclasts following RANK-L stimulation. OPG is a RANK antagonist and competes for
binding with RANK-L, meaning it is a negative regulator/inhibitor of osteoclast
development. MPP, multipotent progenitor cell; CMP, common myeloid progenitor cell;
GMP, granulocyte-macrophage progenitor; M-CSF, macrophage-colony stimulating factor;
5$1./UHFHSWRUDFWLYDWRURI1)Ŧ%OLJDQG23*RVWHRSURWRJHULQ
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When RANK-L binds to RANK, the receptor trimerizes, which facilitates
association with TNF receptor associated factors (TRAFs), in particular TRAF6.
TRAF6 then binds as part of a complex to atypical protein kinase C and p62 in a
multiprotein complex referred to as the sequestosome and this is the start of a
signalling cascade which ultimately leads to the activation of the transcription
IDFWRUV $FWLYDWRU 3URWHLQ  $3 DQG 1)Ŧ% ZKLFK DFWLYDWH JHQHV FULWLFDO IRU
RVWHRFODVWGHYHORSPHQWDVZHOODVWKH,Ŧ%NLQDVHV,..VDQGPLWRJHQDFWLYDWHG
protein kinases (MAPKs) (Boyle et al., 2003; Feng et al., 2007).
LIMD1 binds to both p62 and Traf6 (Feng and Longmore, 2005; Feng et al.,
2007). During RANK-L osteoclast differentiation, and concurrent with Traf6
levels, Limd1 levels are significantly induced and positively regulate the
activation of AP-1 through TRAF6 (Figure 1.8). Limd1-/- mice show normal bone
density and osteoclast numbers when compared to wild type mice, however the
null mice showed a significantly reduced response to stimulation with RANK-L,
but this effect was rescued with reintroduction of Limd1.
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Figure 1.8: RANK-L mediated osteoclast differentiation. RANK-L binding to its
receptor, RANK, causes trimerisation of the receptor. This facilitates association with TRAF
proteins, especially TRAF6. TRAF6 then facilitates the formation of the sequestosome, a
multiprotein complex including p62 and atypical protein kinase C (aPKC). The
sequestosome, through a signalling cascade, causes the activation of the transcription
IDFWRUV 1)Ŧ% DQG $3 ZKLFK DUH FULWLFDO IRU RVWHRFODVW GLIIHUHQWLDWLRQ 7ULPHULVDWLRQ RI
RANK also correlates with an increase in LIMD1 mRNA and protein levels. LIMD1 has been
shown to bind TRAF6 and p62, and positively regulate AP1 activation.
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In summary, LIMD1 expression is down regulated in significant proportions of
lung, breast and head and neck squamous cell carcinomas. In lung cancer,
down-regulation has been attributed to both homozygous and heterozygous
chromosomal gene deletions, with epigenetic silencing also evident in breast and
HNSCC (Sharp et al., 2004; Sharp et al., 2008; Spendlove et al., 2008; Huggins
and Andrulis, 2008; Ghosh et al., 2008).
Mechanistically, loss of LIMD1 protein expression has not been directly correlated
with tumour suppressive activities. LIMD1 interacts with pRb and co-represses
E2F driven transcription, which may enhance the function of pRb, and in doing so
act as a tumour suppressor in this specific pathway (Sharp et al., 2004).
Similarly, LIMD1 is required for microRNA mediated gene silencing, and ablation
of expression would deregulate this pathway, a phenomena that is already a well
characterised event in cancer development (Karube et al., 2005; Sharp et al.,
2008; Melo et al., 2009; Melo et al., 2009; Wu et al., 2010). LIMD1 is also a
regulator of osteoclast differentiation and function, and as such LIMD1 loss could
contribute to diseases of the bone, including osteoporosis and osteopetrosis
(Feng et al., 2007).
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1.7 The Ajuba/Zyxin Family of Proteins
The other members of the Ajuba/Zyxin family of LIM domain containing proteins
share both similar and discrete functions to LIMD1, but as they are not the focus
of this thesis will only be briefly described.
1.7.1 Zyxin
To date zyxin is the most well characterised member of the family originating
from its identification as a novel protein at sites of cell-substrate adhesion and
cell-cell contacts (Beckerle, 1986; Crawford and Beckerle, 1991). Zyxin has been
shown to be important in actin polymerisation (Fradelizi et al., 2001) and
assembly of complexes required for cell motility (Drees et al., 1999; Hoffman et
al., 2006). In a recent study of cells in a 3D matrix, where focal adhesions are
greatly reduced when compared to 2D culture, depletion of zyxin resulted in
increased cell motility (Fraley et al., 2010). Zyxin shuttles between the
cytoplasm and nucleus and as such may transduce signals from the cell
periphery to the nucleus influencing cell dynamics (Nix et al., 2001). In Ewing
tumours which have a highly disrupted actin cytoskeleton, zyxin is expressed at
very low levels and diffusely through the cytoplasm, but ectopic introduction of
zyxin results in organisation of the actin skeleton, coupled with reduced
anchorage independent growth and reduced tumour formation when introduced
into mice (Amsellem et al., 2005).
1.7.2 LPP
Lipoma preferred partner (LPP) was initially identified as a gene at 3q27-28 that
commonly translocated with the HMGiC gene at 12q15 in a major subset of
lipomas (Petit et al., 1996). LPP shares 41% homology with zyxin, and like its
family member is located at focal adhesions, can shuttle to and from the nucleus
(Petit et al., 2000)
where it is a co-activator of the ETS transcription factors PEA3 and ER81 (Guo et
al., 2006). LPP also binds the actin polymerisation associated proteins VASP and
ĮDFWLQLQ 3HWLW HW DO  DQG LV ORFDOL]HG WR IRFDO DGKHVLRQV WKURXJK
interaction with the tumour suppressor protein Scrib (Petit et al., 2005).
1.7.3 TRIP6
Thyroid hormone interacting protein 6 (TRIP6) was identified as a binding
partner for the thyroid hormone receptor following a yeast 2 hybrid screen (Yi
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and Beckerle, 1998). TRIP6 is located on chromosome 7q22, a chromosomal
region that is commonly deleted in uterine leiomyomas (benign smooth muscle
neoplasms) and malignant myeloid diseases (Yi and Beckerle, 1998). TRIP6 is
able to shuttle between focal adhesions and the nucleus, where it is able to
transactivate transcription, but is not able to directly bind to DNA (Wang and
Gilmore, 2001). Similar to LPP, TRIP6 also binds to Scrib, but this interaction is
not what localises TRIP6 to focal adhesions or sites of cell-cell contact (Petit et
al., 2005). Petit et al briefly discussed unpublished preliminary evidence that LPP
could homodimerize as well as heterodimerise with TRIP6 (Petit et al., 2005).
TRIP6 interacts with RIP2 following stimulation by IL-1 or TNF, and facilitates
1)Ŧ%DFWLYDWLRQ/LHWDO0RUHUHFHQWO\75,3ZDVLGHQWLILHGDVEHLQJ
able to bind to the scaffold protein MAGI-1b, which in turn recruits the tumour
suppressor PTEN to sites of cell-cell contacts where it binds to and stabilises E-
cadherin dependent cell contact complexes (Chastre et al., 2009). TRIP6 is over
expressed in colon cancers, which could be the reason for their invasiveness as
ectopic expression of TRIP6 in epithelial MDCK cells also increased their
invasiveness in collagen gel invasiveness assays (Chastre et al., 2009).
1.7.4 Migfilin
Migfilin was the most recently identified member of the Zyxin family. It was
identified through a yeast 2 hybrid assay looking at binding partners of the cell-
extra cellular matrix adhesion site complex protein Mig 2 (Tu et al., 2003). Mig-2
localises migfilin to these adhesion sites, where it binds to the actin binding
protein filamin and influences cell spreading, shape modulation and actin
assembly (Tu et al., 2003). Like other Zyxin family members, migfilin binds to
VASP and shuttles between the cytosol and nucleus (Akazawa et al., 2004; Wu,
2005). Migfilin is only expressed at very low levels in normal smooth muscle
cells. However in leiomyosarcomas (malignant neoplasms composed of cells that
exhibit distinct smooth muscle differentiation) migfilin is found to be expressed
at much higher levels within the cytoplasm, putatively suggesting a role in it
aiding progression of invasiveness within these malignancies (Papachristou et
al., 2007). In mice migfilin does not appear to be necessary for development or
tissue homeostasis as migfilin null mice developed normally and show no
phenotypic differences (Moik et al., 2011). Migfilin also interacts with the cardiac
homeobox transcription factor CSX/NKX2-5, where following stimulation by Ca2+
migfilin translocates into the nucleus and activates CSX/NKX2-5 target gene
transcription and promotes myocardial cell differentiation (Akazawa et al.,
2004).
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1.7.5 Ajuba
Ajuba was identified in 1999 as a binding partner of the erythropoietin receptor
(EPO-R) in a yeast 2 hybrid screen (Goyal et al., 1999). Following serum
stimulation ajuba binds the adapter protein Grb2, which transduces signals from
membrane receptors to Ras and downstream MAP kinase (Goyal et al., 1999).
Furthermore in Xenopus oocytes ajuba promotes maturation in a Grb2/MAP
kinase dependent manner (Goyal et al., 1999). There is contradictory evidence
to the cellular localisation of ajuba; it has been reported to be both absent
(Goyal et al., 1999) and present (Kanungo et al., 2000; Marie et al., 2003) from
focal adhesions. It contains a nuclear export and localisation signal and as such
shuttles between the cytosol and nucleus (Goyal et al., 1999; Kanungo et al.,
 $MXED ELQGV WR )DFWLQ DQG ĮFDWHQLQ ZKLFK ORFDOLVHV LW WR FDGKHULQ
dependent cell junctions (Marie et al., 2003). Over expression of full length
ajuba (or just the pre-LIM region) enhanced proliferation of P19 embryonal cells,
whilst LIM domains alone had the converse effect and induced endodermal
differentiation in a JNK MAP kinase dependent manner (Kanungo et al., 2000).
Ajuba binds the SNAG transcriptional repressor domain within the SNAIL protein,
and co-represses transcription by forming a repressional complex within the
nucleus. Specifically ajuba contributes to epithelial-mesenchymal transitions
(EMT), through co-repressing SNAIL activity which reduces E-cadherin
expression, a glycoprotein involved in cell-cell contacts and loss of which is
intimately involved in invasiveness of breast cancers (Langer et al., 2008;
Ayyanathan et al., 2007). Ajuba is a negative regulator of the Hippo pathway
that regulates cancer development and tissue size; ajuba null Drosophila tissues
have increased apoptosis and reduced proliferation leading to smaller cell/tissue
size (Das et al., 2010). More recently ajuba has been shown to be a critical
component of microRNA mediated gene silencing, a process involved in cell cycle
regulation, homeostasis, disease and cancer progression (James et al., 2010).
1.7.6 WTIP
Wilms tumour interacting protein (WTIP) was again initially identified in a yeast
2 hybrid screen that was looking for binding partners of the Wilms tumour
protein (WT1), a transcription factor essential for normal nephrogenesis that is
mutated in a high proportion of Wilms tumours (Srichai et al., 2004). WTIP
contains a nuclear export signal and is able to shuttle between the cytoplasm
and nucleus where it represses WT1 activated transcription (Srichai et al., 2004).
WTIP is localised both at cytoplasmic spots (Srichai et al., 2004) and at the cell
membrane where it interacts with Ror2, a receptor tyrosine kinase, and
UHSUHVVHV :QW LQGXFHG ǃFDWHQLQ VLJQDOOLQJ YDQ :LMN HW DO  :7,3 LV
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located at cell adheren junctions in podocytes, however it translocates to the
nucleus, via the actin motor protein dyein, following injury and altering actin
dynamics and subsequent podocyte shape (effacement) (Rico et al., 2005; van
Wijk et al., 2009; Kim et al., 2010a). shRNA mediated silencing of WTIP in
podocytes resulted in altered actin dynamics and cell morphology (Kim et al.,
2010a). WTIP is also able to homodimerise via its LIM domains (van Wijk et al.,
2009) and like ajuba, is also a critical regulator of microRNA mediated silencing
(James et al., 2010).
The Ajuba/Zyxin family therefore have important physiological and tumour
suppressive roles. However, the focus of this thesis is the encoded 3p21.3 LIMD1
tumour suppressor gene.
Chromosomal deletions or loss of heterozygosity of a region of genomic DNA that
encodes a tumour suppressor gene will cause a complete loss or reduction in
expression respectively, and this has been demonstrated with loss of LIMD1
expression in adenocarcinomas (Sharp et al., 2008). However, reduced
expression of TSGs cannot always solely be accounted for by chromosomal
alterations; where protein loss is observed independent of chromosomal
deletions it is indicative that loss of expression could be due to deregulation of
gene transcription. This may indeed be the case with LIMD1 as 79% of lung
tumours show LIMD1 protein loss, but only 44% show genetic deletions (Sharp
et al., 2008).
Therefore to investigate if LIMD1 expression is down-regulated at a
transcriptional level, and before describing my investigations into the
transcriptional control of LIMD1 gene expression, it is necessary to describe the
basis of regulation of general gene transcription.
1.8 Control of Gene Transcription
In eukaryotes there are 3 different RNA polymerases that transcribe different
classes of genes. RNA polymerase I transcribes 18S and 28S RNA (Grummt,
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2003); RNA polymerase II transcribes mRNA (Smale and Kadonaga, 2003); and
RNA polymerase III transcribes 5S ribosomal RNA, tRNA and other small
catalytic RNAs (Schramm and Hernandez, 2002). As RNA polymerase II is the
polymerase that transcribes protein coding RNA transcripts, only this polymerase
will be focused on.
Transcription of a specific gene requires RNA pol II to bind to genomic DNA 5 to
the ATG translation initiation codon, at a region known as the core promoter. A
core promoter is defined as the minimal stretch of contiguous DNA sequence
that is sufficient to direct accurate initiation of transcription by the RNA polII
machinery (Butler and Kadonaga, 2002). Essentially, a core promoter is the
minimal consensus that through interactions with transcription factors is able to
facilitate transcription. Binding of RNA polII to the core promoter is facilitated by
trans-acting general transcription factors (GTFs) that together make up the pre-
initiation complex (PIC), and is the culmination of associations between cis-
acting transcription factors that bind to proximal promoters, silencers, enhancers
or insulators, and chromatin remodelling factors (Baumann et al., 2010).
1.8.1 Features of RNA Polymerase II Promoters
There are 2 types of RNA pol II promoters, ones that contain a TATA box and
ones that do not (TATA-less). A TATA box (or Goldberg-Hogness box after its
discoverers) is a core sequence of TATAAA that was initially identified as being
present 25-30 bp upstream of the transcription start site in almost all RNA pol II
transcribed genes examined from mammalian, viral and Drosophila protein
coding genes (Smale and Kadonaga, 2003; Baumann et al., 2010). However,
more recent analysis of 1031 genes by cap analysis of gene expression (CAGE)
showed only approximately 32% of genes contained a TATA box within their
promoters (Suzuki et al., 2001), with this figure decreasing to as low as 10% in
a separate bioinformatic analysis study (Zhu et al., 2008). Further CAGE
sequencing methods have revealed over 70% of TATA boxes are located
between -33 and -28 from the actual transcriptional start site (TSS), with the
majority at positions -31 or -30 (Carninci et al., 2006). The TATA binding protein
(TBP) was initially identified as being part of a subunit of the general
transcription factor TFIID, and it is this subunit that binds the TATA box, and
ultimately recruits RNA pol II (Nakajima et al., 1988; Smale and Kadonaga,
2003; Burley and Roeder, 1996; Greenblatt, 1991).
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Another common feature of RNA pol II associated promoters is an initiator
element (Inr) that encompasses the actual transcription start site, and is present
in up to 85% of promoters (Suzuki et al., 2001). It has the general consensus
sequence Py2-A-N-A/T-Py2, (Py=pyrimidine, N=any base) with transcription
commonly initiating from the A (Smale and Kadonaga, 2003; Baumann et al.,
2010). Inrs are found in both TATA and TATA-less promoters. When the Inr is
located ~30bp from the TATA box, the two elements act synergistically to
enhance transcription, however, both can also act independently to initiate
transcription with TATA being predominant over Inr (O'Shea-Greenfield and
Smale, 1992). When independent of each other TATA initiates transcription
~25bp downstream and Inr initiates at its specific nucleotide within its
consensus sequence (Smale and Kadonaga, 2003). The Inr is recognised by a
complex of TAF1 and 2, which are part of the complex that includes TBP that
form the general transcription factor TFIID (Chalkley and Verrijzer, 1999). In
vitro, RNA pol II is able to weakly bind to the Inr; the interaction and
transcription enhanced through the addition of TFIID, and TFIID is required even
in promoters that lack a TATA consensus (Carcamo et al., 1989; Carcamo et al.,
1991).
Downstream promoter elements (DPE) are also found in up to 85% of gene
promoters. The DPE is found at exactly +28 to +32 relative to the initiating A
within the Inr, has the general consensus A/G(+28)-G-A/T-C/T-G/A/C(+32) and is
often only found in TATA-less promoters (Kadonaga, 2002; Butler and
Kadonaga, 2002). In Drosophila, the DPE is roughly found at the same frequency
as TATA boxes, however in humans there is no correlation between the presence
of a TATA sequence and a DPE (Kutach and Kadonaga, 2000; Gershenzon and
Ioshikhes, 2005). TFIID, through its TAF6 and 9 subunits, binds the DPE (Burke
and Kadonaga, 1997).
The TFIIB recognition element (BRE) is the only other characterised core
promoter motif that is bound by a general transcription factor other than TFIID.
The BRE consensus sequence is G/C-G/C-G/A-C-G-C-C and is immediately
upstream of the TATA (Lagrange et al., 1998). Contradictory observations have
been published regarding the function of the BRE. Lagrange et al identified TFIIB
binding to the BRE enhanced formation of the transcription initiation complex
(Lagrange et al., 1998). However, Evans et al observed an inhibitory effect on
basal transcription which was reversed by addition of a transcriptional activator,
and this observation corroborated with previous studies that identified mutations
of the (then uncharacterised) BRE sequence directly upstream of the TATA box
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that increased levels of transcription (Evans et al., 2001). It was more recently
discovered that there are BREs downstream of the TATA box, with the consensus
G/A-T-T/G/A-T/G-G/T-T/G-T/G (Deng and Roberts, 2005). As such the original
upstream BRE is referred to as BREU and the more recent downstream one as
BRED. The effect of BRED is promoter dependent; it has a positive increase on
transcription in promoters that lack a BREU but a negative effect on transcription
in promoters that also contain a BREU (Deng and Roberts, 2006). The two
different BREs are bound by different binding domains within TFIIB (Deng and
Roberts, 2005).
GC boxes are present in almost all gene promoters (Suzuki et al., 2001). Studies
on the DNA tumour Simian virus 40 (SV40) to identify sequences essential for its
transcriptional activation identified three 21bp repeats, within which were 6
repeated GC rich repeats of GGGCGG. This gave rise to the GC box general
consensus sequence of 5'-G/T-G/A-GGCG-G/T-G/A-G/A-C/T-3', which when
present were found to be critical for transcriptional activation (Dynan et al.,
1985; Gidoni et al., 1985; Imataka et al., 1992). Further studies revealed that
the transcription factor Sp1 binds to these GC boxes and activates transcription
(Briggs et al., 1986; Dynan and Tjian, 1983).
The final feature of gene promoters to be described is CpG Islands, which will
subsequently be shown to be a critical feature of the LIMD1 promoter and thus
gene expression. These are short DNA sequences approximately 1kb in length
that contain a high frequency of 5-CG-3 dinucleotides, further referred to as
CpG, and are associated with up to 100% of all housekeeping genes and
approximately 70% of genes in total (Saxonov et al., 2006; Illingworth and Bird,
2009). Promoters of genes that contain one or more CpG Islands often do not
contain TATA boxes or DPEs, however they are usually rich in GC boxes (both in
5 and 3 CpG Islands) that harbour multiple Sp1 binding sites (Gardiner-Garden
and Frommer, 1987). CpG Islands will be discussed in more detail later on.
The different promoter elements are represented schematically in Figure 1.9.
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Figure 1.9: Schematic diagram of a RNA Pol II promoter. A typical transcribed gene
contains a 5 promoter region that contains elements to facilitate transcription through
the binding of transcriptional activators. Up to 70% of all genes contain a CpG Island
within their promoter that may harbour multiple GC boxes for Sp1 binding. Some
promoters may also contain a TATA box, where the TATA binding protein (TBP) binds or
an upstream or downstream TFIIB recognition element (BREU/D) for binding of TFIIB. Both
TBP and TFIIB recruit other general transcription factors and RNA Pol II to form the pre-
initiation complex and initiate transcription from within the initiator element (Inr). Often
in TATA-less promoters, the presence of a downstream promoter element (DPE) facilitates
the recruitment of TFIID and the PIC.
Assembly of the general transcription factors and RNA pol II into a pre-initiation
complex onto the DNA is the preceding step to transcription. The presence of
TATA boxes and other promoter elements helps guide the transcriptional
machinery to the promoter. However, in order for the Pol II basal machinery to
bind to the promoter, the DNA needs to be in an accessible open or active
conformation.
1.8.2 Active Transcription requires an Open Euchromatin Structure
In its native state DNA is tightly packaged around nucleosomes, which are
octomers of histone proteins that has ~146bp of DNA wrapped around. The N
terminal tails of Histone2B and H3 protrude through the grooves of the DNA
where lysines and argenines interact with the phosphate groups of the DNA to
facilitate the packaging (Ruthenburg et al., 2007; Schnitzler, 2008). Post
translational modifications to the histone tails alters the affinity of the histones
for the DNA, and allows for the DNA to alter between a tightly packaged,
transcription factor inaccessible heterochromatin structure, and a more open and
accessible euchromatin conformation. When referring to histone modifications a
standardised nomenclature is used. The first part of a reference is the histone
(e.g. H3), the next letter is the amino acid being modified, and the final number
is the residue of the amino acid; e.g. H3K9 refers to a modification of lysine 9 of
histone H3.
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One of the major histone modifications associated with active promoters is
acetylation. Histones are reversibly acetylated on lysines within their N-terminal
tails by histone acetyltransferases (HATs). Acetylated histones are associated
with euchromatin, facilitating interactions of transcription factors with the DNA.
Experimentally, permanently acetylated histones are unable to adapt a
heterochromatic conformation (Shogren-Knaak et al., 2006; Garcia-Ramirez et
al., 1995). Many transcriptional co activator proteins contain histone acetylase
activities, for example p300/CBP that is able to link activators including c-Jun,
Elk-1, AF-2, HIF-1 and CREB to the basal Pol II apparatus to increase
transcription (Iyer et al., 2004). Conversely, deacetylation by histone
deacetylases (HDACs) is associated with inhibition of transcriptional activator
association and thus gene silencing, with some transcriptional repressors
including Sin3 and NCoR/SMRT associated with HDACs (Pazin and Kadonaga,
1997). As well as acetylation, histones are also methylated on specific residues
by histone lysine methyltransferases (HKMTs). Methylation of H3K9, 27 and
H4K20 are associated with gene repression, whilst of H3K4, 36 and 79 with
activation; in X chromosome inactivation, the silenced X chromosome has a
significant enrichment H3K9 methylation and reduced H3K4 methylation (Boggs
et al., 2002). Methylation of H4K20 by PR-Set7 has been shown to induce
silencing through preventing acetylation of H4K16 by the transcriptional co-
activator p300 (Nishioka et al., 2002).
Many factors contribute to the formation of either a euchromatin or
heterochromatin structure. One of the major factors that promote a closed DNA
structure is DNA methylation. Methylation facilitates the binding of
transcriptional repressor proteins to the DNA, causing an inactive DNA
conformation, which results in gene silencing. This process often occurs
aberrantly in cancers, and will now be fully introduced.
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1.9 DNA Methylation and Epigenetic Silencing
Epigenetic silencing refers to the heritable change (silencing) of gene expression
that cannot be accounted for by a change in the DNA sequence (Bird, 2007). In
mammalians, epigenetic silencing is due to both pre-programmed and aberrant
DNA methylation of cytosine bases, and this will now be introduced.
1.9.1 5-Methyl Cytosine
In higher eukaryotic organisms from plants to humans, the only base that is
observed to be naturally modified by methylation is cytosine, and this normally
occurs on the 5 position of the cytosine pyrimidine ring in the context of a CpG
dinucleotide (Ehrlich and Wang, 1981; Suzuki and Bird, 2008). m5C accounts for
approximately 1% of bases in human somatic cells (Ehrlich et al., 1982),
however the occurrence of CpG dinucleotides in many animals is much less than
would be statistically expected. The total C and G content of human genomic
DNA is ~40% and so as such the probability of a CpG dinucleotides occurring
statistically would be 0.2 x 0.2 = 0.04. However the observed frequency of CpG
is 0.008, significantly lower than expected (Bird, 1980; Simmen, 2008).
The amount of CpG methylation varies between different species, initially
identified with restriction endonuclease isochizomers that discriminate against
methylation. The restriction endonuclease HpaII will cleave the sequence CCGG,
however not CmCGG, whereas MspI will cleave both sequences indiscriminately.
Therefore a sequence of DNA that is cleaved equally by HpaII and MspI must be
unmethylated, whereas a sequence that is only cleaved by MspI but not HpaII
must be methylated. It was this methodology that revealed the genomic DNA in
Drosophila melanogaster and other insects is largely unmethylated, whereas
vertebrate genomes are heavily methylated, with other species e.g. Echinus
esculentus (sea urchin) are inbetween these extremes and considered to be
partially methylated (Bird and Taggart, 1980).
There is a correlation between the amount of cytosine methylation and CpG
frequency within genomes. Bird et al noted that insects, which have poorly
methylated genomes, are not deficient in CpG dinucleotides, however
vertebrates, which have highly methylated genomes, are deficient in CpG
dinucleotides, and organisms with intermediate amounts of methylation have
CpG content between the two extremes (Bird, 1980). This can be explained as
methylated cytosines (within CpG dinucleotides) are prone to spontaneous
deamination into thymine, thus resulting in TpG rather than CpG. This theory is
also supported by the observation that genomes which have a deficiency in CpG
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have a correlated increase in TpG and CpA dinucleotide frequency (Bird, 1980).
Therefore, organisms with high mCpG content exhibit a slow decay to give rise to
a significantly increased TpG content.
1.9.2 CpG Islands
CpG Islands were originally identified as being small regions of DNA that were
CpG rich, and unmethylated. Digestion of vertebrate genomic DNA with the
restriction nuclease MspI that cuts both CCGG and CmCGG sequences, resulted in
extensive cleavage of DNA. However, digestion with the methylation resistant
nuclease HpaII that only recognises the sequence CCGG but not CmCGG gave
mainly larger fragments of undigested methylated genomic DNA, along with
some smaller digested fragments, representing areas of genomic DNA that were
unmethylated (Cooper et al., 1983).
Further investigations using hybridisation, methylation specific restriction digests
and sequencing revealed that the small HpaII digested regions of DNA (also
called HTFs; HpaII tiny fragments) were mostly unmethylated. Contrary to
previous observations of significantly low CpG frequency compared to the overall
GC content (Cooper et al., 1983), these undigested regions were found to be
both GC rich and not deficient in CpG dinucleotides (which were found at a
similar frequency to GpC dinucleotides) (Bird et al., 1985). Furthermore the
occurrence of these unmethylated HTF Islands were clustered in ~1kb regions
of the genome and contained HpaII sites at 10 times the frequency found in
genomic DNA as a whole (Bird et al., 1985).
Analysis of the hamster adenine phosphoribosyl transferase (aprt) and
dihydrofolate reductase (dhfr) genes revealed that both genes were highly
methylated intragenically, except for the 5 flanking region that was both
unmethylated and contained a high CpG content (Stein et al., 1983). The aprt
gene had previously been shown to be transcriptionally inactive following in vitro
methylation prior to transfection into aprt- mouse cells (Stein et al., 1982). This
therefore lead to one of the earliest evidence based predictions that methylation
of a normally unmethylated 5 CpG rich region of a gene could cause it to be
silenced (Stein et al., 1983).
The murine ɲ2 collagen gene was discovered to be unmethylated in the region
surrounding the transcriptional start site, but methylated within and at the 3
end of the gene itself, and within the tissues examined the methylation remained
constant regardless of expression of the gene (McKeon et al., 1982).
Comparably, the albumin gene was also found to be consistently unmethylated
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at the 5 end, with varying degrees of methylation within the rest of the gene,
and in hepatoma cells hypomethylation of the 5 region was necessary for
expression. The methylation status of the gene could not be directly correlated
with expression, however the 5 proximal gene regions were consistently found
to be unmethylated (Ott et al., 1982).
These identified 5 regions of genes that were CpG rich but unmethylated were
termed CpG Islands. An initial definition of a CpG Island was put forward by
Gardiner-Garden and Frommer of a region of at least 200bp with a GC
percentage that is greater than 50% and with an observed/expected CpG ratio
that is greater than 60% (Gardiner-Garden and Frommer, 1987). Alu repeats
are small interspersed DNA repeats that are ~280bp in length, that were
originally introduced by integration of a retrotransposon, and there are
approximately 1 x 106 Alu repeats in the human genome, accounting for ~10%
of the total genome (Mighell et al., 1997). Alu repeats are GC rich, and as such
the Gardiner-Garden and Frommer CpG Island definition could not always
discriminate between these and actual CpG Islands. Following analysis of
chromosomes 21 and 22 with a range of algorithms in order to avoid detecting
Alu repeats, the more recent and widely accepted definition of a CpG Island was
put forward by Takai and Jones of a region of DNA greater than 500bp with a
GC content of at least 55% and an observed/expected CpG ratio of at least 0.65
(Takai and Jones, 2002).
There are 20-30,000 protein coding genes within the human genome (Lander et
al., 2001; Venter et al., 2001) and CpG Islands are present in the promoters of
up to 70% of all genes in total, with 100% of constitutively expressed
housekeeping genes having one or more promoter CpG Islands (Kundu and Rao,
1999; Illingworth and Bird, 2009). The majority of CpG Islands do not contain
TATA boxes or DPEs (Butler and Kadonaga, 2002). Promoters with TATA boxes
and other core promoter elements tend to have either a single focused
transcription start site, or a few closely clustered start sites within ~40bp.
However, CpG Islands are promoters that give rise to multiple transcription start
sites from within a larger range of ~100bp (Juven-Gershon et al., 2008).
CpG Islands contain multiple binding sites for the transcription factor Sp1 (Butler
and Kadonaga, 2002). Sp1 is a ubiquitously expressed, multi faceted
transcription factor that has been shown to be critical in maintaining the
hypomethylated state of CpG Island promoters; the human and mouse aprt gene
contains a 5 CpG Island with multiple Sp1 sites. The CpG Island is
Chapter 1: Introduction
35
unmethylated, but mutation of the Sp1 sites in ES cells resulted in promoter
methylation (Brandeis et al., 1994). Sp1 also binds to the chromatin remodelling
factors SNI/SWF and the p300/CBP co-activator complex, as well as recruiting
TBP to TATA-less promoters in order to activate transcription (Butler and
Kadonaga, 2002; Esteve et al., 2007). In HepG2 and 3B cells, Sp1 was shown to
be critical for a euchromatic structure and transcriptional activation of the CD151
gene, a gene that in liver cancer is a positive effecter of metastasis and high
expression correlates with poor prognosis (Wang et al., 2010).
However, Sp1 also binds to the HDAC 1/2 and Sin3A transcriptional repressor
complex to repress transcription (Li and Davie, 2010). Furthermore, it binds to
the survivin gene promoter and recruits transcriptional co-repressors including
the methyltransferase Dnmt1 and HDAC1 that leads to methylation of H3K9 on
the promoter, and represses transcription (Esteve et al., 2007). Therefore, the
presence of the Sp1 binding motifs within CpG Islands appears to both repress
and activate transcription in a gene dependent manner.
As well as containing multiple Sp1 sites, CpG Island promoters have a high
incidence of other transcription factor binding motifs, including E2F, Nrf-1 and
ETS family transcription factors (Landolin et al., 2010). Furthermore, in mouse
studies, the presence of these motifs within CpG Islands was indicative of a
constitutively expressed housekeeping gene (Rozenberg et al., 2008).
1.9.3 CpG Islands are Aberrantly Hypermethylated in Multiple Cancers
Initially cancer cells were identified as having a global reduction in m5C content
(Gama-Sosa et al., 1983) and this has since been characterised as being a global
phenomenon in cancers. Early analysis using methylation sensitive restriction
digests of genomic DNA from a cohort of 23 human normal, neoplastic or polyp
colonic cancers showed specific hypomethylation in a selection of genes in the
polyps or neoplasms when compared to normal tissue, including ɶ-crystallin,
growth hormone, ɲ-chorionic gonadotropin and ɶ-globin, which are genes that
are hypermethylated and not expressed in normal colonic epithelium (Goelz et
al., 1985). However, converse to global hypomethylation that had to date been
identified in cancers, Baylin et al then identified the calcitonin gene as having an
increase in methylation in small cell lung cancer and lymphoma cell lines and in
tumour samples from patients with Non-Hodgkins T and B cell lymphoid
neoplasms and acute non-lymphocytic lymphomas when compared to non-
neoplastic cells (Baylin et al., 1987). Since then, CpG Islands within the 5
proximal promoter regions of many genes have been identified as becoming
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hypermethylated in cancers, including BRCA1, p14ARF, p16Ink4A and Rassf1a
(Esteller, 2007).
Observations obtained using restriction landmark genomic scanning (RLGS)
analysis of 1184 CpG Islands in 98 tumour samples revealed stark differences in
aberrant methylation between different tumour types. For example breast, head
and neck and testicular cancers showed low (or no) aberrant methylation,
whereas childhood acute myeloid leukaemias and neuroectodermal tumours,
colon and gliomas showed a significantly higher frequency of methylation
(Costello et al., 2000). Furthermore some CpG Islands were commonly
methylated between different tumour types, whereas others were specific for
one type of cancer (Costello et al., 2000).
Different genes all appear to succumb to different extents of methylation, and
this also varies between different cancer types. Esteller et al produced a CpG
Island hypermethylation profile of human cancer, illustrating the frequency of
which 20 commonly hypermethylated gene promoters are methylated in 18
different primary cancers (Esteller, 2007) (Figure 1.10). This identified that
different cancers show different extents of CpG gene promoter methylation;
ovarian, skin cancers and sarcomas have relatively little hypermethylation in
general compared to colonic, breast, HNSCC, lung and haematological
malignancies. Furthermore, the same genes between different cancers show the
varied levels of hypermethylation. For example the p16INK4A tumour suppressor
gene is reported to be hypermethylated in up to 50% of colon, lung cancer and
lymphomas, whereas has no reports of hypermethylation in ovarian, pancreatic
or stomach cancers (Esteller, 2007).
More recently with the development of high throughput, genome wide
sequencing technologies, deep sequencing (Deep-seq) has been used to quantify
CpG Island methylation in a range of cancers, with simultaneous identification of
methylation within thousands of CpG Islands within the same genome. This
allows for a global comparison of methylation between normal cells and cancer
cells, facilitating the identification of potential tumour suppressor genes. In a
cohort of prostate cancer samples, Deep-seq of methylated CpG enriched
genomic DNA identified 2,481 cancer specific promoter hypermethylation
occurrences, including almost all of 56 previously reported pancreatic cancer
hypermethylated genes (Kim et al., 2011). In a cohort of breast cancer cell lines,
deep-seq analysis identified differential methylation within the promoters of 162
genes that were differentially expressed between estrogen receptor expressing
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and non-expressing cells, which has implications for the understanding and
development of clinical therapeutics (Sun et al., 2011). The large increase in
data obtainable from deep-seq methodology therefore further corroborates
promoter hypermethylation as a characteristic and possible transformation
initiating event in cancer.
Figure 1.10: A CpG Island Hypermethylation Profile of human cancer. An
illustrated histogram of 20 commonly hypermethylated genes in 18 different primary
malignancies (Esteller, 2007).
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1.9.4 DNA Methylation is Epigenetic
Both normal cell and aberrant tumour cell DNA methylation patterns are
inherited following mitosis, and as such methylation is known as an epigenetic
DNA modification. Epigenetics is defined as the study of mitotically and/or
meiotically heritable changes in gene function that cannot be explained by
changes in DNA sequence (Bird, 2007). The first evidence to show the heritable
trait of methylation patterns was when in vitro methylated plasmid DNA was
transfected into cells, and following multiple rounds of host cell replication the
methylation status of the original plasmid was maintained. Furthermore, as the
methylation pattern was maintained this also indicated the presence of a
maintenance methyltransferase (Wigler, 1981; Wigler et al., 1981). Two DNA
methyltransferases of molecular weights 150 and 175kDa were then purified
from murine erythroleukaemia cells and shown to have the highest activity
towards hemi-methylated DNA (Bestor and Ingram, 1983). The identified DNA
methyltransferases (MTase) was subsequently cloned in 1988 (Bestor et al.,
1988).
During gametogenesis, fertilisation and placental implantation, the methylation
pattern of the DNA goes through both transiently dynamic and permanent
changes. Methylation specific restriction analysis initially identified that
methylation decreases post fertilization and then increases again after
implantation (Monk et al., 1987). Pre-implantation embryos are observed to
become globally hypomethylated compared to the fertilising oocyte and sperm
(which themselves are hypomethylated when compared to somatic cells), and
then the level of methylation is increased following implantation (Kafri et al.,
1992; Kafri et al., 1993; Lei et al., 1996). Observations with an anti-5-
methylcytosine antibody that showed the amount of methylation from single cell
embryo to blastocyst decreased (Rougier et al., 1998). Furthermore, it has been
proven that the paternally derived DNA is actively demethylated (as it occurs
prior to DNA replication) whereas the maternal DNA is passively demethylated
following replication due to the absence of a maintenance MTase (Mayer et al.,
2000).
1.9.5 DNA Methylation is Carried out by DNA Methyltransferases
(Dnmts)
From the initial cloning of MTase (Bestor et al., 1988), the existence of additional
methyl transferases came following experimentation using murine embryonic
cells.
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Infection of the Moloney murine leukemia virus (M-MuLV) into murine embryonal
carcinoma (EC) cells (stem cells of teratocarcinomas that are developmentally
totipotent) produced genomes that contained integrated viral DNA. However, no
significant expression of viral specific RNA was detected. Infection into
differentiated EC cells however, resulted in both genomic integration and
successful virus production. DNA analysis revealed that in the EC cells the viral
DNA had become methylated, whereas in the differentiated cells it was
unmethylated. Treatment with the DNA methylation inhibitor 5-azacytidine
demethylated the viral DNA in the undifferentiated EC cells and induced viral
expression (Figure 1.11). These observations indicated that the dynamics of
methylation change following differentiation. Furthermore, and contrary to
previous findings of a preference of the DNA methylase for methylating hemi-
methylated DNA (Bestor and Ingram, 1983), these results indicated the
presence of de novo DNA methylation in undifferentiated/pluripotent cells
(Stewart et al., 1982).
Further evidence to support the existence of a de novo methyltransferase came
following the production of ES cells with mutations in the MTase gene that
rendered a non-functional protein. Infection of M-MuLV into wild type ES cells
rendered identical results to those observed by Stewart et al; the viral DNA
became integrated and then methylated (Figure 1.11). Following viral integration
into ES cells with the non functional MTase the levels of de novo methylation
were again identical to those seen in the wild type ES cells, indicating the
presence of another methyltransferase that exhibited de novo methylation
capabilities. After 8 days, when the levels of methylation peaked in both cell
types, the amount of methylation decreased in the MTase mutant cells, which
was attributed to the lack of a functional maintenance methyltransferase
(MTase) to preserve the methylation status. These observations therefore
indicated other DNA methyltransferases enzymes existed (Stewart et al., 1982;
Lei et al., 1996).
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Figure 1.11 Undifferentiated embryonic cells contain an active de novo
methyltransferase, whereas differentiated cells lose the ability of de novo
methylation. Undifferentiated or differentiated embryonic cells were infected with the
Moloney murine leukaemia virus, and viral DNA was integrated into the host genome. The
differentiated cells produced viral encoded RNA and virus, however the undifferentiated
cells did not; this difference was due to the integrated DNA becoming methylated in the
latter cell type. Treatment with the DNA methylation inhibitor 5-azacytidine prevented
methylation of the integrated DNA, and resulted in viral expression, proving the existence
of an active de novo methyltransferase in undifferentiated cells (Stewart et al., 1982).
Sequence comparisons of 13 prokaryotic cytosine methyltransferases revealed 5
highly conserved domains (Posfai et al., 1989). Using this as a query sequence,
4 human EST clones were identified (Okano et al., 1998a). These were named
DNA methyltransferase (Dnmt) 2, Dnmt3a and Dnmt3b (along with the already
identified Dnmt1/MTase). Human Dnmt3a and b exhibit 98 and 94% homology
respectively with their mouse homologues, whereas only 60% homology is seen
between murine and human Dnmt1 (Okano et al., 1998a; Xie et al., 1999).
Unlike Dnmt1 which shows a preferential activity towards hemi-methylated DNA
(Bestor and Ingram, 1983), Dnmt3a and b were equally active towards both
hemi and un-methylated DNA (Xie et al., 1999). Gene knockout of Dnmt3a
and/or Dnmt3b revealed that homozygous mutant ES cell lines failed to
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differentiate, Dnmt3a-/- mice developed to term but died after ~1 month and
Dnmt3b-/- mice had multiple development and growth defects and no viable mice
survived to birth (Okano et al., 1999). Double Dnmt3a and b null ES cell lines
were unable to methylate integrated M-MuLV DNA (Okano et al., 1999),
demonstrating that both Dnmt3a and b are required for de novo methylation,
whereas Dnmt1 is required to maintain methylation states.
Dnmt2, the other identified mammalian DNA methyltransferase (Yoder and
Bestor, 1998) is not required for either de novo or maintenance methylation
(Okano et al., 1998b) and is localised to both the cytosol and the nucleus in
contrary to the nuclear localisation of Dnmt1 and 3 (Schaefer and Lyko, 2010).
Mice, that harboured inactivating mutations in Dnmt2 were viable, fertile and
had almost identical phenotypes and genotypes to wild-type controls (Goll et al.,
2006). Dnmt2 specifically methylates cytosine 38 in aspartic acid, glycine and
valine transfer RNA (tRNA) both in vivo and in vitro (Goll et al., 2006; Schaefer
and Lyko, 2010; Schaefer et al., 2010). Under oxidative or heat induced stress
Dnmt2 localises to stress granules and RNA processing bodies, and that the
methylation of the tRNAs protects them against stress induced angiogenin
cleavage (Schaefer et al., 2010).
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1.9.6 CpG Methylation is Critical for Normal Cell Physiology
Even though aberrant CpG methylation is observed in cancer cells, it is also a
normal physiological event that is critical for normal differentiation and
development of cells. This is specifically exemplified by X chromosome
inactivation and genetic imprinting.
In somatic cells, diploid organisms contain two copies (alleles) of each gene, one
maternal and one paternal. The only exception to this is the sex chromosome,
where a female inherits two copies of the X chromosome, and a male only one.
In order that the expression of X linked genes is equal between the different
sexes, one X chromosome in human females is silenced, a phenomenon known
as X-chromosome inactivation and is an example of dosage compensation.
The processes involved in X chromosome inactivation are not fully elucidated or
understood. However, briefly, inactivation is dependent on an X-inactivation
centre (Xic) locus that (through undiscovered mechanisms) is responsible for X
chromosome counting to ensure all but one X chromosome is inactivated. Xic
contains a gene called X-inactive specific transcript (Xist) which is transcribed as
a 17kb untranslated RNA, which physically binds and coats the X chromosome to
be inactivated in cis. The active X chromosome produces an anti-sense transcript
Tsix, which represses Xist expression through altering Xist chromatin during
transcription of Tsix. This prevents the active X chromosome from being coated
with Xist. Xist then recruits the chromatin remodelling Polycomb repressor
complex. This ultimately results in modified histone proteins and gene promoter
methylation. The inactive X chromosome exhibits high levels of CpG promoter
methylation in comparison to the active chromosome, and the few genes in the
inactive chromosome that escape inactivation are unmethylated in both copies of
the X chromosome, indicating the critical role of CpG methylation in silencing of
genes in the inactive chromosome (Figure 1.12). (Heard, 2004; Kalantry, 2011;
Kim et al., 2009; Leeb et al., 2009).
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Figure 1.12 Schematic diagram of X chromosome inactivation. To maintain equal
expression of X linked genes in males and females, one X female X chromosome is
inactivated following fertilisation. The mechanism of this is not fully elucidated however,
an X chromosome inactivation locus (Xic) is responsible for counting the X chromosomes
to ensure all but one is inactivated. Xic encompasses the X-inactive specific transcript
gene which is transcribed as a 17kb untranslated RNA that physically coats the X
chromosome that is to be inactivated. At the same time the active chromosome
transcribes the complementary transcript Tsix, which forms a duplex with Xist, preventing
it from coating the chromosome. Xist on the coated chromosome then recruits the
Polycomb repressor complex, resulting in chromatin remodelling and hypermethylation of
the contained genes, rendering the chromosome inactive (Kalantry, 2011).
Similar to X chromosome inactivation is genetic imprinting, which is the
expression of certain genes in a parent specific manner; i.e. one allele of a gene
is inactivated so that expression of a gene is solely from either the maternally or
paternally inherited chromosome. In humans and mice there are 53 and 96 (37
common) functionally characterised imprinted genes respectively (Morison et al.,
2005). During gametogenesis, the methylation status of the maternal/paternal
imprinted gene is erased and then re-imprinted; this is so that the gametes
contain methylation information that is specific to parent it was inherited from,
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rather than from the gene itself. The precise methylation is controlled by cis-
acting imprinting control regions (ICRs), which are CpG rich sequences.
Following fertilisation, the methylation status of the ICR is maintained (even
though there is global hypomethylation), and the genes associated with the ICR
if appropriate are de novo methylated by Dnmt3. The gene methylation is then
preserved through differentiation and proliferation by Dnmt1, resulting in
maternal or paternal specific expression of a gene (Kim et al., 2009; Wood and
Oakey, 2006).
Regulated promoter methylation in normal cells has also been shown to regulate
tissue specific silencing of genes. Methylation analysis from normal peripheral
blood leukocytes identified 258 genes that had CpG islands within their
promoters that were methylated, which corresponded to 4% of all gene
promoters assayed (Shen et al., 2007). The identified methylated genes could
broadly be characterised as being involved in intracellular membrane bound
organelle function, metal ion binding and signalosome function and were shown
to be hypomethylated in multiple cancer cell lines. Furthermore, expression of
the genes in the cell lines correlated with hypomethylation of the promoter
(either by 5-aza deoxycytidine treatment or Dnmt1 and 3b knockout) (Shen et
al., 2007). The promoter of the breast cancer tumour suppressor gene serpin is
unmethylated and expressed in normal epithelia, however is methylated and not
expressed in normal hematopoietic, liver, kidney and heart cells (Futscher et al.,
2002). MAGE1, a gene only expressed in testis and some melanomas, as well as
other multiple testis specific genes, are methylated in normal somatic cells,
meaning they are not expressed, but unmethylated specifically in the
testis/spermatozoa where they are expressed (Zendman et al., 2003; Strathdee
et al., 2004). The HOXA5 gene product is involved in differentiation of both
haematopoietic and epithelial cells, and is also a candidate tumour suppressor in
breast cancer. The HOXA5 promoter was methylated in mesenchymal cells, had
~50% methylation in haematopoietic cells and unmethylated in epithelial cells,
and this correlated with mRNA expression (Strathdee et al., 2007).
Methylation is therefore important for maintaining normal silencing of certain
genes. As previously described, aberrant methylation of gene promoters is also a
well characterised event in multiple cancers. It is therefore important to
understand how methylation of a gene or its promoter results in transcriptional
silencing of the gene.
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1.9.7 Promoter Methylation as a Cause of Transcriptional Silencing
The biochemical link between promoter methylation and transcriptional silencing
was first presented over 20 years ago. de Bustros et al confirmed the earlier
findings by Baylin et al of methylation of the 5 region of the calcitonin gene in
lung cancer, gastrointestinal tumour and teratocarcinoma cell lines (Baylin et al.,
1987; de et al., 1988). They used restriction enzymes to target recognition sites
within the 5 gene region and compared the restriction digests from cells that
were methylated to those that were unmethylated. They discovered that in
unmethylated cells, all restriction sites were accessible and so cleaved by the
enzymes, whereas in the methylated cells not all sites were accessible as
demonstrated by reduced DNA cleavage (Figure 1.13). This lead to the
conclusion that methylation could be linked to a closed chromatin structure, and
furthermore, could prevent transcription from this site (de et al., 1988). More
recently, methylated DNA has been shown using FRET to induce a more compact
and rigid nucleosome structure when compared to unmethylated DNA (Choy et
al., 2010).
Cytosine methylation can directly inhibit binding of transcription factors to their
consensus motifs. AP-2 is inhibited from binding within the human proenkephalin
gene promoter (Comb and Goodman, 1990) and E2F from binding to the
enhancer of the adenoviral E1A gene (Kovesdi et al., 1987), thus directly
inhibiting transcriptional activation. However some transcription factors are
unaffected by methylation, for example Sp1 (Harrington et al., 1988), and as
such, direct inhibition of transcription factor binding is unlikely to be the major
reason for transcriptional silencing.
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Figure 1.13: DNase activity is inhibited by methylation. The calcitonin gene
promoter was observed to become hypomethylated in a subset of lung carcinomas (de et
al., 1988). Restriction digest of this region in cells with an unmethylated promoter
resulted in extensive digestion of the DNA. However, in cells where the promoter was
methylated, the amount of digestion was significantly reduced, which was hypothesised to
be due to a closed chromatin structure inhibiting DNA accessibility.
Other mechanisms of silencing were uncovered by the use of in vitro methylated
DNA. An in vitro methylated Herpes simplex virus-thymidine kinase transfected
into cells was expressed at the same rate as the unmethylated control DNA 48
hours post transfection. Levels of transcription did not decrease in the in vitro
methylated cells until after 100 hours (Buschhausen et al., 1985), suggesting
that whilst some transcription factors may be inhibited from binding by
methylation, it is more likely methylation causes an indirect mechanism of
silencing.
In 1989, a specific methyl CpG binding protein (MBD) was identified as a 120kDa
protein that bound to a synthetic cluster of methylated CpGs (Meehan et al.,
1989) and named MeCP2, giving the first indication that recruitment of proteins
specifically to methylated DNA could cause indirect alterations to silence
transcription (Wakefield et al., 1999). Further studies that identified MeCP2 could
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recruit the transcriptional repressor Sin3A and histone deacetylases to
methylated DNA, implicated a mechanistic connection between DNA methylation
and chromatin remodelling/gene silencing (Jones et al., 1998).
1.9.8 Methyl CpG Binding Domain Proteins
To date, there are 5 characterised mammalian methyl CpG binding domain
proteins; MeCP2, MBD1, MBD2, MBD3 and MBD4.
MeCP2 contains a MBD that interacts with symmetrically methylated CpGs in the
major groove of DNA (Wakefield et al., 1999) and forms a complex with the
histone deacetylases HDAC1 and 2 containing transcriptional repressor complex
mSin3A, (Nan et al., 1998; Jones et al., 1998). It also forms a complex with the
transcriptional co-repressors c-Ski and NCoR (Kokura et al., 2001) and has more
recently also been shown to cause methylation of H3K9 (Fuks et al., 2003).
MBD1, and its 5 isoforms, are able to repress transcription from both methylated
and unmethylated promoters through recruitment of the H3K9 methylases
Suv39h1 and SETDB1 as well as HDAC1 and 2, facilitating the formation of
heterochromatin (Fujita et al., 2003; Fujita et al., 2000). siRNA mediated
depletion of MBD1 causes a loss of H3K9 methylation and expression of the
normally silenced p53BP2 gene in HeLa cells (Sarraf and Stancheva, 2004).
MBD2 is part of the MeCP1 transcriptional repressor complex, associating with
HDAC1 and 2 (Ng et al., 1999), and is able to anchor the Mi2/NuRD
(Nucleosome Remodelling and Deacetylase) complex to methylated DNA (Zhang
et al., 1999). MBD2 knockdown in cancer cell lines reduces their ability for
anchorage independent growth, the ability to implant in vivo in nude mice and
knockdown of MBD2 within already implanted A549 HCT116 tumours reduced
their in vivo growth and tumourogenicity. On the converse MBD2 protein had no
effect on the growth of anchorage dependent normal or tumour cells (Campbell
et al., 2004).
MBD3 does not bind to methylated CpGs in vivo, however it is a component of
the NuRD complex, where it binds directly to HDAC1 and MTA2 to facilitate
formation of heterochromatin (Saito and Ishikawa, 2002).
MBD4 possesses a different function from the other MBD proteins; it binds to
mCpG:TpG mismatches and excises the mis-matched thymine (or uracil) and
initiates DNA repair through interaction with the mismatch repair protein MLH1
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(Hendrich et al., 1999). Mbd4-/- mice show a significant increase in C to T
mutations and a three-fold increase in CG to TA transitions (Millar et al., 2002).
MBD4 has also been shown to form a complex with mSin3A and HDAC1 and
repress reporter driven transcription in vivo and to associate with the p16INK4a
and hMLH1 gene promoters in a methylation specific manner (Kondo et al.,
2005).
The importance of gene structure and epigenetic modifications has been shown
to be critical for accessibility of RNA polymerase to gene promoter elements. For
example in cancers, when aberrant epigenetic modifications such as CpG Island
hypermethylation occurs, this promotes the association of MBD proteins and
chromatin remodelling factors that cause a heterochromatic structure and inhibit
transcription, ultimately causing silencing of the gene. It is this specific aspect of
gene expression that will first be addressed regarding LIMD1 biology.
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1.10 Preliminary Data
1.10.1The LIMD1 Promoter contains a Putative CpG Island
The LIMD1 promoter region encompassing 2039bp relative to the LIMD1 ATG
translation initiation codon had previously been cloned into a pGL4.10 vector
(WT-P). This allowed for activity of the LIMD1 promoter to be assayed indirectly
through transcription and translation of a downstream luciferase gene (Sharp et
al., 2008). Furthermore, a putative CpG Island had been identified, and 3 large
GHOHWLRQ PXWDQWV FUHDWHG Ʃ3 ZKLFK UHPRYHG ES IURP WKH ¶ HQG RI WKH
SURPRWHUƩ3ZKLFKUHPRYHGDQH[WUDESOHDYLQJQRSURPRWHUVHTXHQFH¶
WR WKH &S* ,VODQG DQG Ʃ3 ZKLFK UHPRYHG DOO RI WKH SUHGLFWHG &S* ,VODQG
Initial experiments in the A549, MB435 and U2OS cell lines revealed that the
putative CpG Island was necessary for transcriptional activation from the
promoter (Figure 1.14). The methylation status of the CpG Island in normal or
cancer cells could therefore be a mechanism to control LIMD1 gene expression.
Figure 1.14: The LIMD1 Promoter contains a putative CpG Island that is critical
for LIMD1 promoter driven transcription. The LIMD1 promoter encompassing ~2kb 5
proximal to the ATG initiation codon was cloned into a pGL4.10 vector (WT-P), along with
 ODUJH SURPRWHU WUXQFDWLRQ GHOHWLRQV Ʃ3 Ʃ3 DQG Ʃ3 7KH SURPRWHU SODVPLGV
were co-transfected with a pGL3 renilla plasmid for normalisation into the indicated cell
lines and resultant luciferase activity assayed. The putative CpG Island is critical for
WUDQVFULSWLRQDVGHOHWLRQRILWƩ3DEODWHGWUDQVFULSWLRQDODFWLYLW\6KDUSHWDO
LIMD1 Promoter
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To promote transcription from genes, i.e. enhance RNA polymerase binding, the
association of transcription factors to a gene promoter can facilitate the binding
of the general transcription factor machinery/RNA pol II. Some transcription
factors also contain histone acetyl transferase activity to acetylate histone tails
and promote a euchromatin structure. Therefore, loss or deregulation of a
transcription factor can affect the basal expression of genes under its control,
which if a tumour suppressor, can have detrimental consequences for the cell.
The second results chapter discusses how the Ets family of transcription factors
may control LIMD1 expression and thus biology. Therefore this family of proteins
will next be discussed.
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1.11 Ets Family of Transcription Factors
The Ets family of proteins is one of the largest families of transcription factors
characterised to date. The first member of the Ets family of transcription factors,
v-ets, was identified in 1983 in the E26 avian transforming retrovirus, a
retrovirus that causes avian leukaemias (Leprince et al., 1983). This gave rise to
the name Ets; the E26 transformation specific family and to date 28 human Ets
family members have been identified (Hsu et al., 2004) (Figure 1.15).
1.11.1 The Ets Domain
The common feature of the family is the Ets domain, which is an evolutionary
conserved sequence of 80-85 amino acids forming a DNA binding domain that
binds the core consensus sequence GGAA. Initially identified as a winged helix-
WXUQKHOL[ VWUXFWXUDO VWXGLHVRQ(WV38*$%3Į6$3DQG(ON UHYHDOHG
WKHGRPDLQLVPRUHVSHFLILFDOO\FRPSULVHGRIĮKHOLFHVDQGǃVKHHWVWUDQGV
'1$ELQGLQJ VSHFLILFLW\ LV FRQWUROOHG E\ WKH WKLUG ĮKHOL[ WKHZLQJ EHWZHHQ ǃ
VWUDQGVDQGDQGWKHORRSEHWZHHQĮKHOLFHVDQG6KDUURFNV7KH
flanking Ets domain amino acids and the flanking DNA base pairs around the
core consensus confer specificity and affinity of binding for a particular family
member, with as little as one amino acid conferring specificity of one Ets protein
over another (Verger and Duterque-Coquillaud, 2002).
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Figure 1.15: Schematic diagram of the general structures of the Ets transcription
factor subfamilies. As well as harbouring an Ets domain the Ets family can be
subdivided into smaller groups based on their structures. AD activation domain; HLH helix
loop helix; ID auto-inhibitory domain; RD repression domain. Adapted from (Oikawa and
Yamada, 2003).
The Ets family targets over two hundred genes including those involved in
apoptosis, differentiation, development, angiogenesis and transformation;
H[DPSOHV LQFOXGH S (WV  DQG  1)ǉ% (WV  F\FOLQ ' (WV  5E
*$%3 ,/  (WV  DQG  38 DQG 71)Į (ON 6HPHQWFKHQNR DQG
Watson, 2000). Whereas some family members are ubiquitously expressed (e.g.
(WV *$%3Į 7(/ DQG 7&) VXEIDPLO\ RWKHUV KDYH WLVVXH VSHFLILF GLVWULEXWLRQ
Ets-1 in the brain, lymphoids, and vascular endothelial cells, PEA3/E1AF in
epidermis and mammary glands, Elf-1 in liver, kidney and intestines, Elf-5 in
lung epithelia, Elf-1 in hematopoietic cells, ESE-1 in epithelial cells and PU.1 in
macrophages, neutrophils and B cells (Oikawa and Yamada, 2003).
The majority of Ets proteins are associated with transcriptional activation,
however a few including YAN, ERF, NET, PU.1 and TEL have been shown to
exhibit negative effects upon gene transcription (Mavrothalassitis and Ghysdael,
2000). One mechanism of transcriptional repression is the recruitment of HDACs.
Activation of ERK MAP kinase causes an association of Elk-1 with the mSin3A-
HDAC1 co-repressor complex, resulting in histone deacetylation and gene
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silencing (Yang et al., 2001). TEL also recruits the mSin3A complex, as well as
harbouring gene repressor properties independent of characterised co-repressors
(Chakrabarti and Nucifora, 1999).
1.11.2 PU.1 (Spi1)
Spi-1 (SFFV proviral integration protein) was initially identified in 1988 as a
putative oncogene in murine erythroleukemias that were induced by the
retroviral spleen focus forming virus (SFFV), with its mRNA found in 95% of the
examined erythroid tumours (Moreau-Gachelin et al., 1988). Spi-1 was cloned in
1990, and renamed PU.1, so called due to its binding to a purine rich sequence,
5-GAGGAA-3 that was present in the promoter of the MHC class II gene
following screening with a cDNA library (Klemsz et al., 1990). PU.1 exhibits high
homology with other Ets family members and is most closely related overall to
Spi-B and Spi-C (Kastner and Chan, 2008).
PU.1 contains four distinct protein domains; an acidic domain, a Gln rich domain,
a PEST (proline, glutamic acid, serine and threonine rich) domain and an Ets
domain (Nishiyama et al., 2004; Lloberas et al., 1999) (Figure 1.16). The acidic
and Gln regions are required for transactivation of genes, through mediation with
PU.1 interacting proteins including the general transcription factors TFIID/TBP
and the transcriptional co-activators p300/CBP (Klemsz and Maki, 1996). The
PEST domain interacts with interferon regulatory proteins, including PU.1
interacting partner (PIP), to mediate transcription of interferons in order to
activate the immune defence (Tenen, 2003).
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Figure 1.16: Schematic diagram of PU.1 and its interacting partners. The Ets
transcription family member PU.1 contains an N terminal acidic, glutamine rich and PEST
domain and a C terminal Ets domain. PU.1 interacts with other transcription associated
proteins including the co-activator p300/CBP and the basal transcription factors
TFIID/TBP.
To date the most studied and major role of PU.1 is as a critical regulator of
haematopoiesis, which is the differentiation of pluripotent haematopoietic stem
cells (HSCs) into all the cell lineages that are found in the blood; these include
B/T lymphocytes, erythrocytes, megakaryocytes, basophils, monocytes,
neutrophils and macrophages (Figure 1.17). In HSC, a high concentration of
PU.1 induces commitment to the myeloid lineage, whereas lower concentrations
cause lymphoid lineage commitment (Gallant and Gilkeson, 2006). PU.1 is not
required for all lineage commitments however, as even though PU1-/- embryos
have a significantly reduced number of multipotent myeloid and lymphoid
progenitors, megakaryocytes and erythrocytes can still mature (Scott et al.,
1997).
acidic Gln PEST ETS
DNA Runx-1
c-Jun
GATA1/2
AML-1
c-Myb
IRF4/8
PIP
P300/CBPRb
TFIID
TBP
GATA1/2
Ser41 Ser142 Ser148
phosphorylation
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Figure 1.17: Schematic overview of haematopoiesis. Pluripotent haematopoietic
stem cells (HSC) give rise to lymphoid and myeloid progenitors. Lymphoid progenitors
subsequently give rise to T and B cells. Myeloid progenitors differentiate into colony
forming cells, which in turn produce mature eosinophils, basophils, neutrophils,
monocytes, platelets and red blood cells. LTC-IC, long term culture initiating cells; CFC,
colony forming cell. Adapted from (Corey et al., 2007).
Phosphorylation of PU.1 modulates its protein and DNA binding activity.
Hematopoietic progenitor cells contain levels of PU.1 that are both hypo and
hyper phosphorylated, and the equilibrium of phosphorylation changes following
external stimulation (Gross et al., 2006). For example, activation of Protein
.LQDVH&GHOWD 3.&į FDXVHVSKRVSKRU\ODWLRQRI WKH WUDQVDFWLYDWLRQGRPDLQRI
PU.1 to promote its transcriptional activation capacity, but does not affect its
DNA binding ability, facilitating the differentiation of HSCs into dendritic cells
(Hamdorf et al., 2011). There is also evidence showing phosphorylation of PU.1
E\3.&įFDQVWLPXODWH'1$ELQGLQJDQGLVFRUUHODWHGZLWKLQKLELWLRQRIOHXNHPLF
cell growth (Carey et al., 1996). Furthermore, phosphorylation of ser148 within
PU.1 is required for binding to the nuclear factor NF-EM5 and transcriptional
activation of the immunoglobulin K 3' enhancer (Pongubala et al., 1993) as well
as interaction with PU.1 interaction partner (PIP) (Eisenbeis et al., 1995).
Phosphorylation of ser41 by AKT kinase affects PU.1 transcriptional activity and
B cell proliferation (Gross et al., 2006).
HSC
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1.11.2.1 Pathogenic Role of PU.1
PU.1 deregulation is associated with 2 major hematopoietic associated diseases;
Friends erythroleukaemia and acute myeloid leukaemia.
(i) Friends Erythroleukaemia
PU.1 was initially identified as the over expressed oncogene that was targeted by
the SFFV in murine Friends erythroleukaemias (Moreau-Gachelin et al., 1988).
Transgenic mice that over-expressed PU.1 developed normally, with no mortality
observed until 6 weeks after birth, where 50% of mice developed multi-step
erythroleukaemia, facilitated by an increase in pro-erythroblasts that were
unable to differentiate (Moreau-Gachelin et al., 1996). It has since been shown
that PU.1 expression blocks erythroblasts from differentiating (Dahl and Simon,
2003). PU.1 activation is required for growth of erythroleukaemic cells (Hegde et
al., 2009), and siRNA mediated depletion of PU.1 in erythroleukaemias abrogates
the PU.1 mediated block of differentiation and allows for terminal growth arrest
(Papetti and Skoultchi, 2007). As such PU.1 exhibits oncogenic properties in
erythroleukaemias.
(ii)Acute Myeloid Leukaemia
Conditional deletion of PU.1 in adult mice causes fatal myeloid leukaemia
(Metcalf et al., 2006). Acute myeloid leukaemia is the most common leukaemia
in adults and is characterised by increased levels of undifferentially arrested
granulocyte and monocytes precursors in the blood and bone marrow. PU.1 acts
as a tumour suppressor in myeloid cells, which is opposite to its oncogenic
properties in erythroleukaemias, with multiple studies identifying reduced PU.1
levels associated with leukemogenesis (Mueller et al., 2002; Cook et al., 2004).
As little as a 20% reduction in PU.1 expression results in an increase in pre-
leukemic haematopoietic cell number (Stirewalt, 2004).
In mice, deletion of an upstream regulatory element in the PU.1 promoter
reduces PU.1 protein expression by 80%; up to 2 months in age these mice were
the same size and had the same behaviour as the control mice, but by 8 months
of age 98% of mice had died from a disease akin to human myeloid leukaemia,
all exhibiting enlarged spleens and livers (Rosenbauer et al., 2004). Using Cre-
recombinase, deletion of the PU.1 Ets domain again resulted in mice with
enlarged spleens and high populations of undifferentiated granulocytes that died
of myeloid leukaemia, demonstrating the DNA binding ability of PU.1 is critical
for its function (Metcalf et al., 2006).
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PU.1 is essential for myeloid differentiation; when PU.1 mediated
differentiation/maturation of myeloid precursors is inhibited or blocked this gives
rise to development of leukaemia (Dahl and Simon, 2003). Unsurprisingly,
mutations that effected PU.1 DNA binding, transactivation or protein-protein
binding have been identified in patients suffering from AML (Mueller et al.,
2002).
In the final chapter of results, focus switches from silencing and major
transcriptional activation of LIMD1 to its enhanced expression and concurrent
role in hypoxia. Therefore the identification and concepts of the cellular response
to hypoxia will now be introduced.
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1.12 Hypoxia
1.12.1Identification of the HIF1 Transcription Factor
Using squamous lung carcinomas as an initial study, Thomlinson and Gray
identified that tumours contained a core of necrotic cells surrounded by viable
tumour cells. Furthermore, the necrotic core appeared to correlate with the
distance oxygen was able to diffuse through a solid tumour and distance it was
from the oxygen containing stroma (Thomlinson and Gray, 1955). This
suggested that the necrotic core was the result of anoxia (no oxygen). Otto
Warburg then observed that cancer cells, irrespective of oxygen availability, had
a high rate of anaerobic glycolyis and lactic acid fermentation rather than aerobic
respiration (mitochondrial pyruvate oxidation), and postulated this aberrant
change in metabolism to be an underlying cause of cancer- the Warburg effect
(Warburg, 1956).
From these initial observations of tumours exhibiting areas of hypoxia (low
oxygen tensions/concentrations) and respiring anaerobically, further
investigations identified a global decrease in protein synthesis under conditions
of hypoxia, except for a few proteins whose intensity on a stained SDS-PAGE gel
increased following hypoxic/anoxic exposure. Two of these uncharacterised
proteins were positively identified with molecular weights of 76 and 97kDa
(Sciandra et al., 1984). Levels of specific mRNAs including erythropoietin and
glycolysis related enzymes were also observed to be increased following hypoxic
conditions (Webster, 1987; Schuster et al., 1989).
Further investigations on the Epo gene using Dnase foot printing, reporter and
EMSA analysis revealed there was a 50bp hypoxic responsive enhancer 3 to the
poly-adenylation signal, and this bound to both constitutively expressed proteins
as well as a protein that only bound following hypoxic exposure (1% O2)
(Semenza et al., 1991; Semenza and Wang, 1992). This protein was given the
name hypoxia inducible factor 1, HIF-1 (Semenza and Wang, 1992) and was
subsequently found to be active in a variety of cells (Wang and Semenza, 1993c;
Wang and Semenza, 1993b). HIF-1 levels were shown to peak at 4 hours
following hypoxic exposure and remain stable until after 16 hours; however 5
minutes in 20% oxygen following 4 hours hypoxia reduced HIF-1 levels by 66%
(Wang and Semenza, 1993a). HIF-1 was able to be induced through either
cobalt ions or the iron chelator desferroxamine (Wang and Semenza, 1993b). In
this same study HIF-1 DNA binding activity and induction of Epo RNA was
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ablated by either treatment with the protein kinase inhibitor 2-aminopurine or
calf intestinal alkaline phosphatase (Wang and Semenza, 1993a).
Using DEAE ion exchange and DNA affinity chromatography, HIF1 was purified
DQG LGHQWLILHGDVEHLQJFRPSRVHGRIVXEXQLWVDN'D+,)ĮDQGDN'D
+,)ǃ DOVR UHIHUUHG WR DV $517 VXEXQLW :DQJ DQG 6HPHQ]D 
6FUXWLQLVDWLRQRI DYDLODEOH VHTXHQFHGJHQRPHV UHYHDOHGERWK+,)Į DQG+,)ǃ
contained regions homologous to those found in the Drosophila proteins Per and
Sim, as well as the mammalian aryl hydrocarbon receptor, AHR. This domain as
such was called a PAS domain; Per, AHR and Sim (Wang et al., 1995a). They
were also found to contain a basic helix loop helix (bHLH) domain and so as such
DUH UHIHUUHG WR DV E+/+3$6 SURWHLQV :DQJ HW DO D +,)Į DQG ǃ
heterodimerise both in vivo and in vitro in both in the presence or absence of
DNA (Jiang et al., 1996).
'HSOHWLRQRI+,)ĮLQHPEU\RQLFVWHPFHOOVUHVXOWHGLQWKHUHGXFHGH[SUHVVLRQRI
PDQ\JO\FRO\WLFSDWKZD\HQ]\PHVLQK\SR[LDDQGIXUWKHUPRUH+,)Į-/- ES cells
SUROLIHUDWHPXFKVORZHULQK\SR[LDWKDQ+,)Į+/+ ES cells but have no difference
in normoxia (20% O2/atmospheric O2WHQVLRQ,\HUHWDO+,)Į-/- mice
are also not viable, and even though non-hypoxic ES cells have constitutively
KLJK OHYHOV RI +,)Į GHSOHWLRQ RI +,)Į GRHV QRW DIIHFW SUHLPSODQWDWLRQ
development (Iyer et al., 1998).
7ZRRWKHUSURWHLQVKRPRORJRXVWR+,)ĮZHUHDOVRLGHQWLILHG+,)ĮDOVRFDOOHG
endothelial PAS protein 1, EPAS1; +,)ĮOLNH IDFWRU +/) HIF-related factor,
+5) LV  KRPRORJRXV WR +,)Į DQG DOVR GLPHULVHV ZLWK +,)ǃ ZKHUH LW
activates transcription from hypoxic response elements (HREs) within gene
SURPRWHUV 2
5RXUNH HW DO  7LDQ HW DO  +,)Į DOVR FDOOHG
LQKLELWRU\3$6GRPDLQSURWHLQ ,3$6XQOLNH+,)DQGĮ LPSDLUV LQGXFWLRQRI
hypoxic inducible genes (acting in a dominant negative fashion when co-
H[SUHVVHG ZLWK +,)Į ,W ELQGV +,)Į UHGXFLQJ LWV '1$+5( ELQGLQJ DELOLW\
0DNLQR HW DO  +,)Į DQG LWV VSOLFH YDULDQWV GRHVQ¶W FRQWDLQ D &
terminal activation domain and as such is unable to function as an effective
WUDQVFULSWLRQDODFWLYDWRU)LJXUH)XUWKHUPRUH+,)ĮFRQWDLQVD+5(ZLWKLQ
its promoter that causes an increase in mRNA and protein levels in hypoxia in a
+,)Į GHSHQGHQW PDQQHU LPSOLFDWLQJ LW DV D QHJDWLYH UHJXODWRU RI K\SR[LD
(Makino et al., 2007; Pasanen et al., 2010).
+,)ĮDQG+,)ǃP51$DUHFRQVWLWXWLYHO\H[SUHVVHGLQDZLGHYDULHW\RIKXPDQ
tissues, with transcription of both remaining constant regardless of oxygen
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tension (Huang et al., 1996; Gradin et al., 1996). However, in hypoxia, the
OHYHOVRI+,)ĮSURWHLQVLJQLILFDQWO\LQFUHDVHZKLOVWWKHOHYHORI+,)ǃGRHVQRW
change and this will be further elaborated upon in Section 1.12.3.
Figure 1.18: 6FKHPDWLFGLDJUDPRIWKHKRPRORJRXV+,)DQGĮSURWHLQV. The
+,)Į SURWHLQV DOO VKDUH KLJK KRPRORJ\ ZLWK FRQVHUYHG IXQFWLRQDO GRPDLQV LOOXVWUDWHG
2[\JHQGHSHQGHQWK\GUR[\ODWLRQVLWHVRQ+,)DQGĮDUHDOVRLOOXVWUDWHG7KHIXQFWLRQDO
domains include a basic helix-loop-helix (bHLH) that mediate DNA binding; two Per/Ahr-
$5176LP 3$6 GRPDLQV WR PHGLDWH LQWHUDFWLRQ ZLWK +,)ǃ RQH R[\JHQ GHSHQGHQW
degradation (ODD) domain that encompasses residues required for oxygen dependent
hydroxylation and degradation; N-terminal and C-terminal transactivation domains
(NTAD/CTAD) that facilitate interaction with the p300/CBP transcriptional co-activator and
a nuclear localisation signal (NLS). Hydroxylation of the ODD localised prolines is
facilitated by proline hydroxylase proteins (PHDs), whereas asparagine hydroxylation is
facilitated by factor inhibiting HIF (FIH). Adapted from (Gaber et al., 2005).
1.12.2 HIF1 Allows for Cellular Adaptation to Low Oxygen Tensions
HIF1 allows for cellular survival under low oxygen tensions, through the
transcription of multiple genes that stimulate the activation of different
pathways. With low oxygen tensions, aerobic respiration is unable to effectively
proceed and a switch to glycolysis is observed; this was initially observed by
Warburg (Warburg, 1956). Therefore enzymes involved in the anaerobic
glycolytic pathway are increased, for example glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) (Graven et al., 1999). In association with glycolytic
enzymes, enzymes that increase the availability of glucose for respiration are
also upregulated, this includes for example the glucose transporters 1 and 3
(Iyer et al., 1998; Semenza, 1999; Zagorska and Dulak, 2004) (Figure 1.19). In
order to try and re-establish the oxygen supply, proteins involved in
angiogenesis and red blood cell production/maturation are also increased; this
includes the growth factor VEGF, which stimulates vasculogenesis and
angiogenesis (Forsythe et al., 1996) and the hormone erythropoietin (EPO) that
+,)Į
+,)Į
+,)Į
Chapter 1: Introduction
61
stimulates maturation of erythrocyte precursors into mature red blood cells
(Semenza and Wang, 1992).
Most of the genes up-regulated by HIF1 appear to be adaptive in nature,
KRZHYHU +,)Į FDQ DOVR LQGXFH DSRSWRVLV ,Q K\SR[LD WKH ODFN RI R[\JHQ
inhibits the electron transport chain, causing a decrease in mitochondrial
membrane potential, hyperpermeability of the inner mitochondrial membrane
and cytochrome C release, which initiates the cascade leading to apoptosis
*UHLMHUDQGYDQGHU:DOO,QDGGLWLRQK\SR[LDFDXVHVD+,)ĮGHSHQGHQW
up-regulation in the expression of some pro-apoptotic tumour suppressors,
including WT1 and BNIP3 (Wagner et al., 2003; Guo et al., 2001).
In what seems a counter-intuitive manner, hypoxia also induces expression of
inhibitor of apoptosis protein 2 (IAP-2), which inhibits apoptosis (Dong et al.,
2001). Furthermore, in the human tongue squamous cell carcinoma cell lines
6&& DQG  GHSOHWLRQ RI +,)Į UHVXOWHG LQ LQKLELWLRQ RI FHOO SUROLIHUDWLRQ DQG
induction of apoptosis (Zhang et al., 2004b). HIF-1 therefore appears to exert
both pro- and anti- apoptotic functions. The equilibrium that exists between
hypoxia induced pro-apoptotic and adaptive responses is not fully understood;
IRUH[DPSOHPDQ\FDQFHUFHOOVWKDWH[SUHVVKLJKOHYHOVRI+,)ĮKDYHEHHQIRXQG
to be resistant to hypoxia induced apoptosis, and so further investigations are
therefore required to elucidate and distinguish HIF1 pro- and anti-apoptotic
functions (Greijer and van der Wall, 2004).
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Figure 1.19: Transcriptional targets of HIF1. Multiple genes belonging to many
different pathways are upregulated by HIF1 in order to allow for adaptation to low oxygen
tensions. Unsurprisingly a lot of these genes are found upregulated in solid malignancies.
These genes involved include VEGF and PDGF which are involved in angiogenesis; Epo
and transferring which are crucial for red blood cell production/maturation; lactate
dehydrogenase and glucose transporters 1 and 3 that increase the uptake of glucose and
anaerobic respiration (glycolysis); insulin-like growth factor and WT1 that are involved in
cell proliferation and apoptosis respectively. Adapted from (Zagorska and Dulak, 2004).
1.12.35HJXODWLRQRI+,)Į3URWHLQ'HJUDGDWLRQ
The HIF1 transcription factor is only active under hypoxic conditions;
deregulated activation under normoxic conditions could lead to inappropriate
proliferation of cells coupled with expression of genes that would promote
anaerobic glycolytic respiration rather than the more efficient aerobic respiration.
7KH GLVFRYHU\ RI UHJXODWLRQ RI +,)Į SURWHLQ ZDV DFFRPSOLVKHG WKURXJK
REVHUYDWLRQV RI FKDQJHV LQ +,)Į SURWHLQ OHYHOV IROORZLQJ WUHDWPHQW ZLWK
inhibitors of translation or redox reagents. Inhibition of translation by
cyclohexamide following 2 hours hypoxic incubation did not cause a change in
OHYHOVRI+,)ĮGHPRQVWUDWLQJWKDWWKHK\SR[LFLQFUHDVHLQ+,)ĮZDVQRWGXHWR
an increase in translation rates (Huang et al., 1996). However, incubation of
cells with the redox reagent H2O2 SUHYHQWHG +,)Į SURWHLQ DFFXPXODWLRQ DQG
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'1$ ELQGLQJ ZLWKRXW HIIHFWLQJ +,)Į P51$ OHYHOV RU WUDQVODWLRQ RU +,)ǃ
SURWHLQ RU P51$ VXJJHVWLQJ WKDW UHJXODWLRQ RI +,)Į ZDV GXH WR D UHGR[
reaction targeted against the protein itself (Huang et al., 1996). Similar
observations were also detected with the redox reagents N-ethylmaleimide,
diamide and DTT (Huang et al., 1996; Wang et al., 1995b).
Specific inhibition of the ubiquitin 26S proteasome with lactocystin or MG132,
EXWQRWRIRWKHUFHOOXODUSURWHDVHVSUHYHQWHGGHJUDGDWLRQRI+,)ĮLQQRUPR[LD
following hypoxic exposure (Salceda and Caro, 1997). This gave the first
LQGLFDWLRQ WKDW +,)Į ZDV UHJXODWHG E\ XELTXLWLQDWLRQ DQG 6 SURWHDVRPDO
GHJUDGDWLRQ &RPSDULVRQ RI WKH KXPDQ +,)Į PRXVH +,)Į DQG KLJKO\
homologous Drosophila Sim protein revealed a highly conserved 15 amino acid
VHTXHQFH FRUUHVSRQGLQJ WRDPLQRDFLGVRIKXPDQ+,)Į:KHQ WKLV
sequence alone was expressed in cells, it exhibited the same normoxic/hypoxic
regulation as the full length protein and as such was named the oxygen
dependent degradation (ODD) domain (Huang et al., 1998; Srinivas et al.,
1999).
1.12.4 The von Hippel-Lindau (VHL) Protein
von Hippel-Lindau (VHL) disease is a hereditary human cancer syndrome that
predisposes sufferers to highly angiogenic tumours, particularly of the kidney or
blood vessels (haemangioblastomas). In these cancers, or in VHL deficient renal
cell carcinoma cell lines (RCC4 and 786-0 cells), constitutive high expression of
genes that contain HRE elements including VEGF and GLUT1 is observed, and
this expression was down-regulated following re-expression of functional VHL
(Maxwell et al., 1999). These findings indicated a possible role that VHL may
KDYHLQUHJXODWLRQRI+,)Į9+/ZDVVXEVHTXHQWO\IRXQGWRELQGWR+,)ĮDQG
LWV H[SUHVVLRQ WR GHFUHDVH +,)Į SURWHLQ OHYHOV ZLWKRXW DIIHFWLQJ LWV P51$
expression. Furthermore, in VHL negative cell lines (that have constitutively high
+,)Į SURWHLQ OHYHOV QRUPR[LF +,)Į UHJXODWLRQ ZDV UHVWRUHG IROORZLQJ
functional VHL expression (Maxwell et al., 1999).
9+/ LVFRPSRVHGRIDQĮDQGǃGRPDLQ WKHĮGRPDLQ LVDEOH WRELQGFXOOLQ
elonginB/C and Rbx, This complex of proteins is collectively known as the VBC
FRPSOH[ZKLFKLVDIXQFWLRQDO(OLJDVH7KHǃGRPDLQLVUHVSRQVLEOHIRUELQGLQJ
WRWKH2''GRPDLQRI+,)ĮDQGVSHFLILFDOO\FDXVHVLWVXELTXLWLQDWLRQOHDGLQJWR
subsequent 26S proteasomal degradation (Stebbins et al., 1999; Ohh et al.,
+RZHYHUWKH9%&FRPSOH[ZDVXQDEOHWRXELTXLW\ODWHUHFRPELQDQW+,)Į
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that was produced in E. Coli unless it was pre-incubated with mammalian cell
H[WUDFWVLQGLFDWLQJ9+/UHFRJQLVHGDPRGLILHG+,)Į,YDQHWDO
1.12.5 Proline Hydroxylase (PHD) Proteins
MALDI-TOF and substitution analysis of amino acids within the ODD domain of
+,)ĮVKRZHGWKDW9+/RQO\UHFRJQLVHG+,)ĮZKHQ3UROLQHVDQGZHUH
hydroxylated, however the identity of the endogenous hydroxylase was unknown
(Ivan et al., 2001; Jaakkola et al., 2001; Yu et al., 2001; Masson et al., 2001).
0XOWLSOH JURXSV FRPPRQO\ LGHQWLILHG +,)Į XELTXLW\ODWLRQGHJUDGDWLRQ DV EHLQJ
inhibited by 2-oxoglutarate analogues, iron chelators and hypoxia (Wang and
Semenza, 1993a; Goldberg et al., 1988; Wang and Semenza, 1993b; Epstein et
al., 2001). This implicated that proline hydroxylation could be facilitated by a
member of the 2-oxoglutarate-dependent-oxygenases, as this family is
dependent upon oxygen, iron and 2-oxoglutarate as cofactors.
Subsequent identification and cloning of C. elegans HIF-1 revealed it exhibited
the same regulatory properties as the human homologue. It was rapidly
degraded under normoxic conditions and stabilised in hypoxia with no change in
mRNA levels. Furthermore VHL-/- C.elegans had high HIF-1 levels in normoxia,
and in vitro transcribed and translated (IVTT) VHL and HIF-1 only interacted
following pre-incubation of HIF-1 with C.elegans lysate. This was found to be the
result of hydroxylation of Proline 621 within HIF-1 (Epstein et al., 2001).
Bioinformatic analysis of the C. elegans genome revealed a potential
hydroxylase, egl-9, that when depleted in mutant C. elegans resulted in a
significant increase in HIF-1 levels in normoxia.
Subsequent bioinformatic scrutinisation of the human genome identified 3 prolyl
hydroxylase domain (PHD) containing proteins 1, 2 and 3 that were homologous
to egl-97KHVHSURWHLQVZHUHDEOHWRK\GUR[\ODWH+,)ĮDQGLVWKHFULWLFDOILUVW
step required in order for VHL recognition. Furthermore, in agreement with
earlier studies, the PHD proteins were inhibited by cobalt ions, iron chelators and
2-oxoglutarate analogues (Epstein et al., 2001; Bruick and McKnight, 2001).
Further mutational mapping identified the proline residues 402 and 564 within
+,)ĮDVWKHWDUJHWVIRU3+'K\GUR[\ODWLRQFigure 1.18), with mutation of either
FDXVLQJDVWDELOLVDWLRQRI+,)ĮSURWHLQOHYHOV0DVVRQHWDO
The PHD proteins are therefore the major oxygen sensors within the cell. When
oxygen is abundant (20% O2, normoxia), the PHD proteins are active and
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Under hypoxic conditions, HIF-1 activates transcription by directly binding to the
p300/CBP transcriptional activator proteins (Arany et al., 1996; Ebert and Bunn,
1998). p300/CBP is able to induce transcriptional activation through both the
NAD and CAD. HIF-1 also binds in a hypoxia dependent manner to the
transcriptional activators SRC-1 and TIF-2 (Carrero et al., 2000). However, to
date this interaction has not been proven to be direct, and as such the p300/CBP
interaction has been the most studied. p300/CBP acts as a co-activator,
simultaneously binding HIF-1 and recruiting the general transcription factors to
enhance PIC formation on the promoter, ultimately enhancing the rate of
transcription. (Arany et al., 1996; Ebert and Bunn, 1998; Kallio et al., 1998).
,QDGGLWLRQ WR WKH LGHQWLILFDWLRQRI WKH3+'SURWHLQV WKDWK\GUR[\ODWH+,)Į LQ
2001 through a yeast 2 hybrid screen another protein, factor inhibiting HIF-1
),+ZDV LGHQWLILHGDVELQGLQJ WR WKH&$'ZLWKLQ+,)Į 0DKRQHW DO 
'HSOHWLRQRI),+LQGXFHV+,)ĮUHVSRQVLYHJHQHH[SUHVVLRQ6WRO]HHWDO
and through further studies, differential functions of the NAD and CAD have been
observed, as FIH depletion only effects transcriptional activation of the CAD
(Dayan et al., 2006).
FIH, like the PHDs is an oxygen and Fe2+ dependent hydroxylase (Lando et al.,
2002a). FIH hydroxylates asparagine 803 (which lies within the CAD) under
normoxic conditions and prevents HIFs association with the transcriptional co-
activators p300/CBP, meaning HIF is only transcriptionally active in hypoxia
(Hewitson et al., 2002; Lando et al., 2002b). The interaction between FIH and
+,)Į LV ODUJHO\ DEURJDWHG LQ K\SR[LD DQG LQ QRUPR[LD WKH LQWHUDFWLRQ LV
mediated by VHL (Li et al., 2011). It has been shown that VHL and FIH can bind
to histone deacetylases 1-3 (HDAC1-3) and this could possibly be a further
mechanism of transcriptional inactivation (Mahon et al., 2001).
PHD2 and FIH have different Km values with respect to oxygen, with the latter
still active at lower oxygen tensions than PHD2. It has therefore been proposed
WKDW WKLV FRXOG UHIOHFW GLIIHULQJ GHJUHHV RI +,)Į PHGLDWHG JHQH WUDQVFULSWLRQ
depending on the distance from the blood vessel. Cells that are in close physical
SUR[LPLW\ WR WKH EORRG VXSSO\ ZLOO KDYH LQDFWLYH +,)Į GXH WR KLJK R[\JHQ
tensions allowing for PHD2 and FIH to be active. As the distance from the blood
supply increases and oxygen tension decreases, PHD2 becomes inactivated,
OHDGLQJWRDQLQFUHDVHLQ+,)ĮSURWHLQOHYHOVKRZHYHUDV),+LVVWLOODFWLYHRQO\
the NAD is transcriptionally active. As the distance increases even further,
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approaching anoxic conditions, FIH is then inactivated, resulting in an active NAD
and CAD to fully adapt to the hypoxic environment (Dayan et al., 2006).
2[\JHQGHSHQGHQWGHJUDGDWLRQRI+,)ĮLVUHTXLUHGWRDYRLGQRUPR[LFDFWLYDWHG
+,) JHQH WUDQVFULSWLRQ ,QKLELWLRQ RI +,)Į GHJUDGDWLRQ LQ QRUPR[LD E\
VDWXUDWLQJWKH+,)ĮGHJUDGDWLRQSDWKZD\WKURXJKHFWRSLFRYHUH[SUHVVLRQRID
UHJLRQ RI +,)Į HQFRPSDVVLQJ WKH2''GRPDLQ RU WUHDWPHQW RI FHOOVZLWK WKH
PHD inhibitor DMOG or the 26S proteasome inhibitor MG132 all increased
HQGRJHQRXV QRUPR[LF +,)Į SURWHLQ OHYHOV QXFOHDU DFFXPXODWLRQ DQG +,)
driven transcription (Hagg and Wennstrom, 2005). Therefore, even in normoxia,
XQGHJUDGHG+,)ĮLVDFWLYHDQGFDSDEOHRILQLWLDWLQJDK\SR[LFUHVSRQVH
1.12.73KRVSKRU\ODWLRQRI+,)Į
%HIRUH WKHFORQLQJRU UHJXODWRU\SDWKZD\VRI+,)ĮKDGEHHQ LGHQWLILHG LWZDV
observed that HIF-1 DNA binding activity and induction of Epo RNA was ablated
by either treatment with the protein kinase inhibitor 2-aminopurine or calf
intestinal alkaline phosphatase (Wang and Semenza, 1993a). This evidence
indicated that HIF-1 was positively regulated by phosphorylation.
SDS-PAGE analysis of in vitro WUDQVFULEHG DQG WUDQVODWHG ,977 +,)Į DQG
O\VDWHVIURPGLIIHUHQWFXOWXUHGFHOOVLGHQWLILHGGLIIHUHQFHVLQ+,)ĮPRWLOLWLHVWKH
,977+,)ĮZDVRQHGLVFUHWHEDQGZKHUHDVWKHK\SR[LFH[WUDFWVUDQDVDGLIIXVH
pattern, with a molecular weight of up to 12kDa more (Richard et al., 1999).
Treatment of the hypoxic extracts with the general protein phosphatase lambda
phosphatase abrogated the diffuse pattern observed. Treatment of cells with
serine/threonine phosphatase inhibitor okadaic acid caused an increase in
PROHFXODUZHLJKWRI+,)Į
Observations of hypoxic phosphorylation of Elk-1 by mitogen activated protein
kinases (MAPKs) lead to the identification of the p42 and p44 MAPKs as
SKRVSKRU\ODWLQJ+,)ĮEXWQRW+,)ǃin vitro and in vivo. Furthermore, p42/44
MAPK activation enhanced HIF-1 transcriptional activity (Richard et al., 1999;
Berra et al., 2000). It has also been postulated that other kinases are crucial for
+,)Į DFWLYLW\ ,QKLELWLRQ RI WKH 0(.(5. SDWKZD\ GLG QRW DIIHFW +,)Į
stabilisation, but was crucial for HIF-1 transcriptional activities (Michiels et al.,
2001). The PI-3K/Akt pathway when inhibited also caused an inhibition of
hypoxic VEGF transcription (Minet et al., 2001). On a side note Akt is negatively
regulated by PTEN; glioblastoma cell lines that lack functional PTEN, or
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mutations within the catalytic domain of PTEN, all exhibit increased Akt activity,
and more relevant increased VEGF transcription even in normoxia (Minet et al.,
2001).
7KLV HYLGHQFH WKHUHIRUH VKRZV SKRVSKRU\ODWLRQ RI +,)Į LV FULWLFDO IRU LWV '1$
binding activity. The exact mechanisms and contributing factors are still unclear
ZLWKUHJDUGV WR+,)ĮSKRVSKRU\ODWLRQ7KH UHTXLUHPHQWRISKRVSKRU\ODWLRQ IRU
+,)Į WUDQVFULSWLRQDO DFWLYLW\ LV HYLGHQW EXW IXUWKHU VWXGLHV DUH UHTXLUHG WR
determine the responsible kinases and if the kinases are universal or cell type
specific.
1.12.86XPPDU\RI+,)Į5HJXODWLRQ
In 20% oxygen (normoxia), O2 dependent hydroxylation of two conserved
SUROLQH UHVLGXHV  DQG  E\ 3+'V ZLWKLQ WKH 2'' GRPDLQ RI +,)Į
allows for recognition by the VHL containing E3 ubiquitin ligase VBC complex,
VXEVHTXHQWO\ FDXVLQJ +,)Į XELTXLWLQDWLRQ DQG GHJUDGDWLRQ E\ WKH 6
proteasome. Furthermore, the oxygen dependent asparagine hydroxylase, FIH,
K\GUR[\ODWHV $VQ ZLWKLQ +,)Į SUHYHQWLQJ DVVRFLDWLRQ ZLWK S&%3 DQG
inhibiting the ability of HIF1 to activate transcription. Combined, these two
K\GUR[\ODVHGULYHQSDWKZD\VSUHYHQW+,)ĮDFWLYLW\ LQQRUPR[LF FRQGLWLRQV ,Q
hypoxia the very low rate limiting oxygen tension prevents PHD hydroxylation
DQG WKHUHIRUH D VWDELOLVDWLRQ RI +,)Į SURWHLQ 7KLV DOORZV IRU +,)Į
SKRVSKRU\ODWLRQ WUDQVORFDWLRQ WR WKH QXFOHXV DQG GLPHULVDWLRQ ZLWK +,)ǃ WR
form HIF1. HIF1 then binds to hypoxic responsive elements (HRE) within the
promoters of genes, and due to inactive FIH, associates with the transcriptional
co-activator p300/CBP to enhance their transcription (Figure 1.21).
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Figure 1.21: +,)Į LV UDSLGO\GHJUDGHGXQGHU KLJKR[\JHQ WHQVLRQV. Under high
oxygen tensions (20% O2 3UR  DQG  ZLWKLQ WKH 2'' GRPDLQ RI +,)Į DUH
hydroxylated by PHD2. PHD2 uses oxygen as a cofactor, and is the rate limiting variable
IRU 3+' DFWLYLW\ +\GUR[\ODWLRQ RI +,)Į DOORZV IRU UHFRJQLWLRQ E\ 9+/ ZKLFK LV D
component of the VBC E3 ubiquitin ligase complex. This leads to ubiquitination and
VXEVHTXHQW 6 PHGLDWHG GHJUDGDWLRQ RI +,)Į )XUWKHUPRUH XQGHU KLJK R[\JHQ
WHQVLRQV +,)Į LV DOVR K\GUR[\ODWHG E\ ),+ RQ $VQ  7KLV K\GUR[\ODWLRQ SUHYHQWV
association with the transcriptional co-activator p300/CBP complex, meaning any
XQGHJUDGHG+,)Į LQQRUPR[LD UHPDLQV LQDFWLYH8QGHU ORZR[\JHQ WHQVLRQV K\SR[LD
3+'DQG),+DUHLQDFWLYHDQGVR+,)ĮSURWHLQLVVWDELOLVHG7KLVDOORZVIRUVXEVHTXHQW
SKRVSKRU\ODWLRQ WUDQVORFDWLRQ LQWR WKHQXFOHXVDQGGLPHULVDWLRQZLWK+,)ǃWR IRUPWKH
active transcription factor HIF1. HIF1 then binds to hypoxic responsive elements HREs)
within selected genes that allow for adaptation to low oxygen conditions, recruits
p300/CBP, causing transcriptional activation of the HRE containing genes.
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1.12.95HJXODWLRQRI+,)ĮLQ+\SR[LD
,Q K\SR[LD VWDELOLVHG +,)Į SURWHLQ DOORZV IRU IRUPDWLRQ RI WKH +,)
transcription factor and subsequent enhanced transcription of HRE containing
JHQHV+RZHYHULIOHYHOVRI+,)ĮSURWHLQFRQWLQXHGWRLQFUHDVHLQK\SR[LDWKLV
would lead to an exponential increase in expression of genes that allow for
adaptation and cellular growth in low oxygen conditions, ultimately resulting in
uncontrolled cellular proliferation. Therefore, following an initial stabilisation of
+,)ĮLWLVFULWLFDOWKDWH[SUHVVLRQOHYHOVEHFRPHDWWHQXDWHG
)ROORZLQJDQ LQLWLDO LQFUHDVH LQ+,)ĮSURWHLQZLWKLQKRXUV RI K\SR[LD+,)Į
protein levels decrease following chronic hypoxic exposure (over 24 hours),
whilst, in a seemingly counter-intuitive manner, levels of PHD2 increase
(Ginouves et al., 2008). However, from recent studies it is now clear that in both
acute and chronically hypoxic cells there is PHD2 activity still present, acting to
degrade HIF1a (Chan et al., 2005; Stiehl et al., 2006; Ginouves et al., 2008).
Indeed the study by Stiehl et al demonstrated that siRNA targeted depletion of
PHD2 in hypoxia resulted in a significant increase of HIF1 protein levels, showing
PHD2 to be active in these conditions. This was a surprising observation given
that low oxygen tension was thought to render PHD2 inactive, as molecular
oxygen is the rate limiting Km for PHD2 activity (Stolze et al., 2004).
In vitro assays with recombinant PHD2 revealed that under hypoxic conditions,
VLJQLILFDQW 3+' PHGLDWHG K\GUR[\ODWLRQ RI +,)Į ZDV VWLOO REVHUYHG
Furthermore, increasing the amount of PHD2 protein under hypoxic conditions
compensated for the lower enzymatic activity (due to very low levels of O2 as a
FRIDFWRU DQG FRXOG UHVWRUH WKH DPRXQW RI +,)Į K\GUR[\ODWLRQ LQ K\SR[LD WR
levels observed in normoxia (Stiehl et al., 2006). This suggested that the in vivo
increase in PHD2 protein observed in hypoxia is a compensatory mechanism to
DOORZIRUK\SR[LFK\GUR[\ODWLRQDQGVXEVHTXHQWGHJUDGDWLRQRI+,)Į
PHD1, 2 and 3 mRNA are all up-regulated in both primary and cultured cell lines
(Marxsen et al., 2004; Aprelikova et al., 2004), observed after as little as 60
minutes hypoxic exposure, and remaining elevated even after 7 days hypoxia
(Stiehl et al., 2006; Ginouves et al., 2008). The up-regulation was dependent
XSRQ +,)Į DV HLWKHU VL51$ PHGLDWHG GHSOHWLRQ RI +,)Į RU +,)Į gene
knockout in MEF cells ablated the hypoxic upregulation of the PHDs (Stiehl et al.,
2006; Marxsen et al., 2004).
SAG (sensitive to apoptosis gene) belongs to the same family as Rbx1, a
component of the VHL containing VBC ubiquitin ligase complex. Under hypoxia,
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6$*P51$DQGSURWHLQDUHXSUHJXODWHGDJDLQ LQD+,)ĮGHSHQGHQWPDQQHU
Under hypoxic conditions SAG forms a complex with VHL and facilitates hypoxic
+,)ĮXELTXLWLQDWLRQDQGGHJUDGDWLRQ ,QDVLPLODUHIIHFW WR WKDW REVHUYHGZLWK
PHD2 depletion, siRNA mediated depletion of SAG resulted in a stabilisation of
+,)ĮSURWHLQOHYHOVLQERWKQRUPR[LDDQGK\SR[LD7DQHWDO
FIH protein levels are unaffected by either hypoxia or hypoxia mimics (e.g.
DMOG) (Stolze et al., 2004). Again, unexpectedly, FIH was observed to be active
DQGUHSUHVV+,)ĮPHGLDWHGJHQHH[SUHVVLRQLQR[\JHQWHQVLRQVDVORZDV
Furthermore, at this lower oxygen tension, in a concurrent experiment, PHD2
was totally inactive (Stolze et al., 2004). siRNA mediated depletion of FIH
resulted in an up-regulation of PHD2 and 3, presumable through relief of Asn
802 hydroxylation (Stolze et al., 2004). These proteins are upregulated in
K\SR[LD LQ D +,)Į GHSHQGHQW PDQQHU 6WLHKO HW DO  DQG DV VXFK ),+
FRXOGEHYLHZHGDVDIXUWKHUK\SR[LFUHJXODWRURIERWK3+'VDQG+,)Į
Therefore, a hypoxic negative feedback loop appears to exist to regulate the
H[SUHVVLRQRI+,)ĮDQGH[SODLQ WKHREVHUYHGGHFUHDVH LQ+,)ĮSURWHLQ OHYHOV
following prolonged (chronic) hypoxia (Figure 1.22). A decrease in rate limiting
oxygen tension reduces the activity of PHD2, which reduces hydroxylation and
9+/PHGLDWHGXELTXLWLQDWLRQRI+,)Į7KLVFDXVHVDQLQFUHDVHLQOHYHOVRI+,)Į
protein which leads to increased levels of active HIF-1. Furthermore, FIH also
EHFRPHV LQDFWLYH LQFUHDVLQJDVVRFLDWLRQZLWKS&%3DQG+,)ĮGULYHQJHQH
transcription. As the time in hypoxia increases, the increased transcriptionally
DFWLYH +,)Į FDXVHV DQ LQFUHDVH LQ 3+' P51$ DQG SURWHLQ ZKLFK IDFLOLWDWHV
LQFUHDVHG K\GUR[\ODWLRQ RI +,)Į )XUWKHUPRUH OHYHOV RI 6$* SURWHLQ DOVR
increases, facilitating VHL mediated ubiquitination and degradation of
K\GUR[\ODWHG+,)Į&RQFXUUHQWO\KRZHYHU),+VWLOOH[HUWV LQKLELWRU\HIIHFWVRQ
+,)ĮGULYHQWUDQVFULSWLRQDVLWLVVWLOODFWLYHDWR[\JHQWHQVLRQVORZHUWKDQWKDW
required for PHD2 activity. This causes a slight repression of PHD2 transcription,
FRQWULEXWLQJ WR WKH WLPH ODJ SULRU IRU PD[LPDO +,)Į GHJUDGDWLRQ DV ZHOO DV
inhibiting other HRE driven gene transcription.
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Figure 1.22: /HYHOVRI+,)ĮSURWHLQDUHUHJXODWHGE\QHJDWLYHIHHGEDFNORRSVLQ
hypoxia. Under low oxygen tensions, PHD2 has significantly reduced activity due to low
levels of its rate limiting cofactor O27KLVUHVXOWVLQQRK\GUR[\ODWLRQRI+,)ĮOHDGLQJWRVWDELOLVHGSURWHLQOHYHOV+,)ĮLVWKHQSKRVSKRU\ODWHGDQGWUDQVORFDWHVLQWRWKHQXFOHXV
ZKHUH LW GLPHULVHVZLWK+,)ǃ WR IRUPD+,)GLPHU+,)ELQGV WRK\SR[LF UHVSRQVLYH
elements (HREs) that are contained in the promoters of many genes that allow the cell to
adapt to low oxygen tensions. PHD2 and SAG both contain functional HREs and are
upregulated in hypoxia. The upregulation of PHD2 compensates for its reduced activity,
UHVWRULQJ K\GUR[\ODWLRQ RI +,)Į DQG LWV VXEVHTXHQW GHJUDGDWLRQ 7KLV UHVXOWV LQ
decreased HIF1 formation and a decrease in associated transcription. Furthermore, FIH is
active even under conditions that approach anoxia, and acts as a further negative
UHJXODWRURI WUDQVFULSWLRQE\K\GUR[\ODWLQJ$VQRQ+,)ĮDQGSUHYHQWLQJDVVRFLDWLRQ
with p300/CBP.
In summary, cells are able to adapt and survive in low oxygen tensions by up
regulating expression of proteins and enzymes involved in glycolysis, glucose
uptake, angiogenesis, vascularisation and red blood cell production and
maturation through the transcription factor HIF1. Following prolonged exposure
to hypoxia, up-regulation of PHD and SAG proteins facilitate the hypoxic
GHJUDGDWLRQRI+,)ĮDVLQQRUPR[LDSURYLGLQJDQHJDWLYHUHJXODWRU\IHHGEDFN
ORRS DQG SUHYHQWLQJ DQ H[SRQHQWLDO LQFUHDVH LQ +,)Į SURWHLQ DQG VXEVHTXHQW
HRE containing genes.
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1.13 Preliminary Data
1.13.1 The Role of LIMD1 in Regulation of Hypoxia
In a yeast-2-hybrid screen to identify LIMD1 interacting partners, LIMD1 amino
DFLGV  GHQRWHG ¨ IXVHG WR D *$/ '1$ ELQGLQJ GRPDLQ ZDV
screened against a HeLa cell cDNA library. This obtained a cDNA encoding one of
WKH +,)Į SURO\O K\GUR[\ODVHV 3+' DV EHLQJ D SRWHQWLDO ELQGLQJ SDUWQHU
(Figure 1.23).
Figure 1.23: LIMD1 interacts with prolyl hydroxylase 1 in a yeast 2 hybrid
screen. $ <+ VFUHHQ ZLWK /,0' DPLQR DFLGV  GHQRWHG ¨ IXVHG WR D
GAL4 DNA binding domain identified PHD1 (fused to a GAL4 activation domain) as a
binding partner from a HeLa cDNA library. Binding domain vector only or laminC were
used as negative controls (Dr T. Sharp, unpublished data).
1.13.2LIMD1 binds to the Proline Hydroxylases and VHL
The interaction with PHD1 was then confirmed through co-immunoprecipitation
studies using ectopically over-expressed PHD1, 2 and 3 with LIMD1 and the
other Zyxin family members. This confirmed that LIMD1 bound PHD1, and also
was the only Zyxin family member to bind to PHD2 and 3 (Figure 1.24). As PHD2
LV WKH PDLQ SUROLQH K\GUR[\ODVH LQYROYHG LQ +,)Į K\GUR[\ODWLRQ DQG XQLTXHO\
bound to LIMD1 (but not the other Zyxin family members), this was the main
focus of subsequent studies.
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Figure 1.24: LIMD1 binds to PHD2 in vivo. Xpress tagged Zyxin family members were
co-transfected with un-tagged PHD2 into U2OS cells, and immunoprecipitated with an
anti-Xpress antibody. Following immunoprecipitation of the family members, PHD2 only
co-immunoprecipitated with LIMD1 (Dr T. Webb, unpublished data).
8QGHU QRUPR[LF FRQGLWLRQV +,)Į LV LQLWLDOO\ K\GUR[\ODWHG E\ 3+' DQG WKHQ
recognised by VHL, leading to its ubiquitination and subsequent proteasomal
degradation. As LIMD1 bound to PHD2, further investigations were performed to
examine if VHL also bound to LIMD1, which was indeed found to be the case
(Figure 1.25).
Figure 1.25: LIMD1 binds to VHL in vivo. Xpress tagged Zyxin family members were
co-transfected with V5 tagged VHL into U2OS cells and the family members
immunoprecipitated with anti-Xpress antibody. VHL expresses as both p19 and p30
isoforms due to an internal initiation codon, and both isoforms specifically co-
immunoprecipitated with LIMD1, Ajuba and WTIP (Dr T. Webb, unpublished data).
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1.13.3 LIMD1 Bridges the Association between PHD2 and VHL
LIMD1 was found to bind both PHD2 and VHL, however, as PHD2 and VHL do not
directly interact, it was reasoned that LIMD1 could either exist in the same
complex as, or form a scaffold between, these two proteins. In ectopic
expression studies, immunoprecipitation of VHL in the absence of transfected
LIMD1 resulted in only very low levels of associated PHD2, however, when
LIMD1 was co-transfected this resulted in significantly increased co-
immunoprecipitation of PHD2 with VHL (Figure 1.26). From these observations
the hypothesis was suggested that LIMD1 was acting as a scaffold to bridge the
association between VHL and PHD2 into a single complex, thus creating an
µHQ]\PDWLFQLFKH¶WRHQKDQFHWKHHIILFLHQF\RI+,)ĮGHJUDGDWLRQ
Figure 1.26: LIMD1 acts as a scaffold protein to simultaneously bind VHL and
PHD2. VHL was co-transfected with LIMD1 and PHD2 either individually or in combination
into U2OS cells and VHL immunoprecipitated. (A) 2% input blots indicate protein
expression prior to immunoprecipitation. (B) LIMD1 co-immunoprecipitated both in the
presence and absence of PHD2. However, co-immunoprecipitation of PHD2 was
significantly enhanced upon expression of LIMD1 (Dr T. Webb, unpublished data).
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1.13.4/RVVRI/,0',QKLELWV+,)Į'HJUDGDWLRQ
It was next reasoned that if LIMD1 was indeed forming an enzymatic complex
ZLWK3+'DQG9+/LWZDVUHDVRQHGWKDWXSRQ/,0'ORVVGHSOHWLRQWKH+,)Į
GHJUDGDWLRQ SDWKZD\ ZRXOG EH LQKLELWHG DQG UHVXOW LQ DQ LQFUHDVH LQ +,)Į
protein levels. siRNA mediated depletion of LIMD1 resulted in an increase in
+,)ĮSURWHLQOHYHOVDNLQWRWKDWVHHQIROORZLQJGHSOHWLRQRI3+')LJXUH
Figure 1.27: VL51$ PHGLDWHG GHSOHWLRQ RI /,0' FDXVHV DQ LQFUHDVH LQ +,)Į
protein levels. HEK293 cells were transfected with 20 or 80nM siRNA targeting LIMD1,
PHD2 or a scrambled control. 48 hours post-transfection cells were lysed and lysates
assayed by Western blot. Depletion of LIMD1 or PHD2 caused a significant increase in
OHYHOVRI+,)ĮSURWHLQ'U7:HEEXQSXEOLVKHGGDWD
Collectively, these observations suggest that LIMD1 acts as a scaffold to bridge
the association between VHL and PHD2, concentrating their respective activities
into an enzymatic niche. Furthermore, loss of LIMD1 disrupts this complex
IRUPDWLRQ LQKLELWLQJ +,)Į GHJUDGDWLRQ DQG UHVXOWLQJ LQ DQ LQFUHDVH LQ +,)Į
protein levels in normoxia.
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1.14 Thesis Aims and Objectives
There are three distinct areas of LIMD1 biology that form the aims and
objectives of this thesis.
1. LIMD1 protein expression is down regulated in up to 80% of lung cancers, as
well as in breast cancer and chromosomal alterations identified in HNSCC and
childhood acute lymphoblastic leukaemias (Sharp et al., 2004; Sharp et al.,
2008; Spendlove et al., 2008; Ghosh et al., 2008). Specifically in lung
adenocarcinomas, LIMD1 protein loss could be attributed to gene deletion
(32%) and loss of heterozygosity (12%). However, these 44% of genetic
alterations was significantly lower than the observed 79% of lung cancers
exhibiting protein loss. It was therefore hypothesised that this 35% shortfall
could be explained by LIMD1 promoter methylation within the putative CpG
Island (Figure 1.14), causing epigenetic silencing of the gene. Therefore the
first aim was to investigate if the LIMD1 promoter is methylated in
transformed cells, and if so does it correlate with silencing of the LIMD1
gene.
2. From the preliminary data, the putative CpG Island appeared to be critical for
transcription. The second aim was to identify why the CpG Island was so
important for transcription, and to identify possible transcription factors that
may bind to the promoter to activate LIMD1 gene expression. Identification
of the transcription factor(s) that activates LIMD1 transcription could provide
another explanation for LIMD1 protein loss in transformed cells.
3. 3UHOLPLQDU\ VWXGLHV KDG LGHQWLILHG /,0' DV D QHJDWLYH UHJXODWRU RI +,)Į
(Figure 1.27). The working hypothesis was through formation of a complex
with the oxygen dependent proline hydroxylase PHD2 and the VHL containing
( XELTXLWLQ OLJDVH 9%& FRPSOH[ /,0' IDFLOLWDWHG +,)Į GHJUDGDWLRQ
identifying a novel tumour suppressive function of LIMD1. Therefore, the final
distinct objective within this thesis was to investigate if LIMD1 expression
changes in hypoxia, and to obtain endogenous data to further the
understanding and evidence that LIMD1 may form a complex with PHD2/VHL
to regulate the intracellular hypoxic response.
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2.1 Materials
2.1.1 Media and Selection Drugs
2.1.1.1 Bacterial Media
LB Broth (LB) (L3522-1KG, Sigma-Aldrich, Saint Louis, USA). LB was
dissolved in distilled water (2.5% w/v) and autoclaved at 121oC for 20 minutes.
Stored at room temperature with required antibiotics added immediately prior to
use.
LB-Agar (L2897-1KG, Sigma-Aldrich, Saint Louis, USA). LB-agar
was dissolved in distilled water (3.5%w/v) and autoclaved at 121oC for 20
minutes. The agar was allowed to cool to ~50oC and the required antibiotic was
added, mixed well and poured into sterile petri dishes (25ml/plate). Plates were
allowed to set at room temperature and stored for up to 4 weeks at 4oC.
2.1.1.2 Cell Culture Media
Dulbeccos Modified Eagles Medium (DMEM)(D6429, Sigma-Aldrich, Saint
Louis, USA). DMEM contained 4500mg/L glucose, 2mM L-glutamine and
100mg/L sodium pyruvate and was supplemented with 10% (v/v) Foetal calf
VHUXP)&6DQGYYSHQLFLOOLQVWUHSWRP\FLQDQGVWRUHGDWÛ&6HOHFWLRQ
drugs were added immediately prior to use.
RPMI-1640 Medium: (R8758, -Aldrich, Saint Louis, USA). RPMI contained
2000mg/L glucose and was supplemented with 10% (v/v) Foetal calf serum
)&6DQGYYSHQLFLOOLQVWUHSWRP\FLQDQGVWRUHGDWÛ&
Fetal Bovine Serum (FBS): (F9665, Sigma-Aldrich, Saint Louis, USA).
)%6ZDVDOLTXRWHGLQWRPODOLTXRWVDQGVWRUHGDWÛ&)%6ZDVDGGHGWRFHOO
medium within a cell culture fume hood.
1x Trypsin/EDTA Solution: (T3924, Sigma-Aldrich, Saint Louis, USA).
The solution contained 0.5g/100ml porcine trypsin, 0.2g/100ml EDTA per litre of
Hanks' Balanced Salt Solution (HBSS) and phenol red. Working aliquots were
VWRUHGDWÛFDQGSUHZDUPHGWRFLQDZDWHUEDWKSULRUWRXVH
Opti-MEM®: (31985, GIBCO, N.Y. USA). OptiI-MEM® serum free media was
aliquoted and stored at 4°c.
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2.1.2 Antibiotics and Selection Drugs
5-Aza-2-deoxycytidine: (A3656, Sigma-Aldrich, Saint Louis, USA). A stock
solution was prepared at a concentration of 100mM in DMSO and stored at -
80oC.
Ampicillin: (A2804-50MG, Sigma-Aldrich, Saint Louis, USA). A stock solution
of ampicillin was prepared at a concentration of 100mg/ml in distilled water,
filter sterilised through a 0.2µm filter and stored at -20oC. The standard working
concentration was 100µg/ml.
Chloramphenicol: (C0378, Sigma-Aldrich, Saint Louis, USA). A stock solution
of chloramphenicol was prepared at a concentration of 50mg/ml in 100%
ethanol and stored at -20oC. The standard working concentration was 50µg/ml.
Kanamycin: (420311, Merck Chemicals, Germany). A stock solution of
kanamycin was prepared at a concentration of 50mg/ml in distilled water, filter
sterilised through a 0.2µm filter and stored at -20oC. The standard working
concentration was 50µg/ml.
Penicillin/Streptomycin: (P0781, Sigma-Aldrich, Saint Louis, USA).
Penicillin/Streptomycin solution contained 10,000 units of Penicillin and 10mg/ml
Streptomycin in 0.9% NaCl. Working aliquots were stored at 4°C.
2.1.3 Buffers and Solutions
2.1.4 Bacteriological Buffers and Solutions
Transformation Buffer (TB): 15mM CaCl2, 250mM KCl and 10mM PIPES
were dissolved in distilled water and the pH adjusted to 6.7 with 1M KOH. 55mM
MnCl2 was then dissolved after the pH was adjusted (otherwise it would fall out
of solution) and was filter sterilised through a 0.2µm filter.
PreScission Protease Buffer: 50mM Tris-HCl ph7.0, 150mM NaCl, 1mM
EDTA, 1mM DTT were dissolved in water and stored at 4oC.
2.1.5 DNA Buffers
Tris-Acetate-EDTA (TAE) (50X):2M Tris base, 250mM Sodium Acetate, 50mM
EDTA were dissolved in distilled water and the pH adjusted to 8.0 with HCl. The
50X stock solution was stored at room temperature and diluted to a 1X working
solution with distilled water.
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DNA Agarose Gel Loading Buffer (10x): 50% (v/v) glycerol and 0.25%
(w/v) Bromophenol Blue were dissolved in 1X TAE and stored at room
temperature. When added to a DNA sample the final concentration was 1X.
Oligo Annealing Buffer (1X): 10mM Tris-HCl pH 7.5, 50mM NaCl, 1mM
EDTA were dissolved in distilled water and stored at room temperature.
2.1.6 Cell Lysis/Wash Buffers
Phosphate Buffer Saline (PBS) (10 X): (11666789001, Roche Diagnostics
GmbH, Mannheim, Germany). Premixed 10x PBS contained 2.5mM KH2PO4,
25mM Na2HPO4, 0.34 M NaCl, 6.75mM KCl, pH 7.4 was diluted to 1 X with
distilled water and stored at room temperature.
RIPA: 150 mM NaCl, 1% (v/v) IGEPAL-630, 0.5% (w/v) sodium deoxycholate,
0.1% (w/v) SDS and 50mM Tris were dissolved in distilled water, the pH
adjusted to 8 and stored at 4°c.
Passive Lysis Buffer (PLB) (5 X): (E1941, Promega, Madison, USA). 5 x
PLB, was stored at -30°C and diluted to 1 X with distilled water immediately
before use, with subsequent lysates stable for 6 hours at room temperature.
Chromatin Immunoprecipitation Lysis Buffer: 50mM Tris-HCl pH8.0,
1% SDS, 10mM EDTA. Stored at room temperature.
Hypotonic Lysis Buffer: 20mM HEPES, pH 7.9, 50mM NaCl, 1mM EDTA,
1mM EGTA, 20mM NaF, 1mM Na3VO4, 1mM Na4P2O7, 2mM benzamidine, 1mM
dithiothreitol were dissolved in distilled water and stored at 4°c.
Hypertonic Lysis Buffer: 20mM HEPES, pH 7.9, 420mM NaCl, 1mM EDTA,
1mM EGTA, 20mM NaF, 1mM Na3VO4, 1mM Na4P2O7, 2mM benzamidine, 1mM
dithiothreitol, 20% glycerol were dissolved in distilled water and stored at 4°c.
Protease and Phosphatase Inhibitors: (Roche, Mannheim, Germany). One
Complete EDTA free Protease Inhibitor Cocktail tablet and two PhosSTOP
Phosphatase Inhibitor Cocktail tablets were dissolved in 20ml of lysis buffer and
either stored at 4°C <1 week or at -20°C for <1 month.
MG-132 Proteasome Inhibitor: (PI102-0005, Biomol International, Enzo Life
Sciences Ltd, UK).A 10mM MG-132 stock solution was prepared by dissolving
Chapter 2: Materials and Methods
82
MG-132 powder in sterile DMSO (Dimethyl Sulfoxide, D2438, Sigma-Aldrich) and
stored at -80°c for <2 months. Standard working concentration was 10µM.
2.1.7 Solutions for Sodium Dodecyl Sulphate-Polyacrylamide Gel
Electrophoresis (SDS-PAGE) and Immunoblotting
5 x SDS-PAGE Sample buffer: 50% (v/v) Glycerol, 250mM Tris-HCl pH 6.8,
 ZY 6'6  YY ǃ0HUFDSWRHWKDQRO DQG  ZY %URPRSKHQRO
Blue were dissolved in distilled water and the buffer aliquoted and stored at -
20°c.
PBS-Tween: 0.05% (v/v) Tween®20 (P2287-500ml, Sigma-Aldrich, Saint Louis,
USA) was added to 1 x PBS and stored at room temperature.
SDS-PAGE Running Buffer (10 X): 0.25M Tris, 1.92M Glycine and 1% (w/v)
SDS were dissolved in distilled water and stored at room temperature. A 1 x
solution was prepared by diluting the 10 x stock in distilled water.
Transfer Buffer: Tris-Glycine transfer buffer solution (10 X) (250mM Tris-HCl
pH 7.5, 2M glycine, [93015, Fluka, Sigma-Aldrich, UK]) was diluted to 1X in
distilled water containing 10% (v/v) methanol and stored at 4°C.
Blocking Solution: Marvel dried skimmed milk powder (5% w/v) was dissolved
in 1 x PBS-Tween and stored <1 day at 4°C.
Coomassie Blue Protein Stain: 0.12% (w/v) Coomassie Brilliant Blue R, 50%
(v/v) Methanol and 20% (v/v) Glacial Acetic Acid solution were dissolved in
distilled water, filtered through 3MM filter paper and stored at room
temperature.
Coomassie Blue De-staining solution: 10% (v/v) Methanol and 10% (v/v)
Glacial Acetic Acid were dissolved in distilled water and stored at room
temperature.
Ponceau S Protein Stain: 0.1% [w/v] Ponceau S and 10% (v/v) Glacial Acetic
Acid solution were dissolved in distilled water and stored at room temperature.
Resolving Gel Buffer: ddH2O and bis-acrylamide (30% stock solution) were
supplemented with 0.375M Tris pH8.8 and 0.1% SDS. The amount of bis-
acrylamide was altered to achieve the desired percentage gel depending upon
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the size of protein to be resolved. Generally, 15% bis-acrylamide gels were used
to resolve proteins below 37kDa, and 8% gels used to resolve proteins between
25 and 150kDa. 0.1% ammonium persulphate was added (to cross-link the
acrylamide), and this was catalysed by addition of 0.01% N,N,N,N-
tetramethylethylenediamine (TEMED) immediately before pouring. A straight
horizontal gel was achieved by overlaying with 100% EtOH whilst polymerising.
Stacking Gel Buffer: 5% bis-acrylamide was supplemented with 0.125M Tris
pH6.8, 0.1% SDS and 0.1% ammonium persulphate. 0.01% TEMED was added
to catalyse polymerisation of the gel. Gel combs were inserted straight after
pouring the stacking gel to create wells in the gel to load sample.
2.1.8 Dual-Luciferase Reporter Assay Solutions
Dual-Luciferase Reporter Assay System: (E1960, Promega,
Madison,USA). The kit comprised of 5x Passive Lysis Buffer (see above), a
Luciferase Assay Buffer and Stop & Glo® Reagent for the measurement of firefly
and renilla luciferase respectively. Components were stored at -20°C and once
reconstituted at -20°C for <1 month or -80°C for <6 months.
2.1.9 Human Tumour Samples
One sample each of fresh tumour tissue and normal lung parenchyma distant
from tumour were collected from patients undergoing operative resection of lung
cancer at the Royal Brompton Hospital. Samples were snap-frozen in isopentane
and stored at -80°C. Specific consent for usage of tissue for non-diagnostic use
was obtained from patients. Ethical approval for the study was obtained from the
Brompton, Harefield and NHLI Research Ethics Committee, U.K by Dr Andrew
Nicholson (Ref 03-112).
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2.1.10Antibodies
Antigen
Dilution for
Western
Blot
Host
Species
Molecular
Weight
(kDa)
Company
Catalogue
Number
Primary Antibodies
LIMD1 1:500 Mouse 72
(Sharp et al
2004)
N/A
Xpress 1:5000 Mouse N/A Invitrogen 46-0528
HA 1:1000 Rabbit N/A Sigma-Aldrich H6908
GFP 1:1000 Mouse 27 Roche 11814460001
ǃ$FWLQ  0RXVH  6LJPD$OGULFK $
PU.1 1:1000 Rabbit 32-42 Cell Signalling #2266
Ets-1 1:1000 Mouse 50
BD Transduction
Laboratories E34620
Elk-1 1:1000 Rabbit 45 Santa Cruz SC22804
+,)Į  0RXVH  BD Transduction
Laboratories 610959
PHD2 1:1500 Rabbit 46 Abcam AB4561
PHD2 1:1500 Mouse 46 Millipore 05-1327
VHL 1:400 Mouse 19-30
BD Transduction
Laboratories 536347
Elongin B 1:750 Rabbit 18 Santa Cruz SC11447
Cullin 2 1:750 Rabbit 87 Abcam AB1870
Secondary Antibodies
Mouse 1:2500-5000 Goat - DAKO P0447
Rabbit 1:5000 Goat - DAKO P0448
Table 1: Table of primary and secondary antibodies used for immunoblotting
with the working dilutions, host species, predicted molecular weight,
manufacturing company and catalogue number indicated.
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2.2 Methods
2.2.1 Bacterial Culture methods
2.2.2 Preparation of Chemically-Competent Cells
PORIDVWDUWHUFXOWXUHRI'+ĮE.coli was used to inoculate 200ml of sterile LB.
The bacteria were grown at 22°C overnight with vigorous shaking (220rpm) until
they reached an OD600 of ~0.5. The culture was then chilled on ice for 15
minutes, divided into 4 and pelleted by centrifugation. The bacterial pellets were
each resuspended in 20ml of filter sterilised ice cold transformation buffer (TB)
and the 4 suspensions combined into 2. Cells were then chilled on ice for 10
minutes and then re-centrifuged (15 minutes, 4000g, 4°c). The pellets were
again resuspended in 20ml of ice cold TB and centrifuged as before. The
resulting pellets were then each resuspended in 5ml of ice cold TB, recombined
into one tube and DMSO added (10% v/v). The bacteria were then incubated on
ice for 10 minutes and aliquoted into sterile 1.5ml eppendorf tubes (200µl/tube),
flash frozen in liquid nitrogen and stored at -80°c.
2.2.3 Transformation and Propagation of Chemically Competent '+Į
Bacteria
200µl aliquots of chemically competent '+Į bacteria were gently thawed on ice
and gently tapped to ensure complete resuspension of the cells. 5µl of ligated
DNA or 10ng of plasmid DNA were added to the bacteria and incubatd on ice for
30 minutes. The bacteria were heat shocked in a still water bath (42°C, 45
seconds) and then returned to ice to recover for 2 minutes. 500µl of Luria Broth
(LB) was added to the bacteria before being incubated at 37°C with vigorous
shaking (220 rpm) for 60 minutes. 10-200µl of the bacteria were spread onto
LB-agar plates containing the appropriate antibiotic and incubated overnight at
37°C.
Plates were removed from the incubator the next morning and stored at 4°C.
Late afternoon individual colonies were picked with a sterile 10µl pipette tip and
inoculated in 5ml of LB containing the same appropriate antibiotic. Innoculated
cultures were then incubated overnight (37°C, 220rpm) for a maximum of
16hours and the bacteria harvested through centrifugation (6,000g, 15
minutes).
Chapter 2: Materials and Methods
86
2.2.4 Nucleic Acid Techniques
2.2.5 Plasmid DNA Extraction
Plasmid DNA was extracted from small scale cultures of transformed bacteria
(<10ml) using the QIAprep Spin Miniprep Kit (27106, QIAGEN, Maryland, USA).
Briefly, harvested bacteria were resuspended in 250µl of RNase A containing
buffer P1 and transferred into sterile 1.5ml microcentrifuge tubes. Bacteria were
lysed by addition and gentle mixing of 250µl alkaline lysis buffer P2 and
incubated at room temperature for 5 minutes. Alkaline lysis was neutralised and
cell debris, lipids, chromosomal DNA and SDS precipitated by addition of 350µl
neutralisation buffer N3 followed by centrifugation at 13,000g for 10 minutes.
Plasmid DNA was then bound to the silica membrane within the QIAprep spin
column by passing the cleared supernatant through and centrifugation for 1
minute at 13,000g. Residual salt and other bacterial contaminants were
removed by washing the column with 750µl of wash Buffer PE, followed by
centrifugation for 2 minutes into a clean microcentrifuge tube to remove residual
ethanol from the wash buffer that could interfere with downstream processes.
Plasmid DNA was then eluted into a clean microcentrifuge tube by addition of
75µl HPLC H2O and centrifugation for 1minute at 13,000g.
For large cultures (50ml), plasmid DNA was extracted using the Qiagen Plasmid
Midi Kit (12143, QIAGEN, Maryland, USA). Briefly, bacteria were harvested and
resuspended in 4ml of Buffer P1, lysed through the addition of 4ml Buffer P2 for
5 minutes and neutralised with 4ml Buffer P3. After 15 minute incubation on ice
to aid precipitation of SDS, chromosomal DNA, lipids and cell debris the lysate
was cleared by centrifugation at 20,000g for 30 minutes at 4oC. The cleared
lysate was decanted into a clean centrifuge tube and further cleared by
centrifugation for another 15 minutes. The plasmid DNA was then bound to a
QIAGEN-100 tip (equilibrated with 4ml Buffer QBT) by passing the supernatant
through under gravity flow. The tip was washed by passing 2X 10ml of Buffer QC
through under gravity before elution into a clean centrifuge tube by addition of
5ml Buffer QF. Eluted plasmid DNA was precipitated with 3.5ml isopropanol and
centrifuged at 15,000g for 30 minutes at 4oC. The resultant DNA pellet was
washed and resuspended in 3ml 70% (v/v) ethanol and centrifuged at 15,000g
for 15 minutes at 4oC. The DNA pellet was then air-dryed for 15minutes and
resuspended in 400µl HPLC H2O.
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2.2.6 Genomic DNA Extraction
Genomic DNA from cultured cells and lung tissue samples was extracted using
the QIAamp DNA Mini Kit (51306, QIAGEN, Maryland, USA). Briefly, 5x106
adherent monolayer cells were washed twice in ice cold PBS and then scraped
and resuspended in 1ml of ice cold PBS. Cells were centrifuged 3,500g for 5
minutes at 4oC and the resultant cell pellet resuspended in 200µl ice cold PBS.
20µl of proteinase K and 4µg RNase A was then added. 200µl of lysis Buffer AL
was added and pulse-vortexed for 15seconds prior to incubation at 56oC for
10minutes. 200µl of 100% ethanol was then added, pulse-vortexed for
15seconds, the liquid transferred to a QIAamp Mini spin column and centrifuged
at 8,000g for one minute to bind the DNA to the column. The column was then
sequentially washed and centrifuged (13,000g, one minute) with 500µl each of
wash buffer AW1 and AW2. The column was then centrifuged for an additional
minute to remove any residual wash buffer and the DNA eluted in 2x 200µl of
HPLC H2O.
For lung tissue samples, 50µl of PBS was added to 20mg of tissue in a 1.5ml
microcentrifuge tube and the tissue homogenised until no solid tissue was
visible. 100µl of lysis Buffer ATL and 20µl of proteinase K were added and
incubated at 56oC for 10minutes. 4µg of RNase A was then added and incubated
at room temperature for 2 minutes. 200µl of Buffer AL were then added, pulse-
vortexed for 15seconds and incubated at 70oC for 10minutes. 200µl of 100%
ethanol was then added and the remaining steps carried out identically to the
method for monolayer cells above.
2.2.7 RNA Extraction and cDNA Synthesis
RNA was extracted from lung tissue using TriPure Isolation Reagent
(11667157001 Roche Applied Science, Germany). 50mg of flash frozen lung
tissue was homogenised in 1ml of TriPure and incubated at room temperature
for 5 minutes to allow for complete lysis. Homogenates were then clarified of
insoluble polysaccharides, lipids and membranes by centrifugation at 13,000g
for 10 minutes at 4oC. 0.2ml of chloroform was added and the homogenates
vortexed vigorously for 15 seconds prior to phase separation by centrifugation at
13,000g for 15 minutes. After centrifugation there was 3 phases; an upper
aqueous phase containing RNA and a middle and lower phase containing DNA
and protein. The upper aqueous phase was transferred to a sterile RNA free
microcentrifuge tube containing 0.5ml isopropanol and incubated at room
temperature for 10 minutes to allow precipitation of RNA, which was then
pelleted by centrifugation at 13,000g for 10 minutes at 4oC. The pellet was then
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washed in 1ml of 75% ethanol, re-centrifuged as before and after allowing the
pellet to air dry for 10 minutes, resuspended in 50µl DEPC treated H2O and
stored at -80oC.
2.2.8 Quantification of DNA/RNA Concentration
DNA and RNA concentrations were quantified using a NanoDrop® ND-1000
spectrophotomoter (NanoDrop Technologies Inc., Wilmington, USA). Pre and
post use the pedestals were wiped clean with 100% ethanol and DEPC treated
water. The instrument was blanked with 1µl of the same buffer that the
DNA/RNA was dissolved in. 1µl of the RNA/DNA sample was used per
quantification with both a 260nm and 280nm light absorbance values measured.
Readings were measured in duplicate and an average value taken.
2.2.9 DNA Sequencing
DNA sequencing was performed by Source BioScience UK Limited (previously
Geneservice, Nottingham) on an Applied Biosystems 3730 DNA Analyzer.
2.2.10 Bisulphite Treatment of Genomic DNA
Genomic DNA was bisulphite treated using the EZ DNA Methylation-Gold Kit
(D5006, Zymo Research, Orange, CA, USA). 500ng of genomic DNA was diluted
to a final volume of 20µl using ddH2O. To this 130µl of CT Conversion Reagent
was added and mixed to form a homogeneous solution. The DNA was then
denatured by heating to 98oC for 10 minutes, followed by bisulphite conversion
of unmethylated cytosines into uracil by incubation at 65oC for 2.5 hours. The
bisulphite DNA was then added to 600µl of M Binding Buffer preloaded into a
Zymo-SpinTM IC Column and centrifuged (13,000g, 1 minute). 100µl of M-Wash
Buffer was added to the column to wash the bound DNA and centrifuged
(13,000g, 1minute). 200µl of M-Desulphonation Buffer was then added to the
column and incubated for 20minutes at room temperature to desulphonate the
DNA, followed by centrifugation as before. DNA was then washed with 2 x 200µl
M-Wash Buffer and eluted in 10µl ddH2O. Eluted DNA was stored at -20
oC prior
to PCR analysis.
2.2.11 Site-directed Mutagenesis
Site directed mutagenesis reactions were performed using QuikChange XL Site-
Directed Mutagensis Kit (Stratagene #200517). This allows for mutation
(addition, deletion or substitution) of DNA base pairs within a super-coiled
plasmid. Primers were designed that incorporated the mutation flanked by 15-
25bp of complimentary base pairs either side. The primers anneal to the
denatured plasmid, and are extended around the plasmid with PfuUltra DNA
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polymerase, resulting in a parent strand-mutated strand plasmid duplex. The
parental strand is methylated with the newly synthesised mutated DNA
unmethylated. Digestion with DpnI selectively digests the methylated strand, to
leave only the mutated strand, which is then transformed into competent XL10
Gold bacteria.
The primers utilised for the site-directed mutagenesis are given in Table 2
below.
Mutation Direction Sequence
PU.1
Consensus
Mutagenesis
CC-TT Forward
GCCTGGCGCACTCACTTTTGCGTCCCGCCGC
CCTCCGG
CC-TT Reverse
CCGGAGGGCGGCGGGACGCAAAAGTGAGT
GCGCCAGGC
C-T Forward
GCCTGGCGCACTCACTTCCGCGTCCCGCCGC
CCTCCGG
C-T Reverse
CCGGAGGGCGGCGGGACGCGGAAGTGAGT
GCGCCAGGC
Hypoxic
Responsive
Element
Mutagenesis
ȴHRE1 Forward CCTCTACGAATAACGAGCCTACTAGGGTGTA
TGCTTTTACTGCTGCACTGAGG
ȴHRE1 Reverse CCTCAGTGCAGCAGTAAAAGCATACACCCTA
GTAGGCTCGTTATTCGTAGAGG
ȴHRE2 Forward GCTTTTACTGCTGCACTGAGGATACAAAATG
CGCGCAGGCACAACGAGAC
ȴHRE2 Reverse GTCTCGTTGTGCCTGCGCGCATTTTGTATCC
TCAGTGCAGCAGTAAAAGC
ȴHRE3 Forward CGCCCCGGCGCGGGCTCGGGATACACAGAG
CCGGCGAGCGAGCAGC
ȴHRE3 Reverse GCTGCTCGCTCGCCGGCTCTGTGTATCCCGA
GCCCGCGCCGGGGCG
Table 2: Sequences of primers used for site-directed mutagenesis.
The reaction components and conditions for the mutagenesis reactions were as
follows:
10X Reaction Buffer 5µl
10ng plasmid DNA 1µl
125ng forward primer 1µl
125ng reverse primer 1µl
dNTP mix (final concentration 0.2mM each dNTP) 1µl
QuikSolution 3µl
H2O 37µl
PfuUltra (5Units) 1µl
-------
50µl
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95oC 1min
95oC 1min
60oC 50s 18 cycles
68oC 1min/kb
68oC 7min
+1µl DpnI (20,000Units/ml)
37oC 60min
5µl of the reaction was then transformed into one aliquot of XL10 Gold
competent cells, and resultant colonies screened by sequencing for correct
plasmid mutations. All sequencing chromatograms appear in the Appendix.
2.2.12Polymerase Chain Reaction (PCR)
PCR reactions were carried out using Phire hot start DNA Polymerase (NEB) in a
20µl total reaction volume. Reaction components and conditions were as follows:
H2O 11.6µl
5X Reaction Buffer 4µl
10ng plasmid DNA 1µl
Forward primer (final concentration 0.2µM) 1µl
Reverse primer (final concentration 0.2µM) 1µl
dNTP (final concentration 0.2mM each dNTP) 1µl
Phire DNA Polymerase (10Units) 0.4µl
------
20µl
98oC 2min
98oC 10s
60oC 10s 35 cycles
68oC 30s
68oC 2min
For amplification of PU.1 cDNA and incorporation of restriction endonuclease
sites, primer sequences used were
5CGCGAATTCCAGATGTTACAGGCGTGCAAAATGGAAGGGTTTCCCCTCGTCCCCCCT
CCATC (forward) and 5
GCGGGATCCTCAGTGGGGCGGGTGGCGCCGCTCGGCCAGGCCCCCGCGGCCCAGCA
CTTCGC (reverse).
Successful PCR amplification was analysed by resolving the PCR reaction by
agarose gel electrophoresis.
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2.2.13 TA Cloning of PCR Products
TA cloning® was used to clone purified PCR products that contained a 3
adenosine overhang (introduced through the non-specific terminal transferase
activity of Taq polymerase) into a pcDNA4/HisMax©-TOPO® plasmid vector
(K864-20, Invitrogen, Carlsbad, USA), that possessed a 5 thymidine overhang.
Reactions were performed in a final volume of 5µl, and contain 3.5µl of purified
PCR product, 1µl of salt solution and 0.5µl of TOPO® vector. The reaction was
incubated at room temperature for 30 minutes prior to transformation of 2µl of
the reaction mixture containing ligated PCR insert/TOPO vector backbone TOP10
chemically competent cells. All sequencing chromatograms are included in the
Appendix section.
2.2.14 Cell Culture Techniques
2.2.15 Cell Maintenance and Passaging of Adherent Cells
Adherent monolayer human cell lines were cultured in DMEM supplemented with
10% FCS and 1% penicillin/streptomycin and incubated in a humidified 37 oC 5%
CO2 incubator.
When cells reached 80% confluency (as determined through inspection on an
inverted light microscope) they were passaged through trypsinisation. The cell
media was removed and cells washed twice with room temperature equilibrated
PBS. 1x trypsin-EDTA (2.5ml for a 75cm2 flask, 5ml for a 225cm2 flask) was
added and the cells incubated at 37oC until all the cells had visibly detached (2-
10 minutes depending on cell type). As fetal calf serum contains naturally
occurring trypsin inhibitors, the trypsin was then inactivated by addition of D-
MEM containing 10% FCS (v/v) that was equal to three times the volume of
trypsin originally used. Cells were then homogeneously resuspended prior to
appropriate dilution with D-MEM supplemented with 10% FCS (v/v) and 1%
penicillin/streptomycin solution (v/v) into a new flask.
2.2.16 Cell Maintenance and Passaging of Suspension Cells
Suspension U937 cells were maintained in RPMI 1640 supplemented with 10%
FCS and 1% penicillin/streptomycin and incubated in a humidified 37oC 5% CO2
incubator.
Cells were passaged every 2-3 days as determined by the confluency and
indication of the media colour changing from orange to yellow. One third of the
volume of the cell suspension was added to 2 thirds the volume of new media in
a new flask and mixed by gentle pipetting.
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2.2.17 Cell Freezing
Cells (of a low passage) were trypsinised and resuspended in a final volume of
25ml media. Cells were then gently pelleted by centrifugation (500g, 5 minutes),
resuspended in 25ml of ice cold PBS and re-pelleted. The washed cell pellet was
then resuspended in freezing media (10% (v/v) DMSO in FCS) and transferred
into 2ml cryovials. The cryovials were stored for 24 hours at -80oC and then
transferred into liquid nitrogen for long term storage.
2.2.18 Cell Counting
Cells were manually counted using an Improved Neubauer Hemacytometer
(AC1000, Hawksley & Sons Ltd, Lancing, UK). Cells were trypsinised and
neutralised as described (section 2.41 and 2.42). 10µl of the cell suspension was
pipetted into each chamber of the hemacytometer and cells in each of the 8
large 1mm corner squares counted using an inverted light microscope. Cells that
lay on the top and left border of a square were included in the count, but cells
lying on the bottom and right border were excluded. An average cell count per
1mm square was calculated, and as the volume of each square was 0.1mm3, the
cell count was multiplied by 104 to obtain the number of cells per ml of
neutralized cell suspension.
2.2.19 Cell Seeding
Cells were seeded into sterile tissue culture plates or dishes according to the
transfection reagent protocol. Typically, adherent cells were seeded 24 hours
prior to transfection so that they were 50-70% confluent when transfected. For
seeding of cells for endogenous experiments, cells were plated so that they
would reach the required cell number/density as required by the protocol.
2.2.20 Hypoxic Treatment of Cells
Hypoxic treatment refers to the exposure of cells to 1% oxygen within a
ProOx110 controller chamber (BioSpherix Ltd, New York, USA). The chamber
was humidified and maintained at 37oC.
2.2.21 Transfection of DNA into Monolayer Adherent Cells
U2OS, HeLa and HEK 293 cells were transfected using GeneJuice Transfection
Reagent (70967-6, Merck4Biosciences, Darmstadt, Germany). Briefly, cells were
seeded 24 hours prior to transfection (typically 1.5 x 106 cells per 10cm plate).
The required amount of GeneJuice was mixed in Optimem and incubated for 10
minutes at room temperature. DNA was then added, mixed gently by pipetting,
incubated for 45 minutes at room temperature and then added dropwise to cells.
Cells were then incubated for 24-48 hours.
Chapter 2: Materials and Methods
93
MDA-MB435 cells were transfected using FuGene (11815091001, Roche Applied
Science, Germany) as per manufacturers protocol. Briefly, cells were seeded 24
hours prior to transfection. The required volume of FuGene was mixed with
Optimem, DNA added and mixed by pipetting, incubated for 15 minutes at room
temperature and then added dropwise to the cells.
2.2.22 Transfection of siRNA into Monolayer Adherent Cells
Adherent cells were transfected with siRNA using the DharmaFECT® siRNA
transfection reagent (Thermo Scientific Dharmacon®, Lafayette, USA). 24 hours
prior to transfection, cells were seeded at 5 x 104 cells per well of a 12 well plate
in 0.5ml complete growth medium. siRNA from a 20mM stock solution was added
to serum free Optimem to a final volume of 50µl, so that in 500µl the desired
concentration of siRNA would be achieved. In a separate tube, 1ul of
DharmaFECT® was mixed with 49ul of Optimem, and both tubes were incubated
for 5minutes at room temperature. Both tubes were then combined, gently
mixed by pipetting and incubated for a further 20 minutes. After 20 minutes,
growth media from the cells was removed, the cells washed with PBS and 400µl
of fresh media was added. The DharmaFECT/siRNA mixture was then added drop
wise to the cells to a make a final volume of 500µl. The cells were then
incubated for 24-48 hours prior to subsequent analysis.
2.2.23 Transfection of siRNA into Suspension Cells
siRNA targeted against PU.1, LIMD1, Ets-1 or a scrambled control sequence was
electroporated into the human leukaemic monocytic lymphoma U937 cell line
using the Amaxa Cell Line Nucleofector Kit V (Lonza VCA-1003) on a
Nucleofector II electroporator (Lonza) utilising the U937 cell specific programme
(W-001). Briefly, 2 x106 U937 cells were used per well of knockdown, which
were resuspended in 100µl of the supplied Nucleofector® solution and 160pmol
of siRNA added and mixed by gentle pipetting. Cells were not stored in this
solution for more than 10 minutes. The siRNA/cell suspension was transferred to
a supplied cuvette and electroporated using the manufacturer supplied
programme for U937 cells (#W-001, exact electroporation conditions are not
supplied by the manufacturer). Immediately after electroporation, 400µl of pre-
warmed media was added to the cell solution, and then gently pipetted into a
well of a 12 well plate containing 1.5ml of pre-warmed media to give a final
volume of 2ml. Cells were then incubated for 48hours in a 37oC/5% CO2 prior to
lysis and analysis of mRNA/protein.
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2.2.24 DNA/RNA Analysis Techniques
2.2.25 Bioinformatic Analysis
As a reference point for referring to positions within the LIMD1 promoter, the
unconfirmed transcriptional start site (TSS) was assigned according to the NCBI
reference sequence NM_014240.2. This corresponds to nucleotide 45636323 on
the primary chromosome 3 ref assembly NC_000003.11 and is 49bp upstream
from the AUG translation initiation codon.
2.2.26 CpG Island and Transcription Factor Binding Motif Analysis
The human LIMD1 promoter, which was preliminarily designated as 2.5kbp
upstream of the ATG translation initiation codon, was scrutinised using the
Ensembl Genome Browser (http://www.genome.ucsc.edu) for the presence of
CpG Islands, utilising the default software thresholds. The promoter sequences
of other LIMD1 expressing mammals were extracted from the Ensembl Genome
Browser (http://www.ensembl.org). Sequence alignments throughout were
performed using ClustalW2 (http://www.ebi.ac.uk/Tools/msa/clustalw2). The in
silico screen for transcription factor binding motifs within the promoter was
performed using the MatInspector software programme (http://genomatix.de)
using the Matrix Family Library Version 8.1 and the default threshold values of
0.80 representing a good match and 1.0 representing a perfect match
respectively.
2.2.27 Methylation Specific PCR
15ng of bisulphite treated DNA was amplified using primers specific for
methylated and unmethylated regions within the CpG promoter of LIMD1 to
produce a 151bp product. Genomic DNA from LIMD1 expressing U2OS cells and
non LIMD1 expressing MB435 cells were used as positive and negative controls
respectively, as both cell lines had been characterised as being homogeneously
hypo- and hyper-methylated respectively. The primers specific for the
methylated sequence were 5 GTCGATTCGTCGTCGTTATC (forward) and 5
CGCTAAATCCTCCGCTACTT (reverse), and for the unmethylated sequence were
5 GTTGATTTGTTGTTGTTATT (forward) and 5 CACTAAATCCTCCACTACTT
(reverse). Conditions for the MSP were 95oC for 5 minutes followed by 40
subsequent cycles of 95oC for 1 minute with a 1 minute annealing at 60.7oC for
the methylated or 59oC for unmethylated primers and 1 minute at 70oC. The
methylation status of the RASSF1A CpG promoter was determined using the
previously characterised methylation specific primers 5
GGGTTTTGCGAGAGCGCG (forward) and 5 GCTAACAAACGCGAACCG (reverse)
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and the unmethylated specific primers 5 GGTTTTGTGAGAGTGTGTTTAG
(forward) and 5 CACTAACAAACACAAACCAAAC (reverse) (Burbee et al., 2001).
Conditions for the Rassf1a MSP were 95oC for 5 minutes with 40 subsequent
cycles of 95oC for 1 minute, 60oC for 1 minute and 1 minute at 70oC. The MSP
products were analysed by separation on a 1.5% Agarose gel.
2.2.28 Bisulphite Sequencing
Methylation of the CpG Island within the LIMD1 promoter was analysed using
bisulphite sequencing. Genomic DNA from lung tumour tissue and matched
normal lung tissue from 48 patients was extracted and 500ng bisulphite treated
using EZ DNA Methylation-Gold Kit (Zymo Research, Orange, CA, USA). 10ng of
each treated DNA was amplified using the non-methylation discriminatory
primers 5 GGYGYGGGTTYGGGAYGTGTAGAGTYGG (forward) and 5
CTAAAACTAACRACCCATTATCCRATAAC (reverse), corresponding to -787 to -648
of the LIMD1 ATG. Conditions for the PCR were 94oC for 3 minutes followed by
40 subsequent cycles of 94oC for 15s, 61.5oC for 1minute and 72oC for 30s with
a final elongation at 72oC for 2minutes. The 149bp products were purified by gel
extraction (QIAquick Gel Extraction Kit, Qiagen) and sequenced using the same
forward primer. Methylated cytosines are resistant to the initial bisulphite
treatment, and are conserved after PCR, whereas unmethylated cytosines are
converted to uracil and subsequently appear as thymine when sequenced.
Unmethylated and methylated genomic DNA from LIMD1 expressing U2OS and
non-LIMD1 expressing MDA-MB435 cells respectively were used as controls.
2.2.29 qRT-PCR Analysis
2.2.29.1 Lung Biopsy Samples
Total RNA was extracted from 100mg of 48 tumour and matched normal tissue
pairs, DNase1 treated and 1Pg used for cDNA synthesis as previously described.
Primers and probes were designed using the Roche Universal Probe Library assay
design software algorithm (https://www.roche-applied-
science.com/sis/rtpcr/upl/index.jsp). The primers for LIMD1 were
5TTGTGGACATCTGATCATGGA (forward) and 5AAACAGCCGGGGTGGTAG
(reverse) and for the housekeeping GAPDH 5AGCCACATCGCTCAGACAC
(forward) and 5GCCCAATACGACCAAATCC (reverse), both utilising Probe #60.
Each assay was carried out in triplicate with 200nM of primer and 100nM probe
on an ABI 7000 machine, with a non template control on each plate.
Determination of the Ct threshold was calculated automatically using the 7000
System Software (Applied Biosystems). mRNA levels were quantified through a
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standard curve obtained from a representative serial dilution of 12 sample pairs
and levels of LIMD1 normalised to GAPDH. LIMD1 levels were then normalised to
1 for each matched normal tissue, so levels in each tumour are relative to 1.
2.2.29.2 PU.1 and Hypoxic Responsive Gene mRNA Levels
qRT-PCR analysis was performed in collaboration with Dr Victoria James using
the SYBR green method of amplicon detection, and analysis using the
comparative Ct method (2[delta][delta]Ct). The geometric mean of 2 housekeeping
JHQHVǃWXEXOLQDQG53,,ZDVXVHGIRUQRUPDOLVDWLRQ
For PU.1 mRNA analysis primers utilised were PU.1 5CAGGGGATCTGACCGACTC
IRUZDUGDQG¶*&$&&$**7&77&7*$7**UHYHUVHQRUPDOLVHGWRWKHǃWXEXOLQ
housekeeper 5ATACCTTGAGGCGAGCAAAA (forward) and
5CTGATCACCTCCCAGAACTTG (reverse).
2.2.305-Aza-2'-Deoxycytidine Treatment
MDA-MB435 and U2OS cells were seeded in 6 well plates at 1.5 x 10^5
cells/well. 4 hours after seeding, the DNA methylation inhibitor 5-Aza-2-
deoxycytidine was added to a final concentration of 100µM. The media with fresh
drug was changed every 24 hours for 5 days before cell lysis with 5x SDS gel
loading buffer for Western Blot analysis.
2.2.31 Protein-DNA Interaction Techniques
2.2.32 Mapping and hypoxic responsiveness of the LIMD1 Promoter
The LIMD1 promoter region was previously cloned into a pGL4.0 firefly luciferase
vector and a series of internal deletions within the CpG Island created (Sharp et
al., 2008). 50ng of the mutant promoter containing firefly luciferase was co-
transfected along with 5ng of SV40 driven renilla luciferase (for normalisation)
into U2OS in a 24 well plate. Transfected cells were harvested in 1x PLB 30
hours post transfection. Cells that were exposed to hypoxia were done so that
the end point was 30 hours post transfection. The amount of luciferase was
quantified using the Dual Luciferase Reporter Assay system.
2.2.33 Chromatin Immunoprecipitation
Chromatin immunoprecipitation was used to assay transcription factor binding to
DNA. For endogenous ChIP 1x 107 cells were used and for exogenously
expressed transcription factors 6x 106 cells were used. Cells were starved
overnight in serum-free D-MEM, followed by 30 minute stimulation with 20%
FCS/D-MEM (v/v). Formaldehyde was then added to the culture medium to a
final concentration of 1% to cross-link protein to DNA and the cells incubated for
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10 minutes at 37oC. Cross-linking was quenched by washing the cells twice with
ice cold PBS supplemented with 0.125M glycine and the cells harvested in 1ml
harvesting buffer (0.125M glycine, 1mM EDTA and protease inhibitors in PBS)
and pelleted by centrifugation at 3,500g for 10 minutes at 4oC. The cell pellet
was resuspended in 100µl of lysis buffer (50mM Tris-HCl pH8.0, 1% SDS, 10mM
EDTA plus protease inhibitors) and incubated on ice for 10 minutes. 50µl of
dilution buffer (20mM Tris-HCl pH8.0, 1% Triton X-100, 2mM EDTA, 150mM
NaCl plus protease inhibitors) was added and the lysates sonicated on ice in 15
second pulses to shear the DNA to 200-600bp (the number of sonication pulses
was empirically calculated in preliminary experiments and varied with cell type).
Lysates were cleared of insoluble material by centrifugation at 13,000g for 10
minutes at 4oC. An input sample (5% of total lysate) was taken, the remaining
soluble chromatin containing supernatant diluted to 1ml with dilution buffer and
added to an already antibody conjugated IP matrix and incubated overnight at
4oC with rotation. The next morning the IP matrix beads were harvested by
centrifugation at 4,000 g for 1 minute at 4oC and the beads washed 6x 1ml RIPA
with 5 minute incubations at 4oC with rotation between washes. Bound protein-
DNA complexes were eluted in 2x 75µl elution buffer (1%SDS, 0.1M NaHCO3) for
15 minutes at room temperature with rotation. Cross links were then reversed
for 6 hours at 65oC with NaCl (0.2M), followed by incubation with 20µg
proteinase K, 40mM Tris-HCl pH6.5, 10mM EDTA. DNA was then purified using
the Qiagen PCR purification kit.
2.2.34 Electrophoretic Mobility Shift Assay (EMSA)
80% confluent 10cm plates of HEK293T cells were starved overnight in serum-
free D-MEM, followed by 30 minute stimulation with 20% FCS/D-MEM (v/v).
Cells were then washed twice in ice cold PBS and scraped in 1ml hypotonic buffer
supplemented with protease/phosphatase inhibitors. Cells were quickly pelleted
(14,000g, 30secs, 4°c), cytosolic protein containing supernatant removed and
the pellet resuspended in 150µl hypertonic buffer supplemented with
protease/phosphatase inhibitors. The resuspended nuclear pellet was rotated at
4°c for 60min to ensure complete lysis prior to centrifugation at 13,000g for
20min to pellet the insoluble nuclear membrane and DNA. The supernatant
containing nuclear proteins was then flash frozen in liquid N2 and stored at -80
oc.
2OLJRQXFOHRWLGHV UHSUHVHQWLQJ WKH ZLOG W\SH ,5 VHTXHQFH :7 Ļ
&7&$&77&&*&*7&&&*&&*& IRUZDUG DQG Ļ *&**&***$&*&**$$*7*$*
UHYHUVH RU SRLQW PXWDWHG 07 ,5 VHTXHQFH 07 Ļ
&7&$&7777*&*7&&&*&&*& IRUZDUG DQG Ļ *&**&***$&*&$$$$*7*$*
UHYHUVH 07 Ļ &7&$&**&&*&*7&&&*&&*& IRUZDUG DQG Ļ
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GCGGCGGGACGCGGCCGTGAG (reverse) were 32P end labelled using T4
SRO\QXFOHRWLGH NLQDVH 6LQJOH VWUDQGHG IRUZDUG ROLJR SPRO Ǆ>3@$73
(5mCi), T4 kinase buffer (1x, supplied with the T4 kinase) and T4 polynucleotide
kinase (10Units, NEB M0201S) in a final reaction volume of 10µl were incubated
for 1hour at 37oC, prior to inactivation of the enzyme at 65oC for 10minutes.
10pmol of the complimentary reverse oligo was added along with 90µl of
annealing buffer (10 mM Tris-HCl pH 7.4; 50 mM NaCl; 0.1 mM EDTA pH 8.0).
The solution was heated to 94oC for 1 minute and allowed to cool slowly (-
2oC/minute) to 16oC to allow the oligos to anneal. The annealed oligos were then
purified using the QIAquick Nucleotide removal kit (Qiagen #28304). A mix of
4× binding buffer (140 mM KCl, 18 mM MgCl2, 12 mM spermidine), Poly dI/dC
 ǋJPO ILQDO FRQFHQWUDWLRQ VKHDUHG +HUULQJ VSHUP  ǋJPO ILQDO
concentration) and nuclear extract/recombinant protein was made up. The
volume was made up with incubation buffer (10 mM HEPES, pH 7.8, 5% glycerol,
50 mM KCl, 1 mM EDTA, 1 mM DTT). Antibody or cold probe (either wt or
containing point mutations) was added and the reaction incubated at room
temperature for 1 h. Labelled probe was added and reactions incubated for a
further 10 min at room temperature before loading onto a 5% polyacrylamide
gel (0.5 × TBE). Gels were dried and developed using a Fuji-film LAS-3000
phosphor-imager.
2.2.35 Protein-Protein Interaction Analysis Techniques
2.2.36 Recombinant protein purification
The expression plasmids, pGEX4T and pGEX6P (GE Healthcare), both encode a
glutathione-s-transferase (GST) moiety, which upon expression of a sub-cloned
cDNA, produces a N-terminal GST tag that is separated from the expressed
protein by a recognition sequence for a specific protease. The plasmids contains
a tac promoter (a fusion of the bacterial trp and lac operons), which allows for
inducible expression in bacteria by isopropy-beta-D-thiogalactoside (IPTG).
When expressed in bacteria, the recombinant protein can be purified from other
intracellular bacterial proteins by using sepharose beads with glutathione
moieties attached. The GST tag on the recombinant protein will bind with high
affinity to the glutathione and as such can be purified through isolation and
extensive washing of the sepharose beads.
The pGEX4T vector has a thrombin protease recognition sequence and the
pGEX6P vector has a PreScission protease recognition sequence between the
GST tag and the protein. When immobilised onto glutathione sepharose, the
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recombinant protein can be cleaved and eluted from the beads with thrombin
(for pGEX4T) or PreScission protease (for pGEX6P), resulting in a highly purified
recombinant protein. PreScission protease is itself a recombinant protease that
also contains a GST moiety, and so during cleavage binds to the glutathione
beads thus preventing contamination of the eluted protein.
Recombinant proteins were expressed using the pGEX4T-1 plasmid vector (27-
4580-01, Amersham Biosciences, GE Healthcare, Buckinghamshire, UK)
containing the required cDNA of interest. The plasmid was transformed into the
BL21 (DE3) pLysS strain of E.coli and a single colony was used for a 5ml
LB/ampicillin (100µg/ml) overnight starter culture, which was grown with
vigorous shaking (220rpm) at 37oC. The next morning a new culture was
inoculated 1/50 with the starter culture, still maintaining the same ampicillin
concentration, and grown with vigorous shaking (220rpm) at 37oC for 3 hours.
Protein production was then induced by the addition of 200uM IPTG and the
cultures grown for a further 3 hours. The bacteria were then pelleted (15
minutes, 4,00rpm, 4oC) and resuspended in 1ml of ice cold PBS per 10ml of
culture volume. To aid in lysis the resuspended pellets were then frozen and
thawed. The thawed bacterial suspensions were then sonicated at 100%
intensity on ice 3 x 15 seconds with 15 second intervals between sonications.
The sonicated lysates were then cleared of insoluble lipids and DNA by
centrifugation at 13,000rpm for 10 minutes at 4oC.
Glutathione Sepharose 4B beads (17-0756-01, Amersham Biosciences, GE
Healthcare, Buckinghamshire, UK) have glutathione immobilised on sepharose
beads. The high affinity of the glutathione-s-transferase tag on the recombinant
protein for glutathione allows for the purification of the recombinant protein from
the other bacterial proteins. For each purification 35µl of the glutathione beads
were washed with 3 x 1ml ice cold PBS to remove the 20% ethanol they are
preserved in. The required volume of bacterial lysate was added to the beads,
and the volume made up to 1ml with ice cold PBS. To facilitate binding the beads
were rotated for 30mins at 4oC. After 30 minutes the beads were harvested by
centrifugation (3,000rpm, 1 minute, 4oC) and washed with 1ml RIPA buffer for 5
minutes with rotation in order to remove any non-specifically bound bacterial
proteins. The wash was repeated twice more, and as much of the supernatant
was removed as possible, leaving just the beads bound by the purified
recombinant protein.
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To analyse the amount of protein purified, 35µl of 5 x SDS buffer was added, the
sample boiled for 5 minutes, and resolved by SDS PAGE. The resultant gel was
then visualised by Coomassie staining. For pulldown assays the amount of
different recombinant proteins bound to the glutathione beads was empirically
equalised form the intensity of the bands.
2.2.37 Direct Binding Assay
pGEX4T-PHD2 and vector only and pGEX6T-LIMD1 and vector only were
transformed into, expressed and purified from BL21(DE3) pLysS E. Coli as
described above. Expression of recombinant PHD2 and LIMD1 was confirmed by
immunoblotting with anti- PHD2 or LIMD1 antibodies. The pGEX6P vector
contains a PreScission Protease (GE Healthcare) cleavage site between the GST
tag and the sub cloned protein. PreScission protease is a recombinant protease
that contains a GST tag and so when added to the immobilised and purified
pGEX6P-LIMD1 (or vector only), it will cleave LIMD1 off the GST tag, and will
also itself bind to the glutathione sepharose beads. This leaves purified LIMD1
eluted into the supernatant. Immobilised GST-LIMD1 from an original 5ml
culture was equilibrated in 1ml of PreScission Protease Buffer for 5 minutes with
rotation at 4oC. 10% of the sepharose beads were then taken as an input. 5
units of PreScission protease was added to the remaining beads and incubated
overnight with rotation at 4oC. The following morning the supernatant containing
the cleaved recombinant LIMD1 or vector only was removed and 10% taken as
an input. 5 x SDS loading buffer were added to the cleaved sepharose beads to
analyse the efficiency of cleavage. The cleaved LIMD1 or vector only was added
to immobilised pGEX4T-PHD2 or vector only and incubated for 6 hours with
rotation at 4oC. The supernatant containing any unbound protein was removed
and the beads washed 3 x 1ml of PreScission Protease buffer prior to elution
with 5 x SDS loading buffer and analysis by Western Blot.
2.2.38 Dephosphorylation Assay
U2OS, HeLa and HEK 293T cells were plated at 5 x 105/well in a 6 well plate. 24
hours after seeding cells were exposed to 16 hours hypoxia prior to lysis by
scraping in RIPA supplemented with MG132, protease and phosphatase inhibitors
5RFKH &OHDUHG O\VDWHV ZHUH DGGHG WR J RI +,)Į RU LVRW\SH FRQWURO
antibody conjugated to 10µl settled bed volume of IP matrix (Santa Cruz sc-
 ,PPXQRSUHFLSLWDWLRQRI+,)ĮZDVFDUULHGRXW IRUKRXUVDWoC with
rotation, followed by extensive washing with RIPA buffer (unsupplemented).
Dephosphorylation was carried out in 50µl reaction volumes using 400Units of
lambda protein phosphatase (NEB #P0753S) at 30oC for 60 minutes along with a
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control reaction that omitted the enzyme. The reaction was stopped by addition
RIO[6'6EXIIHUDQG+,)ĮSURWHLQDQDO\VHGE\:HVWHUQEORW
2.2.39 Immunoprecipitation (IP)
In vivo protein-protein interactions were assayed by immunoprecipitation. For
endogenous IP cells were allowed to reach 80-90% confluency, for exogenously
transfected protein interactions cells were transfected 48 hours before lysis. The
immunoprecipitating antibody was firstly conjugated to IP matrix beads (mouse
antibodies used sc-45042; rabbit antibodies used sc-45043, Santa Cruz Biotech,
CA, USA). 40µl of the IP matrix slurry (25% v/v) was made up to 1 ml using ice
cold PBS. Dependent upon antibody and abundance of antigen, 1-5µg of
precipitating antibody was added and rotated overnight at 4oC. The conjugated
antibody-IP matrix was then pelleted by centrifugation at 3,500rpm for 1 minute
at 4oC. Cells were washed 3 times with ice cold PBS, then gently scraped to
harvest in 1ml ice cold PBS. Cells were pelleted by centrifugation (10,000rpm for
1 minute at 4oC) and the resultant pellet lysed by addition of 1ml RIPA
(supplemented with protease and phosphatise inhibitors) and rotated at 4oC for
20 minutes. They lysate was then cleared of insoluble cellular debris by
centrifugation at 13,000rpm for 10 minutes at 4oC. 50µl of lysate was removed
as input, and the remaining supernatant was added to the antibody-IP matrix
beads and incubated at 4oC with rotation for 4-6 hours. The matrix was then
washed 3-6 times in RIPA/PBS (50% v/v) with 5 minute rotation between
washes. Bound proteins were then eluted with 35µl of 5 x SDS buffer and
analysed by Western blot.
2.2.40 Western Blot Analysis
Proteins were resolved by SDS-PAGE, prior to semi-dry electro transfer on a
TransBlot Semi Dry Transfer Cell (Biorad) at a constant 20volts for 1 hour.
Following transfer, membranes were blocked in blocking buffer (5% Marvel milk
powder in PBS-Tween (0.05% v/v)). The required primary antibody was diluted
in blocking buffer and then incubated on the membrane overnight at 4 oC with
gentle agitation. The next morning, membranes were washed 3 x 5mins in PBS-
Tween to remove any unbound antibody, prior to incubation in secondary
antibody (horse radish peroxidise (HRP) conjugated) diluted in blocking buffer
for 1 hour at room temperature with gentle agitation. The membranes were
again washed 3 x 5mins in PBS-Tween before incubation with an Enhanced
Chemiluminescence Reagent (ECL) Western Blotting Detection Solution
(0.1ml/cm2 of membrane, Amersham, GE Healthcare, UK) for 5 minutes to
initiate a HRP-catalysed luminescent reaction. Excess ECL solution was drained
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off, the membranes covered with a single piece of cling film and exposed to
Chemiluminescent Detection Film (Roche Applied Science) for ten seconds up to
one hour dependent upon the signal strength. The film was then hand developed
in PQ Universal Paper Developer (Ilford, UK) and fixed in 2000RT fixer (Ilford)
before being rinsed in water and allowed to air dry.
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Chapter 3 Results: LIMD1 transcription and
promoter methylation in lung cancer
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3.1 Introduction
Reduced LIMD1 protein expression in lung tumours has been reported to be a
result of genetic ablation, specifically chromosomal deletions and/or loss of
heterozygosity (Sharp et al., 2008). Using lung adenocarcinomas (ADC) as a
representative example, the percentage of tumours showing reduced protein
expression is 79%, with 32% and 12% reductions due to LIMD1 gene deletion
and loss of heterozygosity respectively (Sharp et al., 2004; Sharp et al., 2008).
This therefore leaves a deficit (35%) between the overall percentage protein loss
in ADC (79%) and the percent loss that can be accounted for by genetic
deletions (44%). This discrepency in LIMD1 loss therefore may be due to
mechanisms that affect LIMD1 transcription rather than genetic ablations.
The 5-proximal promoter regions of transcribed genes contain binding motifs for
multple transcriptional regulatory proteins, some of which are ubiquitously
expressed, some expressed in response to a stimulii and others in a tissue or
cell type specific manner. To initiate the study of the LIMD1 promoter, and as an
aid for referring to positions within the promoter, the unconfirmed transcriptional
start site (TSS) was assigned according to the NCBI reference sequence
NM_014240.2. This corresponds to nucleotide 45636323 on the primary
chromosome 3 ref assembly NC_000003.11 and is 49bp upstream from the AUG
translation initiation codon.
3.2 The LIMD1 Promoter contains a Single CpG Island
The LIMD1 gene promoter spanning 2kb upstream from the translation start site
was scrutinised using the UCSC Genome Browser to identify the presence of any
CpG Islands (Figure 3.1). Only one CpG Island was identified within the
promoter sequence, predicted as being 842bp long, with a G + C content of
65.3% and an observed/expected CpG ratio of 95%. This meets the criteria set
by both Gardiner-Garden and Takai for the definition of a CpG Island (Gardiner-
Garden and Frommer, 1987; Takai and Jones, 2002).
Chapter 3: Results
105
Figure 3.1: The LIMD1 promoter contains a single CpG Island. The LIMD1 genomic
locus was scrutinised using the Ensembl Genome browser. Parameters were set to (A)
visually identify any CpG Islands upstream of the AUG translation initiation codon. (B)
Further scrutinisation of the details of the CpG Island revealed it spans 842 bases and
contains 85 CpG dinucleotides.
A
B
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The LIMD1 promoter region spanning from -1990 relative to the TSS and up to
the AUG LIMD1 initiation codon (+50) was previously cloned into a pGL4.10
vector (Sharp et al., 2008). This allowed for the transcriptional activity of the
promoter to be assayed indirectly through the transcription and translation of
the luciferase gene under the control of the LIMD1 promoter. A series of ten
consecutive but discreet internal deletions ranging in size from 18 to 35bp were
also created within the CpG Island (Sharp et al., 2008), which are schematically
depicted in Figure 3.2A. The internal mutants were named internal deletion 1-
¶ ,ƩDQGZKHQUHIHUULQJ WR WKHFRUUHVSRQGLQJUHJLRQ WKDWZDVGHOHWHG
the nomenclature internal region 1-10 (IR1-10) is used.
3.2.1 The CpG Island within the LIMD1 Promoter Contains Both
Negative and Positive Regulatory Regions
By utilising the internal promoter deletions, the presence of any positive or
negative regulatory regions within the CpG Island could be identified. If a region
that harboured a consensus binding motif for a negative transcriptional regulator
was removed, an increase in transcriptional activation would be observed, and
vice versa for a positive regulator. To identify these regions, equal amounts
(50ng) of the wild type and internal promoter deletion reporters were separately
co-transfected with a renilla luciferase plasmid (for normalisation) into U2OS
cells, along with the control vector only (VO) and resultant luciferase activity
assayed 24hours post transfection.
The promoter internal deletion mutants exerted different effects on LIMD1
SURPRWHU DFWLYLW\ )LJXUH % 7KH ,Ʃ   DQG  PXWDQWV VKRZHG QR
statistically significant changes in transcriptional activity compared to wild type,
showing that these regions (in the absence of specific external stimuli) in U2OS
cells do not contain binding sites for major transcriptional (co)-activators or
FRUHSUHVVRUV7ZRRIWKHPXWDQWV,ƩDQGVKRZHGDQGLQFUHDVHV
in transcriptional activities compared to wild type respectively. This indicated
these regions may contain binding sites for proteins that negatively regulate
WUDQVFULSWLRQ &RQYHUVHO\ WKH ,Ʃ  DQG  PXWDQWV DOO FDXVHG GHFUHDVHV LQ
transcription of 60%, implicating these regions as containing binding sites for
positive transcriptional regulators. The largest effect on transcription was seen
ZLWKWKH,ƩGHOHWLRQZKLFKFDXVHGDUHGXFWLRQLQWUDQVFULSWLRQ
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7KH ,ƩPXWDQW VKRZHG WKH JUHDWHVW UHGXFWLRQ LQ WUDQVFULSWLRQ RI ZKLFK
indicated that it may contain the binding motif or consensus for the protein(s)
that were responsible for basal LIMD1 transcription. Therefore this region was
focused upon for subsequent analyses.
Figure 3.2: The LIMD1 promoter contains positive and negative regulatory
regions. (A) Schematic diagram showing the cloned LIMD1 promoter in the pGL4
OXFLIHUDVHYHFWRUZLWKWKH&S*,VODQGDQGWHQLQWHUQDOGHOHWLRQV,ƩLQGLFDWHG%DVH
pair numbering is relative to the transcriptional start site as assigned according to the
NCBI reference sequence NM_014240.2 (nucleotide 45636323 on the primary
chromosome 3 ref assembly NC_000003.11). (B) The indicated internal deletion mutants
were co-transfected with a Renilla luciferase for normalisation into U2OS cells and
resulting luciferase activity assayed 24 hours post transfection. Results shown as mean
+/- 1 standard deviation; representative experiment of n=3.
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3.3 Analysis of LIMD1 Promoter Methylation
3.3.1 Identification of the Methylation Status of the LIMD1 promoter in
LIMD1 expressing and non-expressing cell lines.
A common phenomenom that causes silencing of tumour supressor genes in
cancer is epigenetic silencing, which is a result of aberrant promoter
hypermethylation (Esteller, 2007). Hypermethylation of promoters, specifically
cytosine residues within CpG dinucleotides, inhibits transcription by blocking the
binding of transcriptional activator proteins either directly via the methylated
cytosine, or indirectly through chromatin remodelling facilitated by the
recruitment of methyl binding proteins and histone remodelling proteins.
One of the cell lines maintained in the lab is the MDA-MB435 breast epithelial
cell line, which does not express LIMD1 protein or mRNA (Sharp et al., 2004)
however PCR analysis of the genomic locus revealed that the gene, including
promoter, introns and exons were all present and so loss of expression was not
due to genetic deletions (data not shown). This therefore gave an indication that
an epigenetic factor could be the reason for non-expression of LIMD1. To test
this hypothesis, the methylation status of the promoter region, specifically IR5,
was analysed to assess if there were any differences between LIMD1 non-
expressing MB435 cells and LIMD1 expressing U2OS cells. Genomic DNA from
both cell types was extracted and then treated with sodium bisulphite using an
EZ DNA Methylation Gold kit (Zymo Research).
Sodium bisulphite deaminates unmethylated cytosines into uracil, whereas 5-
methyl cytosines are resistant (Figure 3.3). The result of this is a different
sequence of DNA dependent upon original methylation status and as such
traditional PCR based methods can subsequently be utilised to assay the original
methylation status of the DNA. In methylation specific PCR, specific primers that
will only bind to cytosine rich (i.e. originally methylated) DNA, or thymine rich
(i.e. originally unmethylated) DNA are used. If the DNA was originally
methylated, only the methylation specific primers would produce an amplicon,
whereas the unmethylated specific primers would not anneal to the different
sequence and so will not produce an amplicon (Figure 3.3). These amplicons can
then be ethidium bromide stained and visualised by agarose gel electrophoresis.
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Figure 3.3: Sodium bisulphite can modify cytosine to uracil but not methyl-
cytosine. Sulphonation followed by deamination and desulphonation of cytosine by
sodium bisulphite results in formation of uracil, which during a subsequent PCR reaction
leads to the incorporation of thymine in the amplicon as opposed to the original cytosine.
5-methyl cytosine however is resistant to bisulphite modification and so remains as
cytosine after treatment. The differences in sequence following bisulphite treatment can
be exploited for either restriction endonuclease or PCR/ sequencing analysis. Adapted
from (Darst et al., 2010).
Primers were initially designed to amplify the region surrounding IR5 within the
promoter. The design was such that the primers would anneal to the promoter
region without discriminating against if it was initially methylated or not in order
that they would produce an amplicon in both U2OS and MB435 cells.
The resultant amplicon from each cell line was gel excised, purified and
sequenced using the same forward primer used for the PCR. The sequencing
chromatograms revealed that the IR5 region (which harbours 4 CpG
dinucleotides) of the LIMD1 promoter in the U2OS (LIMD1 expressing) cell line
was unmethylated, whereas the same region within the MB435 (LIMD1 non-
expressing) cell line was methylated (Figure 3.4). It was also noticed that the
region surrounding IR5 was also methylated in the MB435 cells compared to
U2OS. Thus at the genetic level the only difference between the promoters
encompassing IR5 in U2OS and MB435 genomic DNA was the methylation
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tissue controls. To investigate this, a cohort of 48 paired lung tumour tissue
samples with matched normal tissue biopsies was examined.
To assess the methylation status of the promoter region, methylation specific
PCR (MSP) analysis was employed. MSP utilises primers that are specifically
designed to anneal to a region containing multiple CpG dinucleotides. Originally
unmethylated CG dinucleotides following bisulphite treatment become TG,
whereas originally methylated CpG remain as CG. Therefore by differentially
designing the primer to anneal to TG as opposed to CG, differences in
methylation can be detected by PCR.
The promoter of the characterised Rassf1a TSG has been reported to be
methylated in lung tumours. Burbee et al reported 75% of lung cancer cell lines,
30% of primary NSCLC and 100% of SCLC cell lines had Rassf1a promoter
methylation (Burbee et al., 2001). Agathanggelou et al and Dammann et al
reported similar findings of methylation in 72% of SCLC and 35% of NSCLC
primary and cell lines and 100% of SCLC and 38% of NSCLC respectively
(Agathanggelou et al., 2001; Dammann et al., 2000). Therefore to place the
results obtained for the LIMD1 promoter into perspective the methylation status
of the characterised Rassf1a promoter was assayed alongside that of LIMD1 in
the same cohort of tumour and matched normal tissue samples. This firstly
ensured that if the proportion of Rassf1a methylation matched published findings
then the cohort could be considered a representative sample. Secondly, it would
allow for any LIMD1 methylation to be put into context by comparing against
the results for Rassf1a. MSP primer sequences for Rassf1a were taken from
Burbee et al (Burbee et al., 2001).
3.3.3 Optimisation of methylation specific PCR (MSP)
To confirm the methylation specific primers could distinguish between DNA that
was methylated or unmethylated the designed primers were initially used to
amplify U2OS and MB435 genomic DNA. These two genomic DNA samples were
chosen as the different methylation states had been identified by sequencing
and the genomic DNA was from homogeneous cell populations, unlike primary
tissue samples which could contain mixed cell populations.
The initial methylation specific PCR reaction using annealing temperatures of
550C gave multiple non-specific banding. Furthermore, amplicons were produced
by the unmethylated DNA specific primers in the MB435 (which should only
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produce an amplicon with the methylated specific primers) showing a degree of
non specific binding. Therefore the PCR was optimised by initially increasing the
Mg2+ concentration and then carrying out a PCR using a temperature gradient of
primer annealing temperatures from 48oC to 62oC. One feature of the primers
that differs between the methylation specific and unmethylated specific primers
is the CG content, with the latter having a lower CG content than the former
because, as described following bisulphite treatment, methylated cytosines
remain as cytosines, whilst unmethylated cytosines become thymines. This
means the primers end up having different optimum annealing temperatures due
to different GC contents.
The gradient PCR showed that at higher annealing temperatures, the non
specific amplicons disappeared, to leave one specific amplicon (Figure 3.5). At
60.4oC the unmethylated specific primers (U) give a single amplicon with U2OS
bisulphite treated DNA but no amplicon with the methylated MB435 treated DNA
(Figure 3.5). At the slightly higher temperature of 62oC the methylation specific
primers (M) give a single amplicon with the treated MB435 genomic DNA, but
not with the U2OS treated DNA (Figure 3.5). The amplicons were then confirmed
as being of the correct sequence by direct sequencing with the same forward
primer (data not shown).
Figure 3.5: Optimisation of annealing temperatures of primers specific for
methylated and unmethylated genomic DNA from U2OS and MB435 cells.
Genomic DNA from LIMD1 expressing U2OS and non-expressing MDA-MB435 cells was
extracted and bisulphite treated. PCR was performed on the treated DNA using primers
that were specific and would only anneal to methylated (M) or unmethylated (U) DNA. In
order to obtain a single specific amplified band with the methylated primers for MB435
and unmethylated primers for U2OS a temperature gradient PCR of annealing
temperatures was carried out to find the optimal annealing temperature for each set of
primers. The optimal annealing temperatures were 62oC for the methylated specific
primers and 60.4oC for the unmethylated primers (indicated with red arrows).
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3.3.4 MSP of Primary Lung Tissue and Matched Lung Tumours
Once the methylation specific primers and PCR reaction had been optimised and
validated, the methylation status of IR5 from genomic DNA from matched
normal and lung tumour tissues was assayed. Genomic DNA and RNA were
extracted from the cohort of 48 lung tumour and matched normal tissues. The
genomic DNA was then bisulphite treated as described for U2OS and MB435
genomic DNA.
Equal amounts of DNA (15ng) were used for each MSP, and for each reaction a
water only PCR negative control (H2O) and a positive control of U2OS or MB435
genomic DNA (+ve) were included. To ensure reproducibility of results, each
PCR with controls was performed in two independent experiments. As the focus
of the MSP was to assay methylation increases in tumour samples, only
methylation specific primers were used. The hypothesis for this experiment was
that the results for the normal tissue (which were assumed to be LIMD1
expressing) would mirror the results within the U2OS cells, that is the promoter
would be unmethylated, whilst a proportion of the tumour tissue (in which ~70-
80% would be expected not to express LIMD1 (Sharp et al., 2004; Sharp et al.,
2008)) would mirror the MB435 cells and be methylated. A representative
sample of normal (N) and matched tumour samples (T) following MSP is shown
in Figure 3.6.
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Figure 3.6: Representative methylation specific PCR results for the LIMD1 and
Rassf1a promoters. Genomic DNA was extracted from a cohort of 48 lung tumour and
matched normal lung tissue samples and bisulphite treated. After bisulphite treatment,
PCR utilising methylation specific primers was carried out to assess any change in
methylation status of the (A) LIMD1 and (B) Rassf1a promoters.
For nine of the LIMD1 and three of the Rassf1a promoter analyses either the
normal and/or tumour sample failed to give an amplicon, and as such were
omitted from the comparative analysis. The results of the MSP for the LIMD1
and Rassf1a promoters are summarised in Table 3 and Figure 3.7. The overall
percentage changes in methylation changes of both the LIMD1 and Rassf1a
promoters were similar; 55-60% exhibited no change in methylation status and
20% showed an increase in methylation in the tumour tissue compared to the
matched normal tissue. The surprising result, however, was ~20% showed a
decrease in methylation from the matched normal to tumour tissue, which was
counter intuitive as to what would be expected and indeed hypothesised.
No correlation was observed between tumour type and changes in methylation
state of either promoter. Furthermore there was no positive or negative
correlation between the two promoters; an increase or decrease in one did not
correlate with an increase or decrease in the other. Out of the cohort of
informative sample pairs, 9 tumours showed an increase in LIMD1 promoter
methylation with a different 9 tumours showing an increase in Rassf1a
methylation when compared to the matched normal tissue. A decrease in LIMD1
LIMD1
150
N T N T N T N T N T H2O +ve
8 35 41 307
100
bp
Rassf1a
200
N T N T N T N T N T H2O +ve
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methylation was observed in 7 tumours and Rassf1a methylation in a total of 8
tumours, with two tumours showing a common decrease in methylation of both
promoters. There was no change in methylation between the normal and tumour
tissue of the LIMD1 promoter in 20 samples or of the Rassf1a promoter in 26
samples.
Table 3: Summary of methylation specific PCR (MSP) analysis of the LIMD1 and
Rassf1a promoters in a cohort of lung tumour and matched normal tissue.
Genomic DNA was extracted from a cohort of 48 lung tumour and matched normal tissue
and bisulphite treated. The treated DNA was then subject to MSP with methylation
specific primers for either the LIMD1 promoter or the Rassf1a promoter. Also indicated is
the tumour type. A, adenocarcinoma; S, squamous cell carcinoma; TC, typical carcinoid;
AC, atypical carcinoid; BC, basaloid carcinoma; PC, pleomorphic carcinoma; LCC, large
cell carcinoma.
Promoter Methylation Status Promoter Methylation Status
Sample No. Tumour LIMD1 RASSF1A Sample No. Tumour LIMD1 RASSF1A
1 A - No change 25 A Increase Decrease
2 S No change No change 26 BC No change Increase
3 S Decrease Decrease 27 S Decrease No change
4 S No change Increase 28 A Increase No change
5 A No change No change 29 A No change No change
6 A Increase No change 30 S No change Decrease
7 A Increase Decrease 31 PC Increase No change
8 TC Increase Decrease 32 S No change No change
9 LCC No change No change 33 A No change No change
10 A - - 34 S Decrease Increase
11 A No change No change 35 S Increase Decrease
12 A Decrease Increase 36 LCC No change No change
13 A No change No change 37 S No change Increase
14 A No change No change 38 A No change Decrease
15 S - No change 39 A No change No change
16 A Increase No change 40 S No change No change
17 AC - No change 41 A Increase No change
18 A - No change 42 TC Decrease No change
19 A - No change 43 BC Decrease No change
20 S - Increase 44 TC No change Increase
21 A - - 45 A No change Increase
22 TC - - 46 S No change Increase
23 A No change - 47 AC No change No change
24 BC Decrease Decrease 48 TC - -
Total n= 36 43
Increase 9 9
Decrease 7 8
No change 20 26
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Figure 3.7: Summary of the changes in methylation status of the LIMD1 and
Rassf1a promoters in lung tumour tissue as compared to matched normal tissue
as analysed by methylation specific PCR. Genomic DNA was extracted from a cohort
of 48 lung tumour and matched normal tissue and bisulphite treated. The treated DNA
was then subject to MSP with methylation specific primers for either the LIMD1 promoter
or the Rassf1a promoter.
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The results from the MSP analysis gave an indication that there were changes in
methylation status of both the LIMD1 and Rassf1a promoters between normal
and tumour tissue. However 19% of samples showed that the promoters of both
genes were methylated in normal tissue and hypomethylated in the tumour
samples. Due to these unexpected findings, no clear conclusions could be drawn
about changes in methylation between normal and tumour tissue. Methylation
specific PCR as an analytical tool does have disadvantages, the main one being
that only the methylation status of the CpG dinucleotides within the primer
sequences can be quantified as being methylated or not. The regions in between
the forward and reverse primers remain uncharacterised. Furthermore it is
possible for primers to anneal with a base pair mismatch, so one CpG within the
primer could be methylated and the others unmethylated, yet the primer could
still be able to anneal and give a false positive amplicon.
A better methodology for assaying specific methylation of DNA is to sequence
the bisulphite treated DNA (bisulphite sequencing). With sequencing, primers
that anneal to the DNA irrespective of methylation status can be used, and the
purity/extent of methylation can be visualised by examining the resultant
sequenced chromatogram. Therefore bisulphite sequencing of the LIMD1 and
Rassf1a promoters were performed using the same cohort of bisulphite treated
genomic DNA.
3.3.5 Optimisation of Bisulphite Sequencing the LIMD1 Promoter
For bisulphite sequencing, primers were designed so that they would (a) only
anneal to bisulphite treated DNA, (b) anneal to the DNA irrespective of
methylation status and (c) produce an amplicon of suitable size to be directly
sequenced without having to first sub-clone into a vector which would
significantly increase the cost of the assay. These primer specifications would
allow for an amplicon to be produced and sequenced without the possible
contamination of DNA that hadnt been bisulphite treated (the bisulphite reaction
converts 99% of DNA as quoted by the manufacturers protocol). It also
removes any bias of primers annealing more efficiently to either methylated or
unmethylated DNA, and after successful amplification would allow for simple
preparation of samples for sequencing as the amplicon would only have to be gel
purified and quantified.
To optimise the conditions for PCR and sequencing, genomic DNA from U2OS,
HeLa (LIMD1 expressing) and MDA-MB435 cells (LIMD1 non-expressing) was
extracted. Again, using cultured cell lines ensured a homogeneous cell
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population. Using just one set of methylation indiscriminatory primers, PCR
reactions were carried out on the extracted genomic DNA both pre and post
bisulphite treatment. Only the genomic DNA which had been bisulphite treated
produced an amplicon of the correct size (147bp) (Figure 3.8). To ensure the
amplicon corresponded to the correct section of genomic DNA, the amplicon was
gel extracted, purified and sequenced. In agreement with the previous findings,
the MDA-MB435 amplicon was found to be methylated and the U2OS and HeLa
amplicons unmethylated (data not shown).
Figure 3.8: PCR amplicons of the correct size are only obtained from genomic
DNA that has been bisulphite treated. Genomic DNA was extracted from U2OS, MDA-
MB435 and HeLa cells and bisulphite treated. PCR was then carried out using bisulphite
treated specific but methylation in-discriminatory primers. No amplicon of the correct
(147bp) size was obtained with untreated genomic DNA (-), however after bisulphite
sequencing (+) specific amplicons were obtained. To confirm the sequence specificity of
the amplicons, the amplicons were gel excised and sequenced.
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3.3.6 Bisulphite Sequencing of the IR5 Region within the LIMD1
Promoter identified Aberrant Methylation in Primary Lung
Tumours
Once the specificity of the bisulphite specific primers had been confirmed, the
bisulphite treated genomic DNA from the cohort of lung and matched normal
tissue was bisulphite sequenced. Due to the number of samples (48x2=96 plus
controls) that had to be manually processed, the PCR reactions and gel
purifications were carried out in batches of 20 samples. As internal controls for
each batch of samples, U2OS and MDA-MB435 bisulphite DNA was included and
sequenced to ensure reproducible results were obtained.
Due to the high costs involved in sequencing and the predominant interest in the
IR5 region (Figure 3.2), only the methylation status of this region was
examined. The sequence of IR5 is 5-CTCACTTCCGCGTCCCGCCGC, containing 4
CpG dinucleotides (underlined) and it was the methylation status of these that
were scrutinised. When the sequencing results were received, the sequence text
file for each was scrutinised alongside the chromatogram to be confident any
miscalled bases by the sequence analyser software were not included as false
positive results. Furthermore, for some samples a mixed signal peak for a
cytosine base was obtained, which the sequencing text file alone did not identify.
It has been observed that primary tumour cells from biopsies potentially contain
mixed cell populations, for example from infiltrating blood lymphocytes or
chromosomal loss of heterozygosity in some cells. The result of this is a sample
that contains genomic DNA with potentially different extents of methylation,
which following bisulphite sequencing gives rise to a mixed C/T chromatogram
peak for a single cytosine within a CpG dinucleotide. Therefore to distinguish
between a single C or T peak and a mixed C/T peak, nomenclature from
previously published papers was used (Beedanagari et al., 2010; Mishra et al.,
2010). The nomenclature is as follows; a cytosine residue was considered to be
fully methylated if on the chromatogram trace there was only a single cytosine
peak, it was considered to be partially methylated if a mixed overlapping C and
T peak for a single cytosine was observed, and unmethylated if the trace was
exclusively T. An example of the partial and full methylation observed is
demonstrated in Figure 3.9 taken from the chromatograms of tumour samples
30 and 16.
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Figure 3.9: Representative sequencing chromatograms demonstrating partial
and full methylation. Bisulphite treated genomic DNA was amplified by PCR using
methylation indiscriminatory primers and the resultant amplicon sequenced using the
same forward primer. Shown are two chromatograms from tumour samples 30 and 16 in
order to illustrate a mixed peak of C and T representing partial methylation and then a
single peak showing full methylation respectively, as indicated by the arrows. The 4 CpG
dinucleotides within the IR5 region are numbered 1-4.
Thirty eight out of the 48 matched samples gave a PCR amplicon and/or
sequencing data for both the tumour and matched normal tissue. The results of
the bisulphite sequencing are shown in Figure 3.10. Samples where data was not
obtained are shaded in grey, unmethylated cytosines are shaded yellow,
partially methylated cytosines are orange and fully methylated cytosines are red.
Of all the normal tissue samples, only 3 showed a partial methylation (samples
19, 23 and 24) exclusively at the 4th CpG. In the tumour samples 9 showed full
methylation (samples 9, 16, 19, 24-28 and 32) and one partial methylation
(sample 30), again exclusively of the 4th CpG. Sample 26 in addition to being
methylated at position 4, was the only sample to show methylation at an
additional CpG. Out of the three normal tissue samples that exhibited partial
methylation, samples 19 and 24 showed a further increase in methylation in the
corresponding tumour sample. No amplicon was obtained for the matched
tumour of the other partially methylated sample (sample 23). Samples 10, 22
and 48 gave no amplicon in either the normal or tumour tissue, possibly
indicating these were subject to large chromosomal gene deletion.
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Figure 3.10: Summary of the methylation status of the individual cytosine
residues of the CpG dinucleotides within the IR5 region of the LIMD1 promoter
in lung tumours and matched normal tissue. Genomic DNA was extracted from a
cohort of 48 lung tumour and matched normal tissue and bisulphite treated. A region
encompassing IR5 was then amplified using methylation non-discriminatory primers. The
amplicon was then gel extracted and purified and sequenced using the same forward
primer used for amplification. Each of the 4 CpG dinucleotides within IR5 are identified
(1-4) and colour coded according to the methylation status; red- methylated, orange-
partially methylated, yellow- unmethylated and grey- no data was obtainable for that
sample. Only 3 of the normal lung tissue samples showed partial methylation at the 4th
CpG dinucleotide, whereas 9 showed full and 1 partial methylation in the tumour
samples.
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In summary, 21% (8/39) of the matched samples showed tumour specific
methylation compared to the matched normal tissue and a further 5% (2/39)
showed an increase in methylation in the tumour tissue compared to the normal
matched control. 74% (28/38) of samples showed no evidence of methylation
within IR5 in either the normal or tumour tissue. Chromatograms for the
samples where methylation was observed are included in the Appendix (Figure
8.3)
3.4 LIMD1 and Rassf1a mRNA Expression is Reduced in the
Majority of Primary Lung Tumours Examined
In addition to genomic DNA, RNA was also extracted from the cohort of lung and
matched normal tissue in order that qRT-PCR analysis of mRNA expression could
be performed. cDNA was synthesised from the extracted RNA and LIMD1 mRNA
expression quantified to detect any differences in expression between lung
tumour and matched normal tissue. Rassf1a mRNA expression was also
quantified for the same reasons as was done for the MSP analysis.
The tumour mRNA levels of both genes showed a wide variation, with samples
having decreased, unchanged and increased amounts of expression when
compared to their matched normal tissue (Figure 3.11). For LIMD1 mRNA
expression levels, approximately 20% of tumours had no significant change in
mRNA expression, 50% of tumours showed an 80% or greater loss of expression
and a further 10% of tumours showed an increased expression. Similar changes
were also observed for Rassf1a mRNA expression; approximately 12% had no
change in expression levels, 50% showed an 80% or greater loss of expression
and 12% had an increase in expression.
Of the tumours analysed, similar changes in expression of both LIMD1 and
Rassf1a mRNA within the same sample were observed. Sample 16 showed no
significant changes in expression of either gene between normal and tumour
tissue. Samples 1, 3 and 43 showed a 50% reduction in mRNA of both genes in
the tumour samples, whilst samples 4, 28, 32 and 36 had no mRNA detected in
the tumour samples at all. Conversely, sample 10 showed an increase in both
gene expressions in the tumour sample.
Out of the nine tumour samples that exhibited evidence of LIMD1 methylation
(Figure 3.10), three showed greater than 50% decreases in mRNA expression.
Three samples had tumours that failed to generate a significantly analysable CT
value by qRT-PCR, putatively indicating that the gene is not expressed at all in
these samples. Interestingly two of these three samples (28 and 32) gave the
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same result when Rassf1a mRNA was assayed. Due to the close proximity of the
LIMD1 and Rassf1a genes, this could implicate within these tumours a large 3p
chromosomal alteration may have occurred.
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Figure 3.11: qRT-PCR analysis for LIMD1 and Rassf1a mRNA expression in lung
tumours when normalised to mRNA expression levels in matched normal lung
tissue. RNA was extracted from a cohort of 48 lung tumours and matched normal tissue
and cDNA synthesised. qRT-PCR was used to assay levels of (A) LIMD1 and (B) Rassf1a
mRNA and normalised to levels of the housekeeper GAPDH mRNA. Levels of
LIMD1/Rassf1a mRNA in normal tissue was then normalised to 1 (bold red line), so the
values displayed on the histogram are tumour mRNA levels as a proportion of normal
tissue mRNA levels. * p<0.05. Comparable data not obtained for LIMD1 samples 4, 19,
28, 32, 36 and 38 and for Rassf1a samples 4, 7, 8, 9, 28, 32, 36, 47.
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3.5 Epigenetic Silencing of LIMD1
Multiple tumour suppressor genes have been found to undergo promoter
PHWK\ODWLRQ LQ FDQFHUV WKDW FDXVH WKHP WR EHFRPH VLOHQFHG $]DĻ
deoxycytidine is a potent DNA methylation inhibitor that as a cytosine analogue
when incorporated into DNA during replication covalently binds to the
methylation maintenance methyltransferase Dnmt1. This reduces the available
free pool of Dnmt1 available to maintain the methylation pattern during mitosis,
as well as resulting in DNA repair, replacing potential methyl cytosines with
cytosine (Egger et al., 2004). As maintenance of the methylation pattern is
inhibited this ultimately causes DNA hypomethylation, and the re-expression of
genes. As methylation within the lung tumours examined in this study was
observed (Figure 3.10) in addition to the MB435 cell line (which does not
express LIMD1 despite having an intact gene; Figure 3.4), the possibility of
LIMD1 gene silencing by methylation was further investigated.
3.5.1 Optimisation of 5-azacytidine Treatment
Extensive studies on DNA methylation have revealed that different cell types and
genes respond to different concentrations of 5-azacytidine. Therefore a titration
of concentrations and time points of treatment with 5-azacytidine was carried
out on the MB435 cell line. Cells were treated with 5, 10, 20, 40, 60 or 100µM 5-
azacytidine for either 3 or 5 days. Expression of LIMD1 was analysed by Western
blot and hypomethylation of IR5 confirmed by sequencing using the same
primers as in Figure 3.4 (data not shown). After cells had been treated for 3
days, in all concentrations of 5-azacytidine, no LIMD1 expression was detected.
However, after 5 days of treatment with media changes every day with fresh
drug, LIMD1 expression was observed by Western blot at 40µM concentrations
of the drug and above (Figure 3.12). As a positive control for the Western blot,
lysate from LIMD1 expressing U2OS cells was used.
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Figure 3.12: Optimisation of the concentration of the DNA methylation inhibitor
GUXJ $]DĻGHR[\F\WLGLQH QHHGHG WR UHVWRUH /,0' H[SUHVVLRQ LQ WKH 0'$
MB435 cell line. MDA-MB435 cells were treated with differing concentrations of 5-Aza-
Cdr from 5 to 100µM for 5 days. Cells were then lysed and LIMD1 expression analysed by
:HVWHUQEORWZLWKǃDFWLQDVDORDGLQJFRQWURODQG826FHOOO\VDWHDVDSRVLWLYHFRQWURO
for LIMD1 expression. LIMD1 expression increases with increasing concentrations of the
drug.
The highest expression of LIMD1 was observed at the higher concentrations of
5-azacytidine (>40µM). MB435 cells were therefore subsequently treated for 5
days with 100µM azacytidine (with new drug containing media changed every
24hours). In addition to having untreated MB435 cells as a control, U2OS cells
were also treated with 5-azacytidine.
3.5.2 LIMD1 is Epigenetically Silenced in the non-LIMD1 Expressing
MDA-MB435 Cell Line
Treatment of LIMD1 expressing U2OS cells with 100µM 5-deoxycytidine had no
significant changes on LIMD1 expression when compared to untreated cells
(Figure 3.13). However, treatment of the non-LIMD1 expressing MDA-MB435
cells with 5-azacytidine caused LIMD1 expression (Figure 3.13). As a
confirmation that the expression was due to promoter hypomethylation, genomic
DNA was extracted and IR5 bisulphite sequenced (data not shown). The
sequencing result confirmed that following 5-azacytidine treatment, the region of
the promoter analysed was hypomethylated in the MDA-MB435 cell line, whilst
the promoter in U2OS cells maintained its hypomethylated state. Therefore, in
the MB435 cell line, LIMD1 is epigenetically silenced.
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Figure 3.13: Treatment of the non LIMD1 expressing MDA-MB435 cells with the
methylation inhibitor drug 5-Aza 2-deoxycytidine restores expression of LIMD1.
LIMD1 expressing U2OS and non LIMD1 expressing MDA-MB435 cells were treated with
100µM 5Aza-Cdr for 5 days. Cells were then lysed and LIMD1 expression analysed by
Western blot. Treatment of MDA-MB435 cells with 5Aza-Cdr resulted in LIMD1
expression.
3.6 Summary
Within the CpG Island in the LIMD1 promoter (Figure 3.1) a small 21bp region
(IR5) was been identified as being critical for transcription, as deletion of this
region reduced transcriptional activation by 90% (Figure 3.2). Within the LIMD1
expressing U2OS cell line, cytosine bases within CpG dinucleotides within the
IR5 region are unmethylated; however in the MDA-MB435 cell line that does not
express LIMD1 the bases are methylated (Figure 3.4). In a cohort of lung
tumours with matched normal tissue this same region also had evidence of
methylation in the tumour tissue, specifically at the fourth CpG dinucleotide
(Figure 3.10). qRT-PCR analysis of the same lung tumour cohort revealed the
presence of methylation correlated with a reduction in LIMD1 mRNA levels, and
the reduction in mRNA levels overall was similar to that of another well
characterised 3p21.3 tumour suppressor gene Rassf1a (Figure 3.11).
Furthermore, treatment of the MDA-MB435 cell line with the potent DNA
methylation inhibitor, 5-azacytidine, caused demethylation of IR5 within the
LIMD1 promoter and expression of LIMD1 protein (Figure 3.13), thus
demonstrating LIMD1, like other characterised tumour suppressor genes,
undergoes epigenetic silencing.
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Chapter 4 Results: Identification of PU.1 as a Major
Transcriptional Activator of LIMD1
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4.1 Introduction
The 21bp IR5 region within the CpG Island of the LIMD1 promoter is critical for
transcriptional activation; deletion of IR5 resulted in a 90% decrease in
transcription (Figure 3.2) and methylation of this region contributes to epigentic
silencing of LIMD1 (Figure 3.13). It was therefore hypothesised that the
reduction in transcription was indicative that IR5 contained a binding motif for
one or more critical transcriptional activators. The identity of such a factor(s)
was therefore the aim of this chapter of investigation.
4.1.1 IR5 within the LIMD1 Promoter is Perfectly Conserved Between
Different Mammalian Species
Species which diverged many millions of years ago, for example humans and
mice ca.75 million years ago, will have undergone evolutionary mutations and
selections, causing diversity in genomic sequences and resultant phenotypes.
However, genes and regulatory elements involved in expression of proteins
essential for cellular survival (e.g. TSG) and fertility (e.g. enzymes involved in
gametogenesis) remain conserved; a mutation that is either fatal or renders the
species infertile by definition is not inherited and as such these sequences
remain conserved (Boffelli et al., 2004). As such, homology of nucleotide
sequences between species has been used as a tool for identifying both genes
and enhancers whose protein product has a pivotol function in the survival of an
organism (Pennacchio and Rubin, 2001).
The LIMD1 promoter sequences from 13 different LIMD1 expressing mammalian
species were extracted from the Ensembl Genome Browser and aligned using the
multiple sequence alignment tool ClustalW. Initial attempts to simultaneously
align 2.5kb upstream of the ATG initiation codon between 13 different
mammalians proved problamatic due to a large number of small conserved
stretches of nucleotides causing mis-alignments. To overcome this problem, 200
base pair regions that encompassed 100bp both 5 and 3 to IR5 were aligned
and scrutinised for areas of homology (Figure 4.1). IR5 and a core region of IR7
were perfectly conserved bewteen all the mammalian genomes examined.
Interestingly IR6 was also highly (>80%) conserved between 8 of the species
examined. As deletion of IR7 did not result in a significant change in
transcriptional activity of the promoter, no further analysis of this region was
performed.
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Figure 4.1: IR5 within the LIMD1 promoter is perfectly conserved between
different mammalians and contains a putative PU.1 binding motif. LIMD1
promoter sequences from different mammalian organisms that express LIMD1 were
extracted from the Ensembl genome browser and aligned using ClustalW. Perfect
homology is observed at the IR5 and within the IR7 consensus. Further scrutinisation of
IR5 using MatInspector in silico transcription factor binding software identified a putative
PU.1 binding consensus sequence.
4.2 In Silico Analysis of the LIMD1 Promoter identifed a Binding
Motif for an Ets Transcription Factor
The combined observation of a 90% reduction in promoter transcriptional
activity by deletion of IR5 together with the perfect homology of IR5 between
the 13 species examined, indicated that this region likely contained a binding
site for one or more positive regulatory proteins. To identify any DNA binding
consensus sequences for specific transcription factors within this region, an in
silico transcription factor binding motif analysis was performed using the
MatInspector software. This analysis compares the genomic DNA nucleotide
sequence with the known nucleotide binding motifs of DNA binding proteins,
specifically transcription factors or co-activators. The computer algorithm then
assigns a score between 0 and 1.00 for any putative binding site matches, which
reflects the similiarity between the query sequence and the database of known
binding sequences. A score of 1.00 indicates a perfect match of the input
sequence with a previously identified binding consensus of a known transcription
factor, with any deviations in the consensus reducing the score accordingly. Any
score above 0.8 is considered a good score, which indicates a transcription
factor could bind to the sequence even though there may be one or more
H. sapien GCAGCAGGGA CTG-CGCCTG GCGCACTCAC TTCCGCGTCC CGCCGCCCTC CGGCCCGC-- GCGCGCCGAT CCGCCGCCGC CATCGGACAA TGGGCCGCCA
B. taurus GCGGCGGGGA CGG-CGTCCG GCGCACTCAC TTCCGCGTCC CGCCGCCCTC CGGCTCGC-- GCGCGCCCAG CCCCCGCCGC CATCGGACAA TAGACCAACC
S. scrofa GCGGCGGGGA CGG-CGTCCG GCGTACTCAC TTCCGCGTCC CGCCGCCCTC CGGCCCGC-- GCGCGCCTAG CCACCGTCAC CATCGGACAA TAGGCCGCCA
M. mulatta GCAGCAGGGA CTG-CTCCTG GCGCACTCAC TTCCGCGTCC CGCCGCCCTC CGGCCCGC-- GCGCCTCGAT CCGCCGCCGC CATCGGACAA TGGGCCGCCA
P. troglodytes GCAGCAGGGA CTG-CGCCTG GCGCACTCAC TTCCGCGTCC CGCCGCCCTC CGGCCCGC-- GCGCGCCGAT CCGCCGCCGC CATCGGACAA TGGGCCGCCA
P. pygmaeus GCAGCAGGGA CTG-CGCCTG GCGCACTCAC TTCCGCGTCC CGCCGCCCTC CGGTCCGC-- GCGCGCCGAT CCGCCGCCGC CATCGGACAA TGGGCCGCCA
G. gorilla GCAGCAGGGA CTG-CGCCTG GCGCACTCAC TTCCGCGTCC CGCCGCCCTC CGGCCCGC-- GCGCGCCGAT CCGCCGCCGC CATCGGACAA TGGGCCGCCA
C. jacchus GCCGTAGGGA TTG-TGCCTG GCGCACTCAC TTCCGCGTCC CGCCGCCCTC CGGCCCGC-- GCGCGCCCAG CCGCCGCCGC CATCGGACAA TGGGTCGACC
O. princeps GCGGCGGGGA CTG-CTCCCG GTGCACTCAC TTCCGCGTCC CGCCGCC--- ---------- ---------- --------GC CATCGGACAA TGGGCCGTCC
O. cuniculus GCGGCGGGGA CTG-CTCCGG GCGCACTCAC TTCCGCGTCC CGCCGCCCTC CGGCTGGCTC GTGCGCCGGG CCGCCGCCGC CATCGGACAA TGGGCCGCCC
M. musculus GCTCCCGGGA CTGACGACCC GCGCGCTCAC TTCCGCGTCC CGCCGCCG-- ---------- ---------- --GCCGCCGC CATCGGACAA TGGGCCGCGC
R. norvegicus GCTCCGGGGA TTGACTACTC GCGCGCTCAC TTCCGCGTCC CGCCGCCG-- ---------- ---------- --GCCGCCGC CATCGGACAA TGGGCCGCGC
C. familiaris GCGGCGGGGA CTG-CGTGCG GCGCGCTCAC TTCCGCGTCC CGCCGCCCTC CGGCCCGCG- ---------- --CCCGCCGC CATCGGACAA TAG------C
** **** * * * ***** ********** ******* * ********** * * .
IR5 IR7
PU.1
consensus
-678 -658
5’ctcacTTCCgcgtcccgccgc 3’
3’gagtgAAGGcgcagggcggcg 5’
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nucleotide discrepencies between the query sequence and the database of
known sequences.
To avoid the possibility of disrupting a putative consensus sequence by
selectively only analysing IR5 or the immediate surrounding regions, the entire
cloned promoter was analysed in the in silico search. From this analysis, three
transcription factors received a perfect match score of 1.0, including the well
characterised basal Transcription Factor II B (TFIIB), which makes up part of the
RNA Polymerase II Preintiation Complex. As the promoter deletion analysis
hypothesised that IR5 may contain an important transcription factor binding site,
this region was then selectively scrutinised. This revelaed a potential binding
consensus for the human and murine Ets factor Spi1/PU.1, which obtained a
score of 0.989. IR5 contained a matched consensus of gcGGAAgt on the anti-
sense strand at base pair position -673 to -670 relative to the predicted TSS
(Figure 4.2). As the algorithm screened the LIMD1 promoter in a 5 to 3
direction, the start, end and anchor positions for each transcription factor are
distance from the 5 end of the promoter, which itsef is at base -1990 relative to
the TSS. The positions of the binding sites relative to the TSS can therefore be
calculated by subtracting 1990 from the stated positions (i.e 1320-1990=-670).
The putative PU.1 binding site within IR5 has been annotated onto Figure 4.1.
The in silico analysis was the first indication that the transcription factor PU.1
may bind to the LIMD1 promoter within IR5 and so could be responsible for the
major transcriptional activation. However, as the Ets family of proteins bind to a
very similar core sequence of GGAA (Hsu et al., 2004), there was a probability
that another Ets factor may also bind this element. The raw data for DNA motif
analysis within the LIMD1 promoter is available at
http://www.sciencedirect.com/science/article/pii/S0014579311001669.
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Figure 4.2: In silico analysis of the LIMD1 promoter for transcription factor
binding sites. The cloned sequence of the LIMD1 promoter was scrutinised for
transcription factor binding sites using the MatInspector transcription factor binding
software. Analysis around the IR5 region identified Spi1/PU.1 as having a high matrix
similarity score of 0.989 (where 0.8 is classed as a good match and 1.00 is a perfect
match).
4.2.1 Mutation of the DNA Consensus for Ets Factor Binding within IR5
Reduces LIMD1 Promoter Driven Transcription
In silico analysis is a fast and simple method of identifying potential DNA binding
proteins for a specific consensus. However, as it is based on an algorithm and is
purely computational, when applied to an uncharacterised promoter it does not
prove the protein-DNA interaction occurs in vivo. To ascertain if the predicted
interaction occurs, in vitro and in vivo experiments were performed. It was
initially hypothesised that if PU.1 were to bind the predicted motif, mutation of
the consensus should abrogate any interaction between PU.1 and the LIMD1
promoter, and thus result in a significant decrease in transcriptional activity,
FRPSDUDEOHWRWKDWVHHQZLWK,Ʃ)LJXUH
Site directed mutagenesis was performed to mutate the putative PU.1/Ets
consensus from TTCC to TTTT (CCAPTT) and confirmed by sequencing. Since the
LIMD1-luciferase plasmid was ~8kb, it was not feasible to sequence check the
whole plasmid for other mutations that may have been introduced through PCR
amplification, although a proof reading Pfu was used in the PCR reactions.
Therefore the mutation was reverse mutated back to the wild type consensus
(TTAPCC) to check the resultant luciferase values returned to that of the wild
type promoter, ruling out any unseen mutations that may have given a false
Matrix
Family Detailed Family Information Matrix
Start
position
End
position
Anchor
position Strand
Core
sim.
Matrix
sim. Sequence
V$E2FF E2F-myc activator/cell cycle regulator V$E2F.03 1257 1273 1265 + 0.81 0.855 cgcggGCTCgggacgtg
V$HIFF Hypoxia inducible factor, bHLH/PAS protein family V$HRE.01 1262 1278 1270 + 1 0.931 gctcgggaCGTGcagag
V$CREB cAMP-responsive element binding proteins V$ATF6.02 1261 1281 1271 + 1 0.896 ggctcggGACGtgcagagccg
V$AP1R MAF and AP1 related factors V$MAFA.01 1269 1289 1279 + 0.905 0.942 acgTGCAgagccggcgagcga
V$NRSF Neuron-restrictive silencer factor V$NRSF.01 1284 1314 1299 + 1 0.737 gagcgAGCAgcagggactgcg
V$ZF5F ZF5 POZ domain zinc finger V$ZF5.01 1306 1316 1311 - 1 0.952 gagtGCGCcag
V$ETSF Human and murine ETS1 factors V$SPI1_PU1 1310 1330 1320 - 1 0.989 cgggacgcGGAAgtgagtgcg
V$SP1F GC-Box factors SP1/GC V$SP2.01 1322 1336 1329 - 1 0.849 gggcggcgGGACgcg
V$SP1F GC-Box factors SP1/GC V$SP1.03 1325 1339 1332 - 1 0.918 ggaGGGCggcgggac
V$CTCF
CTCF and BORIS gene family, transcriptional
regulators with 11 highly conserved zinc finger
domains
V$CTCF.02 1323 1349 1336 - 0.75 0.699 cgcgcgggccggagggcGGCGgga
V$STAF Selenocysteine tRNA activating factor V$ZNF76_143.01 1330 1352 1341 + 0.81 0.77 gccgCCCTccggcccgcgcgcgc
V$NRF1 Nuclear respiratory factor 1 V$NRF1.01 1337 1353 1345 - 1 0.839 ggcGCGCgcgggccgga
V$NRF1 Nuclear respiratory factor 1 V$NRF1.01 1338 1354 1346 + 0.75 0.797 ccgGCCCgcgcgcgccg
V$NRF1 Nuclear respiratory factor 1 V$NRF1.01 1339 1355 1347 - 1 0.789 tcgGCGCgcgcgggccg
V$ZF5F ZF5 POZ domain zinc finger V$ZF5.01 1342 1352 1347 - 1 0.967 gcgcGCGCggg
V$HESF Vertebrate homologues of enhancer of split complex V$HES1.01 1341 1355 1348 - 0.944 0.948 tcggcgcGCGCgggc
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positive result. As an additional control, a further downstream cytosine (still
within IR5) was mutated and then reverted back to wild type (CAPT and TAPC
respectively) (Figure 4.3A). This cytosine corresponded to the commonly
methylated cytosine in the primary lung tumours (Figure 3.10). These new
promoter mutated plasmids were co-transfected with a Renilla luciferase
normalisation vector into U2OS cells, and luciferase activity assayed after 24
hours. In addition to the new mutations, the Iȴ5 promoter mutation was also
transfected as a control for loss of transcriptional activity.
Mutation of the putative PU.1 consensus (CCAPTT) reduced LIMD1 promoter
driven transcription by over 90% (Figure 4.3B). This was comparable to that
VHHQZLWKWKH,ƩSURPRWHUGHOHWLRQ7KHVSHFLILFLW\LQUHGXFWLRQLQWUDQVFULSWLRQ
was confirmed as reversion of the mutation back to wild type restored luciferase
levels to that of the wild type promoter. Furthermore, mutating the downstream
cytosine resulted in luciferase values that were not significantly different to that
of the wild type promoter.
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Figure 4.3: Mutagenesis of the putative PU.1 motif reduces transcriptional
activity by 90%. (A) The PU.1 consensus (bold) within the full length LIMD1 promoter
was mutated using site directed mutagenesis from TTCC to TTTT (CC-TT; underlined). As
a control a separate C to T point mutant was created (C-T; underlined). Both mutant
consensus plasmids were reverse mutagenised back to the wild type sequence as a
FRQWURO %QJRI WKHPXWDWHGSODVPLGV DORQJZLWK WKHZLOG W\SHDQG ,ƩSURPRWHU
plasmids were co-transfected with 5ng of Renilla luciferase into U2OS cells and resultant
luciferase activity assayed 24hours post transfection. Mutation of the putative PU.1
consensus reduced transcriptional activity by 90%, comparable to the reduction seen with
WKH,ƩPXWDQW
WT CTCACTTCCGCGTCCCGCCGC
CC TT CTCACTTTTGCGTCCCGCCGC
TT CC CTCACTTCCGCGTCCCGCCGC
C T CTCACTTCCGCGTCCCGCTGC
T C CTCACTTCCGCGTCCCGCCGC
PU.1
consensus
0
0.2
0.4
0.6
0.8
1
1.2
No
rm
a
lis
e
d
Lu
c
ife
ra
s
e
Ac
tiv
ity
A
B
Chapter 4: Results
135
4.3 Identification of PU.1 Binding to the LIMD1 Promoter and
Activating Transcription
4.3.1 Sub-cloning of PU.1 into pcDNA4 His/Max TOPO and pCMV-HA
Vectors
Luciferase assays with the PU.1 consensus mutations provided the first in vivo
evidence to suggest PU.1/Ets factor binding to the LIMD1 promoter. In order to
investigate the identity of the protein that bound to the Ets consensus, in vivo
chromatin immunoprecipitation (ChIP) and in vitro electrophoretic mobility shift
assays (EMSA) were performed. These assays use antibodies targeted against a
specific protein, in this investigation PU.1, to analyse the presence of the protein
bound to the IR5 region of the LIMD1 promoter, and both techniques will be
discussed fully later on. To facilitate the ChIP and EMSA analysis, PU.1 cDNA was
subcloned into two expression vectors to allow for ectopic over expression;
pcDNA4 His/Max TOPO which encodes an Xpress and hexa-His epitope, and
pCMV-HA, which encodes a HA epitope onto the N terminal of the expressed
protein.
Human PU.1 cDNA was a kind gift from A. Rizzino (University of Nebraska
Medical Centre). Prior to sub-cloning of the cDNA, it was sequenced using
primers against the T7 promoter within the plasmid. Upon analysis of the
sequence, nucleic acid codons for the first four N terminal amino acids were
found to be omitted, and the sequence started with an alternative internal ATG
codon.
PCR primers were designed to incorporate the 4 missing codons, as well as 5
EcoR1 and a 3 BamH1 restriction enzyme sites to facilitate the downstream sub-
cloning of PU.1. Due to the long length of the primers, a gradient PCR was
carried out to determine the optimal annealing temperature using the high
fidelity hot start Phire (NEB) polymerase (Figure 4.4A). The correct sized
amplicon (816bp as obtained from Ref Seq NM_001080547.1) was generated
with all annealing temperatures from 52.0 to 64.0oC, the lower temperatures
gave a stronger more intense band than at higher annealing temperatures when
visualised under UV light with ethidium bromide staining, however this was also
accompanied by more smearing on the gel (Figure 4.4A). The PCR was therefore
repeated using a compromise annealing temperature of 57.1oC. After the PCR
had completed 35 cycles, one Unit of Taq Polymerase was added for ten minutes
at 70oC. The reason for this is that the high fidelity hot start Phire polymerase
does not possess the ability to add the 3 dA overhangs which were needed for
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The PU.1 cDNA was then subcloned into a pCMV-HA vector, which encorporates
a HA epitope tag onto the N terminus of the subcloned protein. PU.1 cDNA was
excised from the newly created pcDNA4-PU.1 plasmid using the encorporated
EcoR1 and BamH1 flanking restriction sites and ligated into the similarly cut
pCMV-HA vector (Figure 4.4D). Again colonies were selected after
transformation of the ligation and postive clones identified by restriction digest
and sequencing (Figure 4.4E).
4.3.1.1 PU.1 binds to the LIMD1 Promoter in vivo as demonstrated by
Chromatin Immunoprecipitation Assays
To identify if PU.1 was able to directly bind IR5, a chromatin
immunoprecipitation (ChIP) assay was employed. ChIP is a method for assaying
protein-DNA ineractions. In the assay, formaldehyde is used to crosslink protein
to DNA in cells (i.e transcription factors to the DNA promoters of genes) so that
any interactions (which may be transient) are stabilised throughout the
experiment. The nucleii are then extracted and the genomic DNA is sheared,
followed by subsequent immunoprecipitation of the transcription factor of
interest and analysis of any co-immunoprecipitated DNA by PCR and/or
sequencing.
For ChIP analysis, pcDNA4-PU.1 or pcDNA4-vector only (VO, as a control) were
transfected into HEK 293T cells. After formaldehyde crosslinking genomic DNA
was sheared by sonication to 200-500bp in length. The number of sonications
had to be empirically optimised for each cell type in order to generate fragments
of the correct size; too few sonications would produce larger DNA fragments
whilst too many sonications would produce much smaller DNA fragments. The
optimum number of sonications for the HEK 293T cells was 4 x 15s (Figure 4.5).
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Figure 4.5: Optimisation of HEK 293T genomic DNA shearing for subsequent
ChIP analysis. HEK 293T cells were treated with formaldehyde to crosslink protein to
DNA prior to lysis by sonication. For accurate ChIP analysis, the optimal genomic DNA
fragment length is 200-500bp, which is achieved through differential amounts of
sonication followed by analysis by visualisation on an ethidium bromide stained 1%
agarose gel. 4 x 15s pulses of sonication produce the correct sized fragments (4 x 15s
sonications), whereas less sonications (2 x 15s) produce a longer smear of genomic DNA
on the gel representing larger DNA fragments due to insufficient sonication.
The pcDNA4 vector encompasses an Xpress® epitope tag onto the subcloned
DNA, and so the ectopically expressed PU.1 or the VO were immunoprecipitated
with an anti-Xpress antibody. Protein immunoprecipitation was confirmed by
Western blot (Figure 4.6A). As a positive control for the ChIP assay, primers for
the previously characterised CD11b promoter to which PU.1 binds (Brugnoli et
al., 2009) were used alongside primers to encompass IR5 of the LIMD1
promoter. When PU.1 was immunoprecipitated, both the CD11b and LIMD1
promoter regions that encompass the PU.1 binding motif were co-
immunoprecipitated, as detected by PCR (Figure 4.6). These regions were not
detected when the VO was precipitated, showing that ectopic PU.1 specifically
binds to the LIMD1 promoter in vivo in HEK 293T cells.
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Figure 4.6: Exogenous PU.1 binds to the LIMD1 promoter in HEK 293T cells.
pcDNA4-PU.1 or vector only (VO) was transfected into HEK 293T cells. 48 hours post
transfection cells were serum starved overnight, then stimulated with 20% FCS before
protein and DNA were crosslinked and DNA was sheared by sonication. (A) PU.1 or
control VO were immunoprecipitated with 2.5µg of anti-Xpress and confirmed by Western
blot probed with anti-PU.1. (B) Co-immunoprecipitated DNA was purified and analysed by
PCR utilising primers for the previously characterised CD11b promoter as a positive
control along with primers encompassing the PU.1 motif within the LIMD1 promoter.
To then ascertain the relevance of ectopically expressed PU.1 bound to the
LIMD1 promoter the interaction between endogenous PU.1 and the LIMD1
promoter was assayed. As PU.1 is expressed at high levels in haematopoietic
derived cell lineages, the U937 histiocytic lymphoma cell line was assayed for
endogenous expression of both PU.1 and LIMD1 protein. Total cell lysate from
U937 cells was Western blotted and probed with anti-PU.1 and anti-LIMD1
antibodies. This analysis showed both proteins were expressed (Figure 4.7A) and
as such was a suitable cell line for endogenous ChIP analysis.
For ChIP analysis, endogenous PU.1 was immunoprecipitated from U937 cell
nuclei with an anti-PU.1 rabbit polyclonal antibody. As a matched isotype control
for antibody specificity, IgG from a non-immunised rabbit was used.
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4.3.2 PU.1 binds the IR5 region of the LIMD1 Promoter in vitro as
demonstrated by Electrophoretic Mobility Shift Assay
To further verify PU.1 binding to the LIMD1 promoter, in vitro electrophoretic
mobility shift assays (EMSA) were also performed. HEK 293T cells were
transfected with pCMV-HA-PU.1 48 hours prior to nuclear extraction and lysis.
Nuclear extracts were then incubated with a 32P-labelled oligo probe that had the
identical 21bp sequence of IR5. If PU.1 bound specifically to the probe, then a
protein-DNA complex would form and migrate slower on a non-denaturing gel
than the probe or PU.1 protein alone, and is known as a band shift. To identify if
the band shift contained PU.1 rather than a different nuclear protein complex,
addition of an anti-PU.1 antibody to the reaction would result in an even larger
antibody-PU.1-32P-oligo complex and would be retarded on a gel even further.
This is known as a super-shift. Any band shifts are visualised using
autoradiography on a phosphorimager.
Upon addition of HEK 293T HA-PU.1 transfected nuclear lysate to the 32P-labelled
oligo probe, 3 distinct band shifts are observed, corresponding to the formation
of protein-DNA complexes (Figure 4.8A lane 3). One of these bands is commonly
observed following addition of nuclear extract both in the presence and absence
of PU.1 (Figure 4.8A lanes 2 and 3). This band is unlikely to be PU.1 as HEK
293T cells do not express PU.1 at levels detectable by Western blot and so could
QRW EH DQ HQGRJHQRXV 38 FRPSOH[ 8SRQ DGGLWLRQ RI HLWKHU Į38 RU Į+$
antibodies, a supershift was observed. The intensity of the original band shift
significantly diminished (denoted by the arrow) and a new band of higher
molecular weight in the gel is observed (Figure 4.8A lanes 4 and 7). This
indicated the complex specifically contained PU.1. As a control for specificity of
PU.1 binding, antibodies against the Ets transcription factor family members Ets-
1 or Elk-1, or another transcription factor STAT3 were used. None of these
antibodies gave a supershift (Figure 4.8A lanes 5, 6 and 8), demonstrating the
band shift complex that formed contained PU.1, further strengthening the
evidence that PU.1 binds to the LIMD1 promoter.
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Figure 4.8: PU.1 specifically binds to the wild type but not mutated IR5
consensus. (A) HA-PU.1 was expressed in HEK 293T cells and nuclear extracts were
incubated with a 32P labelled oligonucleotide probe with sequence identical to that of IR5,
resulting in a band shift. Upon addition of either an anti-PU.1 or anti-HA antibody a
supershift is observed, but not with addition of control Ets-1, Elk-1 or STAT3 antibodies.
(B) Recombinant Ets domain of PU.1 was incubated with the same 32P labelled oligo
probe, resulting in a band shift. No band shift is seen with the recombinant Ets domain of
Ets-1. Upon addition of a 100 fold excess of cold unlabelled probe the band shift is out
competed. A 100 fold excess of cold probe where the PU.1 consensus has been mutated
does not compete out PU.1 binding and so the band shift remains. EMSA experiments
were kindly performed by Professor. P. E. Shaw.
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4.3.3 The Ets-domain alone of PU.1 binds to the LIMD1 Promoter
The Ets family of transcription factors exhibit a diverse range of functions, and
are able to specifically bind to highly homologous DNA sequences, with as little
as one base pair selecting for one transcription factor over another(Verger and
Duterque-Coquillaud, 2002). To show the specificity of PU.1s Ets domain alone
as the critical protein domain responsible for binding to the LIMD1 promoter, the
PU.1 Ets domain was sub-cloned into a pQE60 vector, which when transformed
into E. Coli produced recombinant glutathione-s-transferase (GST) and hexa-His
tagged PU.1 Ets domain. A further EMSA experiment was then performed with
the recombinant Ets domains used in place of nuclear extract. The Ets-domain of
Elk-1 had previously been cloned into the same vector and so was used as a
negative control. When recombinant PU.1 Ets domain was added to a radio-
labelled IR5 oligo probe, a band shift was observed, followed by a supershift
XSRQDGGLWLRQRIĮ+$DQWLERG\)LJXUH% ODQHVDQG7KLVFRUURERUDWHG
the previous results observed with HA-PU.1 transfected HEK 293T nuclear
extract. Addition of the Ets domain of Elk-1 did not cause a band shift (Figure
4.8B lane 4), showing the specificity for the Ets domain of PU.1 in binding the
LIMD1 promoter.
Previous mutational analysis of the PU.1 consensus resulted in a 90% decrease
in transcriptional activation from the promoter (Figure 4.3), which was
hypothesised to be due to inhibition of PU.1 binding. To prove if mutation of the
consensus did inhibit PU.1 binding, a further EMSA using the recombinant Ets
domains of PU.1 was carried out in a competition assay. When a 100 fold excess
of cold unlabelled IR5 oligo probe (compared to labelled probe) was added to the
assay, it was able to compete for binding to the PU.1 Ets domain, resulting in a
significant decrease in intensity of the band shift (Figure 4.8B lanes 2 and 5).
However, when a 100 fold excess of cold oligo containing a mutated PU.1
binding consensus was added instead (mt1 and mt2), this was unable to
compete for PU.1 binding and so did not affect band shift intensity (Figure 4.8B
lanes 2, 6 and 7). These data therefore support the initial reporter and ChIP
assay findings that PU.1 binds to the predicted PU.1 binding motif within the
LIMD1 promoter, and mutation of the consensus abrogates PU.1 binding and
reduces transcription accordingly.
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4.3.4 siRNA Mediated Depletion of PU.1 reduces LIMD1 Protein Levels
ChIP and EMSA analyses of the LIMD1 promoter (Figure 4.6, Figure 4.7 and
Figure 4.8) demonstrated that PU.1 was able to bind to the LIMD1 promoter
specifically at the PU.1 binding motif within IR5, and mutation of the consensus
abrogates this binding. In order to assess the physiological significance of this
interaction we reasoned that if PU.1 was a major transcriptional activator of
LIMD1 expression through binding to its promoter, loss of endogenous PU.1
protein should cause a loss of endogenous LIMD1 protein expression.
siRNA mediated gene silencing was therefore used to deplete endogenous PU.1
protein. For continuity with the endogenous ChIP assay (Figure 4.7B),
endogenous PU.1 depletion was carried out using U937 cells. U937 cells are a
suspension cell line that are difficult to transfect with either siRNA or DNA
(Martinet et al., 2003; Stroh et al., 2010). This compared to other monolyer
adherent cell lines within the lab (U2OS, HEK-293T, HeLa and MDA-MB435) that
were easy to transfect with both siRNA and DNA. Initially siRNA knockdown was
attempted with the standard laboratory siRNA transfection reagent Dharmafect 1
(Thermo Fisher). However, even at siRNA concentrations at up to 300nM,
knockdown of PU.1 was unsuccessful.
Another siRNA transfection reagent, Interferin (Polyplus Transfection) was tested
for ability to transfect the U937 cells. Transfection of high concentrations of
siRNA with this reagent proved unreliable due to low transfection efficiency,
however this was still more efficient than the Dharmafect 1 reagent. To check
that the transfection difficulties were due to cell type and not siRNA degradation
or a non-optimum sequence target, siRNA targeted against LIMD1 and using
Interferin was transfected into U2OS and HeLa cells alongside U937, utilising the
same mastermix of siRNA and reagent. Significant protein knockdown of LIMD1
was achieved in both the U2OS and HeLa cell lines (as quantified by Western
blot), however no significant knockdown was achieved in the U937 cells (Figure
4.9). This further confirmed that it was the U937 cells rather than the siRNA or
transfection reagent that was the problem. Electroporation had been reported as
being a successful way of transfecting monocytic cell lines, as limited DNA
trafficking in these cells prevents nuclear delivery of DNA through traditional
lipid based transfection reagents (Martinet et al., 2003; Stroh et al., 2010).
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Figure 4.9: Optimisation of siRNA transfection into U937 cells with a lipid based
transfection reagent. U937, U2OS and HeLa cells were transfected with 100nM LIMD1
or scrambled control siRNA using Interferin siRNA transfection reagent. 48 hours post
transfection cells were lysed in RIPA buffer supplemented with protease inhibitors and
LIMD1 protein levels assayed by Western blot, with actin as a loading control. In U2OS
and HeLa cells significant depletion of endogenous LIMD1 was observed, however in U937
cells no significant knockdown was observed. As depletion of LIMD1 was observed in
U2OS and HeLa cells, this indicated that the U937 cell line, rather than the siRNA and/or
the transfection reagent was the reason why protein depletion was not being achieved.
Using electroporation, 160pmol of siRNA oligo duplexes were electroporated into
a suspension of 1x106 cells, which successfully resulted in a significant
knockdown of PU.1 as detected by Western blot. siRNA depletion of endogenous
PU.1 in U937 cells caused a reduction in endogenous LIMD1 protein levels as
detected by Western blot (Figure 4.10A). As a control, siRNA depletion of Ets
family member Ets-1 had no effect on LIMD1 protein levels when compared to
the scrambled control, showing the reduction in LIMD1 was specific for PU.1
depletion. As a confirmation of the specificity of the siRNAs used in the
experiment, PU.1 mRNA levels were quantified following each of the siRNA
knockdowns (Figure 4.10B). Only the PU.1 directed siRNA caused a decrease in
PU.1 mRNA, ruling out any off target affects of the siRNA.
As the initial reporter assays were carried out in U2OS cells, the same siRNA
depletion experiment was also carried out in this cell line, where PU.1 levels
were detectable only by qRT-PCR and not Western Blot. siRNA depletion of PU.1
resulted in significantly reduced LIMD1 protein levels, almost as much as direct
LIMD1 targeted siRNA depletion (Figure 4.10C). Again as a control, siRNA
depletion of Elk-1 did not cause a decrease in LIMD1 protein levels. As with the
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results obtained from the U937 cells, qRT-PCR analysis of PU.1 mRNA levels
indicated only PU.1 directed siRNA caused a decrease (~70%) in PU.1 mRNA
levels (Figure 4.10D). Of note was a decrease in Elk-1 levels following LIMD1
depletion (Figure 4.10C), possibly implicating LIMD1 as a regulatory protein of
Elk-1 expression. This effect was seen to a lesser extent with PU.1 knockdown;
however, this can most probably be attributed to reduced LIMD1 protein levels
as a result of PU.1 knockdown.
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Figure 4.10: Depletion of endogenous PU.1 protein significantly reduces
endogenous LIMD1 protein levels. (A) siRNA targeted against LIMD1, PU.1, Ets-1 or
scrambled control were transfected into U937 cells and protein knockdown assayed by
Western blot. siRNA depletion of PU.1 protein resulted in a significant decrease in
endogenous LIMD1 protein levels. (B) As a control for siRNA specificity, PU.1 mRNA levels
for each siRNA knockdown were quantified by qRT-PCR, confirming only PU.1 targeted
siRNA negatively affects PU.1 mRNA. (C) siRNA targeted against LIMD1, PU.1, Elk-1 or
scrambled control were transfected into U2OS cells and protein knockdown assayed by
Western blot. siRNA targeted against PU.1 again significantly reduced LIMD1 protein
levels, comparable to the reduction seen. (D) Due to the low levels of PU.1 in U2OS, PU.1
knockdown was quantified by qRT-PCR, along with PU.1 mRNA levels following
transfection of the other targeting siRNAs. qRT-PCR analysis was kindly performed by Dr.
V. James.
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4.4 Summary
In this chapter, sequence alignment of the IR5 region within the LIMD1 promoter
of LIMD1 expressing mammalians identified the transcriptionally critical IR5
region is perfectly conserved between all species examined (Figure 4.1). In silico
analysis revealed a potential PU.1 binding site within IR5 (Figure 4.2), that when
mutated, resulted in a 90% decrease in transcriptional activity from the
promoter, similar to deletion of the whole IR5 (Figure 4.3). ChIP analysis
showed that both exogenous and endogenous PU.1 binds to the LIMD1 promoter
in vivo (Figure 4.6 and Figure 4.7), which also corroborated with both full length
and Ets domain only of PU.1 being able to bind to the IR5 consensus in EMSA
assays in vitro (Figure 4.8). Furthermore, mutation of the PU.1 consensus
prevented PU.1 binding (Figure 4.8B). The physiological relevance of PU.1
binding to the LIMD1 promoter was then confirmed by siRNA mediated depletion
of endogenous PU.1. This resulted in a significant reduction in LIMD1 protein
levels (Figure 4.10). Therefore, it can be concluded that PU.1 is a major
transcriptional activator of LIMD1 gene transcription.
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Chapter 5 Results: LIMD1 as a Regulator of the
Hypoxic Response
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5.1 Introduction
The intracellular response to low oxygen tensions is mediated by the protein
+,)Į,QQRUPR[LDR[\JHQ+,)ĮLVK\GUR[\ODWHGE\WKHDFWLYHSUROLQH
hydroxylase PHD2, whose activity is rate limited by the availability of oxygen.
)ROORZLQJ K\GUR[\ODWLRQ RI SUROLQHV  DQG  E\ 3+' K\GUR[\O +,)Į LV
recognised by the VHL component of the VBC E3 ubiquitin ligase complex, which
causes its ubiquitylation and subsequent 26S proteasome mediated degradation.
However, under hypoxic conditions, the low oxygen tension is rate limiting for
3+' DFWLYLW\ DQG DV VXFK LV QR ORQJHU DFWLYH 7KHUHIRUH +,)Į HVFDSHV
hydroxylation, and so recognition and ubiquitination by VHL cannot occur. The
QHW UHVXOW LV DQ LQFUHDVH LQ +,)Į SURWHLQ OHYHOV GXH WR LQFUHDVHG SURWHLQ
VWDELOLW\ 6WDELOLVHG +,)Į LV WKHQ SKRVSKRU\ODWHG DQG GLPHULVHV ZLWK +,)ǃ LQ
the nucleus to form the HIF1 transcription factor, which binds to hypoxic
responsive elements (HREs) within the 5 proximal promoter region of selected
genes, and enhances transcription through recruitment of p300/CBP. Preliminary
data identified over-expressed PHD2 and VHL as binding to LIMD1. Furthermore
PHD2 and the VHL containing VCB complex are both upregulated in hypoxia
through the presence of a HRE within their promoters. The in silico transcription
factor binding screen that identified the PU.1 binding motif also identified three
putative HRE elements within the LIMD1 promoter; therefore it was
hypothesised that LIMD1, like PHD2 and VHL, may also be responsive to
hypoxia.
5.2 The LIMD1 Promoter is Responsive to Hypoxia
5.2.1 LIMD1 Promoter Driven Transcription Increases Following
Hypoxic Exposure
To investigate if the LIMD1 promoter was responsive to hypoxia, the same
pGL4-LIMD1 promoter or vector only reporter plasmids used in the previous
promoter analysis (Figure 3.2) were transfected into U2OS cells and placed into
hypoxia for 0, 4, 8 or 24 hours. Cells were lysed in 1 x Passive Lysis Buffer and
luciferase activity assayed. Renilla luciferase values were normalised to firefly
values, and then for each time point the vector only values were normalised to
1. As an internal control for the hypoxic response in each experiment, additional
triplicate wells of U2OS were transfected with a luciferase plasmid that contained
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5x synthetic hypoxic responsive elements (HRE) within its promoter. As levels of
DFWLYH+,)ĮLQFUHDVHGLQK\SR[LDWKLVZRXOGLQFUHDVHWKHELQGLQJRI+,)WRWKH
HREs within the luciferase promoter, which would increase the levels of
luciferase transcript and protein produced. This thus gives an indirect
quantification of the intracellular hypoxic response.
The LIMD1 promoter showed an increase in luciferase activity at 8 and 24 hours
hypoxia (1% O2), with the 24 hours time-point showing the most significant
increase of activity (2 fold) when compared to the normoxic (20% O2) values
(Figure 5.1A). For analysis of the luciferase values in hypoxia, the corresponding
vector only time points were all normalised to 1, allowing the hypoxic LIMD1
promoter values to be directly comparable between each time point. The hypoxic
UHVSRQVHLH LQFUHDVHG+,)ĮSURWHLQ OHYHOVZDVFRQILUPHGE\DQ LQFUHDVH LQ
the HRE driven luciferase internal control (Figure 5.1B).
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Figure 5.1: Hypoxia causes an increase in LIMD1 promoter driven transcription.
(A) LIMD1 promoter driven firefly luciferase or firefly luciferase alone vector was co-
transfected along with a renilla luciferase vector for normalisation into U2OS cells.
Transfected cells were exposed to hypoxia (1% O2) for 0, 4, 8 or 24 hours and the
resultant luciferase protein assayed. LIMD1 promoter driven transcription was normalised
to the vector only values. After 24 hours hypoxia, a 2 fold increase in transcription is
observed. (B) A synthetic 5x hypoxic responsive element (HRE) driven renilla luciferase
was concurrently transfected into U2OS cells that were exposed to the same hypoxic time
course as in (A). The increase in resultant luciferase over the time course confirms an
LQFUHDVHLQK\SR[LF+,)ĮSURWHLQLQGXFWLRQ
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5.2.2 LIMD1 Protein Levels Increase Following Prolonged Hypoxic
Exposure
To confirm that the increase in synthetic luciferase mirrored a physiological
increase in LIMD1 protein total U2OS cell lysates were assayed by Western blot
following 24hours hypoxia, as this was the time point with the largest increase in
promoter driven transcription (Figure 5.1A). In order to observe modest
inductions in protein, the amount of lysate loaded onto the gel was titrated. This
was to ensure that when the blots were developed, the signal intensity was such
that the band intensity was semi-quantitative of the amount of protein on the
gel.
Following hypoxic exposure, a modest but significant increase in LIMD1 protein
was observed when lower amounts (2 and 4µl) of protein were loaded onto the
gel (Figure 5.2). As a control, PHD2 which is characterised as being up-regulated
in hypoxia, was also blotted as a control, and showed a clear increase in
K\SR[LDǃDFWLQZDVXVHGDVDFRQWUROIRUHTXDOORDGLQJRIFHOOQXPEHU2IQRWH
are the slightly higher amounts of actin observed in the normoxic samples,
indicating a higher cell number, which further supports the hypoxic dependent
increase in LIMD1 and PHD2 protein levels observed.
Figure 5.2: Hypoxic exposure increases LIMD1 protein levels. U2OS cells were
exposed to 24hours hypoxia prior to lysis and protein analysis by immunoblotting. In
order to visualise any differences in normoxic and hypoxic protein levels differing
amounts of lysate were loaded onto the gel (2µl to 8 µl) in order to capture band
intensities whilst they were in the quantitative stage. LIMD1 protein shows a modest
LQFUHDVH LQK\SR[LD O DQGO ODQHV DVGRHV WKHSUHYLRXVO\ FKDUDFWHULVHG3+'ǃ
actin was utilised as a loading control.
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5.3 Characterisation of the Hypoxic Responsive Element in the
LIMD1 Promoter
5.3.1 The IR3 Region of the LIMD1 Promoter is required for Hypoxic
Responsiveness.
This initial reporter experiment demonstrated that the LIMD1 promoter shows
increased transcriptional activity in hypoxia (Figure 5.1). To map the precise
region of the promoter responsible for this, the ten internal CpG Island deletion
mutants that were described previously (Figure 3.2) were again utilised. The ten
deletion mutants were transfected in U2OS cells, and the cells exposed to either
normoxia or 24 hours hypoxia prior to lysis as previously described. The
luciferase values were then double normalised. Firstly the values for the vector
only plasmids were normalised to one, and then the normoxic values for each
mutant were normalised to one. This resulted in clearer visualisation of the data,
as the hypoxic values represented the fold induction in transcriptional up-
regulation of the promoter in hypoxia compared to normoxia. Again the
induction of hypoxia was confirmed by using the HRE driven luciferase plasmid
internal control (data not shown).
The ten internal deletion mutants exhibited the same pattern of increases and
decreases in transcriptional activity that were observed in the initial promoter
analysis experiment (Figure 3.2 and Figure 5.3A). This pattern was mirrored
when cells were exposed to hypoxia. The wild type promoter exhibited a 3.5 fold
induction in activity in hypoxia (Figure 5.3), which was slightly higher than the
fold inductions seen previously. However the internal control HRE driven
luciferase plasmid also had a higher induction in hypoxia than in previous
experiments, which validates the hypoxic promoter inductions observed. The
LIMD1 promoter mutants exhibited a 2-3 fold increase in promoter activity, even
the Iȴ5 mutant that exhibited a 90% repression in normoxia showed increased
transcriptional activity following hypoxic exposure. The only exception was the
,Ʃ PXWDQW 7KH ,Ʃ PXWDQW VKRZHG QR VLJQLILFDQW LQFUHDVH LQ WUDQVFULSWLRQ
following hypoxic induction, indicating this region most probably contained a
functional HRE.
To more clearly assess the hypoxic inductions observed, for each deletion
mutant, the luciferase values (that had already been normalised to the renilla
values) were normalised to their respective matched normoxic value. The result
of this was the value for normoxia was 1.0, and the hypoxic value was then the
fold induction in transcription (Figure 5.3B). This allowed for clearer analysis of
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the hypoxic response, showing the Iȴ3 mutant had no significant increase in
transcription in hypoxia.
Figure 5.3: Deletion of internal region 3 (IR3) abolishes the hypoxic
responsiveness of the LIMD1 promoter. Ten consecutive internal deletions within the
LIMD1 promoter were co-transfected with a renilla normalisation plasmid into U2OS and
exposed to either 20% (N; normoxia) or 1% oxygen (H; hypoxia) for 24 hours. Cells
were then lysed and resultant luciferase protein assayed, with firefly values normalised to
renilla values. Luciferase values were double normalised (A) firstly to vector only values
to account for differential basal transcriptional activities under different oxygen tensions
and then to (B) the normoxic value so that the hypoxic value represented the fold
LQGXFWLRQ LQ WUDQVFULSWLRQ 'HOHWLRQ RI WKH ,Ʃ UHJLRQ DEROLVKHG WKH LQFUHDVH LQ
transcriptional activity in hypoxia observed with the wild type promoter, indicating this
region as containing a functional HRE.
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5.3.2 0XWDJHQHVLVRIWKH+5(RU+,)Į'HSOHWLRQ$EROLVKHVWKH+\SR[LF
Response of the LIMD1 Promoter
The hypoxic promoter analysis thus far had been carried out blind with respect
to comparing the result to the in silico promoter screening. Experimentally the
HRE within LIMD1 had been narrowed to IR3; this agreed exactly with one of the
matches in the in silico screen, which also predicted a HRE element within IR3.
The other two potential HRE elements predicted were 5 to the CpG Island.
+RZHYHU DV WKH ,Ʃ GHOHWLRQ DEODWHG WKH K\SR[LF UHVSRQVLYHQHVV RI WKH
promoter (Figure 5.3), this implicated the in silico identified non-CpG Island
HREs as being a false positive result.
To confirm the HRE within IR3 was functional and responsible for the increased
promoter activity in hypoxia, site directed mutagenesis was used to mutate the
HRE motif from CGTG to TACA. As the in silico analysis identified a total of three
potential HREs, for completeness, the other two predicted HREs were also
PXWDWHG LQ WKH VDPH ZD\ 7KH +5( PXWDQW SODVPLGV ZHUH QDPHG GHOWD Ʃ
HRE1, HRE2 and HRE3 in the order they appeared from the 5 end of the
SURPRWHU 7KHUHIRUH Ʃ+5( DQG  ZHUH WKH SXWDWLYH QRQIXQFWLRQDO UHVSRQVH
HOHPHQWV WKDWZHUHRXWVLGH WKH&S* ,VODQG DQGƩ+5(ZDVZLWKLQ ,5 LQ WKH
CpG Island. Similar to the hypothesis with PU.1 binding to the promoter, it was
K\SRWKHVLVHG WKDW LI +,)Į ZDV ELQGLQJ WR D +5( ZLWKLQ WKH SURPRWHU UHJLRQ
then mutation of the consensus should prevent the binding interaction, and as
such prevent the hypoxic response of the promoter.
In conjunction with the promoter HRE mutational analysis, another technique to
FRQILUP WKH K\SR[LF UHVSRQVH ZRXOG EH WR GHSOHWH +,)Į WKH PDMRU K\SR[LF
UHVSRQVLYH WUDQVFULSWLRQDO HQKDQFHU +,)Į LV RQO\ DFWLYH LQ K\SR[LD GXH WR
proteasomal degradation under normoxic conditions as previously described.
7KHUHIRUH GHSOHWLRQ RI +,)Į VKRXOG DEODWH DQ\ GLIIHUHQFHV LQ WUDQVFULSWLRQDO
activation as a result of hypoxia. Plasmids encoding shRNA targeted against
+,)Į RU D QHJDWLYH FRQWURO GURVRSKLOD +,)Į VK+,)Į RU VKGURV+,)Į
respectively) were transfected into U2OS cells 24 hours prior to transfection with
WKH PXWDWHG +5( SURPRWHU FRQVWUXFWV Ʃ+5( &HOOV ZHUH WKHQ H[SRVHG WR
either normoxia or 24 hours hypoxia prior to lysis and analysis of luciferase
(Figure 5.4).
7KHZLOG W\SHƩ+5(DQGƩ+5(LIMD1 promoter constructs all exhibited a 2
fold increase in transcriptional activation in hypoxia with the control shRNA,
showing that in U2OS cells there is no functional HRE at HRE1 or 2 (Figure 5.4).
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5.3.3 'HSOHWLRQRI(QGRJHQRXV+,)Į6LJQLILFDQWO\5HGXFHV(QGRJHQRXV
LIMD1 Protein.
To demonstrate the physiological significance of the hypoxic responsive element
within the LIMD1 promoter, the effect of depleting HIF1ɲ on endogenous LIMD1
protein expression within U2OS cells was examined. It was hypothesised that if
+,)ĮDFWLYLW\ZDVWKHPDLQUHTXLUHPHQWIRUWKHK\SR[LFUHVSRQVLYHQHVVRIWKH
LIMD1 SURPRWHU WKHQGHSOHWLRQRI+,)Į VKRXOGSUHYHQW DQ LQFUHDVH LQ /,0'
proteins levels in hypoxia.
7RWHVWWKLVK\SRWKHVLVHQGRJHQRXV+,)ĮZDVGHSOHWHGIURP826FHOOVXVLQJ
shRNA and LIMD1 protein levels assayed by Western blot following either
normoxic or hypoxic exposure. Again as a negative control shRNA against
'URVRSKLOD+,)ĮZDVLQFOXGHGKRXUVSRVWWUDQVIHFWLRQFHOOVZHUHH[SRVHGWR
1% oxygen for 24hours, and then lysed in RIPA supplemented with protease
inhibitors and MG132 (a potent inhibitor of the 26S proteasome, used to prevent
GHJUDGDWLRQRI+,)ĮIROORZLQJFHOOO\VLV([SUHVVLRQOHYHOVRI+,)ĮDQG/,0'
SURWHLQ ZHUH WKHQ TXDQWLILHG E\ :HVWHUQ EORW ZLWK ǃ DFWLQ XVHG DV D ORDGLQJ
control.
.QRFNGRZQRI+,)Į LQK\SR[LDUHVXOWHG LQDUHGXFWLRQ LQ/,0'SURWHLQOHYHOV
ZKHQ FRPSDUHG WR WKH FRQWURO GURVRSKLOD +,)Į GHSOHWHG FHOO H[WUDFWV )LJXUH
5.5). These data support the reporter assay data (Figure 5.1) showing that
LIMD1 driven transcription is up regulated in hypoxia and the HRE mutation
H[SHULPHQWV ZKLFK VXJJHVWHG +,)Į PHGLDWHV WKH K\SR[LF UHVSRQVH RI WKH
LIMD1 promoter (Figure 5.4). The shRNA experiment also showed that a
GHSOHWLRQRIWKHORZOHYHOVRI+,)ĮLQQRUPR[LDDOVRUHVXOWHGLQDGHFUHDVHLQ
LIMD1 protein (Figure 5.5).
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5.4.1 LIMD1 Binds Directly to PHD2 in vitro
In order to address if LIMD1 directly bound to PHD2, an in vitro direct binding
assay using recombinant LIMD1 and recombinant PHD2 was performed.
pGEX4T-PHD2 and pGEX6P-LIMD1 were transformed separately into the pLysS
strain of BL21 E.coli, and expression of the recombinant proteins induced with
0.5mM IPTG. pGEX6P-LIMD1 was purified onto glutathione beads and eluted
with PreScission protease, with the extent of purification assayed by Western
blot (Figure 5.6). GST-LIMD1 is 100kDa in size (GST=25kDa, LIMD1=75kDa);
following cleavage a band of 75kDa is observed in the supernatant (Figure 5.6
middle lane), showing successful cleavage of GST-LIMD1. The lower banding
represents shorter fragments of LIMD1 that arise from degradation of the full
length GST-LIMD1. To confirm loss of recombinant LIMD1 from the glutathione
sepharose beads, following cleavage the beads were also subject to Western
blot. Fifty times more beads were loaded onto the gel post cleavage than pre-
cleavage, yet the intensity of bands is still significantly less than the input,
confirming successful recombinant LIMD1 cleavage (Figure 5.6 lanes 1 and 3).
Figure 5.6: Recombinant pGEX6P-LIMD1 can be expressed, purified and cleaved
from glutathione sepharose. pGEX6P-LIMD1 or vector only was transformed into BL21
pLysS E.Coli and protein expression induced by IPTG. Bacteria were lysed by sonication
and recombinant GST-LIMD1 or vector only purified onto glutathione sepharose. The
protein was cleaved from the glutathione-s-transferase tag using PreScission protease.
Successful cleavage was detected by resolving the indicated cleaved supernatants or
reduced glutathione sepharose by SDS PAGE and immunoblotting with anti-LIMD1.
Recombinant LIMD1 was successfully purified onto glutathione sepharose (Purified GST
protein (1%)), then eluted following cleavage with PreScission protease(Cleaved GST
Protein (1%)), leaving only a small amount of uncleaved protein on the beads
(Glutathione beads post cleavage (50%), note 50% more beads in lane 3 than lane 1).
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pGEX4T-PHD2 (GST=25kDa, PHD2=50kDa) was expressed and purified onto
glutathione beads (but not eluted), and expression confirmed by Western blot
with an anti-PHD2 antibody (Figure 5.7A). The purified and cleaved recombinant
LIMD1 was then incubated with the purified and immobilised PHD2, and
following washing of the beads any bound protein was eluted with SDS sample
buffer and analysed by Western blot. Recombinant purified and cleaved LIMD1
specifically bound to the purified and immobilised recombinant GST-PHD2
(Figure 5.7B), thus demonstrating LIMD1 directly interacts with PHD2.
Figure 5.7: Recombinant LIMD1 directly binds to recombinant PHD2. (A)
Recombinant GST-PHD2 or vector only was bound and purified onto glutathione
sepharose 4B. (B) Recombinant LIMD1 was purified onto glutathione sepharose, and
cleaved from the GST moiety using an on bead digest with PreScission protease. Eluted
LIMD1 was added to GST-PHD2 or vector only from (A), incubated for 6 hours, washed
and proteins eluted from the glutathione beads with SDS sample buffer. Eluted proteins
were analysed by immunoblotting. Recombinant LIMD1 was found to directly bind to
recombinant PHD2 in vitro.
kDa
BLOT: PHD2
75
50
37
100
25
BLOT: LIMD1
75
50
37
100
25
kDa
A B
Chapter 5: Results
162
5.4.2 LIMD1 interacts Endogenously with PHD2, VHL and VCB Complex
Proteins
The direct binding assay indicated that PHD2 and LIMD1 were able to interact in
vitro and preliminary over-expression data identified that PHD2, VHL and LIMD1
all interact. However for physiological relevance it was critical to demonstrate
that this interaction occurred endogenously. Therefore, in vivo endogenous
immunoprecipitations were performed next.
5.4.3 Optimisation of Endogenous Co-immunoprecipitations Methods
Endogenous immunoprecipitations required significant optimisation in order to
obtain robust evidence of an in vivo interaction. Initially, immunoprecipitations
were performed with antibodies against LIMD1, PHD2 and VHL. Dependent upon
the epitope binding region, binding of an antibody to its target protein can
disrupt endogenous protein-protein binding, and so the three different antibodies
were used to avoid this issue.
As the majority of the work regarding LIMD1 and its role in hypoxic regulation
had been performed in U2OS cells, these cells were again used for the initial
immunoprecipitations. To obtain complete cell lysis, cells were lysed in RIPA
buffer, which contains the denaturing agent SDS, the detergent NP40 and a
physiological concentration of NaCl (150mM), making it a stringent buffer. Initial
immunoprecipitations were performed in RIPA, followed by 4 washes of the IP-
bead matrix, again with RIPA. These results indicated that the anti-LIMD1 and
VHL antibodies were able to successfully immunoprecipitate their target protein
(Figure 5.8A and B).
PHD2 is 48kDa in size, and due to cross reactivity of the secondary antibody
with the immunoprecipitating PHD2 IgG heavy chain (molecular weight 50kDa) it
was difficult to distinguish between PHD2 and the IgG heavy chain via Western
blot (Figure 5.8C). Therefore until optimisation of the immunoprecipitations had
been fully carried out, immunoprecipitation with this antibody was omitted.
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For the first experiments, the standard lab protocol was to carry out 4 x 5min
washes of the IP matrix using RIPA buffer following incubation of the antibody
and lysates. However, following this the co-immunoprecipitated proteins were
only detectable as faint bands (Figure 5.9A). Furthermore, with the LIMD1
antibody, the amount of precipitated and co-immunoprecipitated protein was
substantially less than with the VHL antibody (Figure 5.9A). Therefore, for
optimisation purposes only immunoprecipitation with the VHL antibody was
pursued.
Nonspecific binding to the isotype control antibody was the major problem
incurred with the immunoprecipitation experiments. To optimise this, the length
of time the antibody was incubated with the cellular lysates was reduced from
overnight (16-20 hours) to 4 hours, which significantly reduced the non specific
binding (Figure 5.9B).
To further eliminate non-specific binding, whilst maintaining specific co-
immunoprecipitation, the buffer for washing of the IP-bead matrix, along with
the number of times the IP matrix was washed following incubation was
optimised by carrying out a titration of between 2 and 6 washes. The level of co-
immunoprecipited protein was high at 2 washes and systematically decreased as
the number of washes increased. However, with fewer washes the level of non-
specific binding to the isotype control increased. The optimal point for these two
parameters was 3 washes. Furthermore, instead of using pure RIPA for the
washes, a wash buffer of 50/50 PBS/RIPA was used to reduce the stringency of
the washes; this helped eliminate binding of proteins to the isotype control
whilst concurrently being the correct stringency so that the degree of co-
LPPXQRSUHFLSLWDWHG SURWHLQV ZHUH PDLQWDLQHG ZLWK WKH VSHFLILF Į9+/ ,3
complex.
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Figure 5.9: Optimisation of endogenous immunoprecipitations. (A) Following initial
RYHUQLJKWLPPXQRSUHFLSLWDWLRQZLWKDQWL/,0'9+/DQGLVRW\SHFRQWUROĮ*)3Į
cortactin) antibodies where the IP matrix was washed 6 times, only low levels of co-
immunoprecipitated PHD2 protein was detected after a long exposure Western blot.
Furthermore, co-immunoprecipitated protein with the VHL antibody was significantly
greater than that observed with the LIMD1 antibody. (B) Reduction of the incubation time
between the antibody and cell lysate from 16hr to 4hr resulted in a significant decrease in
QRQ VSHFLILFELQGLQJRI SURWHLQ WR WKH FRQWURO Į*)3DQWLERG\ &  7RHVWDEOLVK LI FHOO
number was a limiting factor in the experiment, HeLa and HEK293T cells were used as
they have a greater cell number per area when confluent compared to U2OS cells.
Immunoprecipitation of VHL resulted in co-immunoprecipitation of LIMD1 in all three lines
tested; however, larger amounts of input and co-immunoprecipitated proteins were
observed in the HeLa and HEK293T lysates.
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For immunoprecipitations, U2OS cells from a confluent 15cm plate were used.
Contact inhibition in this cell line meant that the cell density achievable in a
confluent 15cm plate of U2OS was less than that of other cell lines. To establish
if cell number (i.e. amount of protein) was limiting the immunoprecipitations, 2
other well established cell lines within the lab, HeLa and HEK293T, were used in
the immunoprecipitations as in a 15cm plate format, a greater cell
number/density could be achieved compared to U2OS. The higher cell number
was reflected by greater protein input levels (as detected by Western blotting
1% of the total cell lysate), and subsequently greater levels of co-
immunoprecipitated protein (Figure 5.9C).
The final step of optimisation was to increase the amount of antibody used in the
immunoprecipitation from 4µg to 5µg. So far the other possibly limiting steps
(antibody, number of washes, wash buffer and cell number) had been optimised.
Increasing the amount of immunoprecipitating antibody made the significant
difference in these experiments; the amount of co-immunoprecipitated protein
was substantially increased. This implied that the lower amount of
immunoprecipitating antibody in the initial experiments was the limiting factor
and not sufficient to precipitate all of the available endogenous complexes.
5.4.4 Endogenous VHL, LIMD1 and PHD2 Co-Immunoprecipitate In
Vivo.
Immunoprecipitation of endogenous VHL from HEK 293T cells using 5µg of anti-
VHL antibody, resulted in co-immunoprecipitation of endogenous LIMD1 and
PHD2, demonstrating their association in an endogenous in vivo complex (Figure
5.10). In addition to having the isotype antibody as a control, two proteins that
are part of the VCB complex and bind VHL, elongin B and cullin 2, also co-
immunoprecipitated, further corroborating the specificity and integrity of the
endogenous complex in vivo.
When VHL was immunoprecipitated, there are five bands of different molecular
weights between ~19 and 35kDa observed. However, in the input lane, only two
molecular weights are observed, which correspond to the characterised p19 and
p25 isoforms. The other bands are of unknown origin; multiple VHL banding has
been previously identified (Liu et al., 2011), but the identity of the modification
was unknown. Similarly, following co-immunoprecipitation of LIMD1, as well as a
molecular weight band of 75kDa that corresponds to what is observed in the
input, three additional higher molecular weight bands are also observed that
correspond to a modified LIMD1. However, as both LIMD1 and VHL are part of a
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concentrated ubiquitin ligase complex, and VHL itself becomes ubiquitylated (Liu
et al., 2011), it could be speculated that these extra forms could represent
ubiquitylated VHL or LIMD1.
Figure 5.10: Co-immunoprecipitation of LIMD1, PHD2, elongin B and cullin 2
when VHL is immunoprecipitated. A confluent 15cm plate of HEK 293T cells were
lysed and the clarified lysate was added to 5µg of anti-VHL or anti-GFP (used as an
isotype control as both antibodies are IgGŦ) antibody conjugated to 35µl of IP matrix
beads. After 4 hours incubation at 4oC with rotation, the beads were washed three times
and eluted in 5 x SDS loading buffer and co-immunoprecipitated proteins analysed by
Western blot.
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The same protocol was then repeated for endogenous co-immunoprecipitations
using HeLa and U2OS cell extracts. By comparing the intensity of the input
bands between the different cell lysates (Figure 5.10 and Figure 5.11), it can be
seen that there was substantially more protein in the HEK 293T cell lysate than
in U2OS or HeLa lysates. However, LIMD1 still co-immunoprecipitated in both
these cell lines. Elongin B and cullin 2 also co-immunoprecipitated with VHL in
the HeLa cell line. However, due to the lower protein concentration in the U2OS
lysate cullin 2 or Elongin B could not be detected by Western blot in the input or
co-immunoprecipitated samples (data not shown).
Figure 5.11 LIMD1 co-immunoprecipitates with VHL in U2OS and HeLa cell lines.
A confluent 15cm plate of HeLa or U2OS cells were lysed and the clarified lysate was
added to 5µg of anti-VHL or anti-GFP (used as an isotype control as both antibodies are
IgG clones) antibody conjugated to 35µl of IP matrix beads. After 4 hours incubation at
4oC with rotation, the beads were washed three times and eluted in 5 x SDS loading
buffer and co-immunoprecipitated proteins analysed by Western blot. (A) LIMD1
specifically co-immunoprecipitates with VHL in U2OS cells and (B) in HeLa cells, where
elongin B and cullin2 also co-immunoprecipitate.
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The endogenous immunoprecipitations were then repeated using a PHD2
antibody for the immunoprecipitation. In order to overcome the problems
previously described regarding cross reactivity of the secondary anti-rabbit
antibody with the anti-PHD2 IgG heavy chain (Figure 5.8C) a mouse monoclonal
PHD2 antibody was purchased. Immunoprecipitations were carried out with the
mouse monoclonal PHD2 antibody, and Western blot analysis with the rabbit
polyclonal antibody, thus eliminating the cross-reactivity issue. This modification
to the protocol allowed clear visualisation of immunoprecipitated PHD2 with co-
immunoprecipitation of LIMD1 in all the cell lines analysed; HEK 293T, HeLa and
U2OS (Figure 5.12).
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Figure 5.12: Endogenous co-immunoprecipitation of LIMD1 with PHD2. A
confluent 15cm plate of HEK-293T, U2OS and HeLa cells were lysed and added to 5µg of
anti-PHD2 or anti-GFP (used as an isotype control as both antibodies shared the same
IgG) antibody conjugated to 35µl of IP matrix beads. After 4 hours incubation at 4oC with
rotation, the beads were washed three times and eluted in 5 x SDS loading buffer.
Immunoprecipitation of PHD2 and co-immunoprecipitation of LIMD1 was analysed using
Western blot with rabbit polyclonal anti-PHD2 and monoclonal anti-LIMD1 in (A) HEK
293-T, (B) U2OS and (C) HeLa cells.
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As a final confirmation for specificity and integrity of the immunoprecipitation
experiments, reactivity of the immunoprecipitating antibody alone with the
DQWLERGLHV XVHG IRU :HVWHUQ EORW DQDO\VLV ZDV DVVD\HG 7KH Į9+/ 3+' DQG
LIMD1 monoclonal antibodies were conjugated to the IP matrix beads and
incubated overnight, as was done for the actual immunoprecipitation
experiments. The antibodies were then eluted from the beads using 5 x SDS
EXIIHUDQGDQDO\VHGE\:HVWHUQEORWZLWKĮ/,0'DQG9+/DQWLERGLHV )LJXUH
5.13).
Figure 5.13: 7KHĮ9+//,0'DQG3+'PRQRFORQDODQWLERGLHVGRQRWSURGXFH
any non-IgG bands on a Western blot when probed with VHL or LIMD1
antibodies. To confirm specificity of the bands observed following Western blot of the
LPPXQRSUHFLSLWDWLRQ H[SHULPHQWV Į9+/ 3+' DQG /,0' DQWLERGLHVZHUH FRQMXJDWHG
overnight to IP matrix beads, eluted with 5 x SDS loading buffer and analysed by
:HVWHUQEORW&URVVUHDFWLYLW\RIWKHĮPRXVHVHFRQGDU\DQWLERG\FDXVHVWKHDSSHDUDQFH
of the IgG heavy (50kDa) and light (25kDa) chains on a Western blot when probed with
$ Į/,0' RU % Į9+/ DQWLERGLHV1R RWKHU EDQGV DUH REVHUYHG HYHQ DIWHU D ORQJ
exposure, showing the bands observed following the immunoprecipitation experiments
are from specific in vivo protein-protein interactions.
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Following Western blot analysis, cross reactivity of the mouse monoclonal
LPPXQRSUHFLSLWDWLQJ DQWLERG\ ZLWK WKH ĮPRXVH VHFRQGDU\ DQWLERG\ SURGXFHG
bands on the blots that corresponded to the IgG heavy (50kDa) and light
(25kDa) chains (Figure 5.13). No other bands were observed, even after a long
30minute exposure. Therefore, it can be concluded that the bands observed
following the endogenous immunoprecipitation experiments are specific, and as
such reinforces the integrity of the identified in vivo endogenous interactions.
5.4.5 LIMD1 Protein Loss Inhibits Adaptation to Chronic Hypoxia
8QGHU H[SRVXUH WR D UHGXFHG R[\JHQ WHQVLRQ WKH OHYHO RI +,)Į SURWHLQ
LQFUHDVHVGXHWRGHFUHDVHG3+'DFWLYLW\WKDWSUHYHQWVK\GUR[\ODWLRQRI+,)Į
and subsequent recognition and ubiquitylation by VHL. The increase in protein
continues until approximately 24 hours post hypoxia, during a phase known as
acute hypoxia. After the initial 24 hours, cells enter a period of prolonged
oxygen starvation known as chronic hypoxia, where the cell begins to adapt to
WKH K\SR[LF FRQGLWLRQV DQG LV FKDUDFWHULVHG E\ D GHFUHDVH LQ OHYHOV RI +,)Į
SURWHLQ$GDSWDWLRQ WRK\SR[LD LV FULWLFDODV+,)ĮSURPRWHV WKHH[SUHVVLRQRI
angiogenic and proliferative genes, as well as growth factors that induce signal-
transduction pathways that promote cell survival and so to avoid cellular
WUDQVIRUPDWLRQ DQG XQFRQWUROODEOH SUROLIHUDWLRQ WKH OHYHOV RI +,)Į DQG
associated genes must be attenuated (Semenza, 2003).
PHD2 is the proline hydroxylase within cells that has the greatest activity
WRZDUGV+,)ĮZKHUHLWIDFLOLWDWHVSUROLQHK\GUR[\ODWLRQRI+,)ĮZKLOVWXWLOLVLQJ
O2 as a substrate. Thus under hypoxic conditions where O2 is limiting,
K\GUR[\ODWLRQRI+,)ĮGRHVQRWRFFXUDQGVRWKHSURWHLQLVVWDELOLVHGDVLWLVQRW
recognised by VHL, ubiquitinated or degraded. Contradictory to this central
GRJPD RI +,)Į UHJXODWLRQ D QXPEHU RI SXEOLFDWLRQV KDYH GHPRQVWUDWHG WKDW
PHD2 is still active under hypoxic conditions. siRNA mediated depletion of PHD2
LQK\SR[LDKDVEHHQVKRZQWRFDXVHDQ LQFUHDVH LQ OHYHOVRI+,)Į LQK\SR[LD
implicating PHD2 to still be active under these conditions. Furthermore, the
promoter of PHD2 contains a HRE and as such under hypoxia an increase in
protein levels is observed. To date the reason for this is not fully understood,
however it is generally postulated that the increased levels are to pre-empt the
FHOOVIRUUDSLGGHJUDGDWLRQRI+,)ĮVKRXOGWKH\EHFRPHUHR[\JHQLVHGLQRUGHU
to ablate the hypoxic response. The increase in levels of PHD2 in hypoxia is one
RIWKHPDMRUFDYHDWVLQWKHXQGHUVWDQGLQJRI+,)ĮELRORJ\
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%RWK3+'DQG/,0'DUHLQYROYHGLQWKHGHJUDGDWLRQSDWKZD\IRU+,)Į/,0'
directly binds to PHD2 (Figure 5.7), forming a complex with VHL (Figure 5.10
and Figure 5.11) and contains a HRE in its promoter causing its up-regulation in
hypoxia (Figure 5.1). It was therefore hypothesised that if LIMD1 was a true
FRPSRQHQWRIWKH+,)ĮGHJUDGDWLRQSDWKZD\GHSOHWLRQRI/,0'ZRXOGFDXVHD
VWDELOLVDWLRQRI+,)ĮSURWHLQVLPLODUWRWKHGHVFULEHGHIIHFWVRI3+'GHSOHWLRQ
To assay this, siRNA mediated depletion of LIMD1 was carried out in U2OS cells,
which were then exposed to up to 72 hours hypoxia. As controls scrambled or
PHD2 siRNA were transfected in parallel, along with a combination of LIMD1 and
PHD2 siRNA. Cells were then lysed in 1 x Passive Lysis Buffer (Promega)
VXSSOHPHQWHGZLWK00*DQGOHYHOVRI+,)Į/,0'3+'DQGDFWLQDV
a control for equalised loading) in the lysates were assayed by Western blot
(Figure 5.14).
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Figure 5.14: siRNA mediated depletion of LIMD1, PHD2 or combined LIMD1 and
3+'NQRFNGRZQLQFUHDVHV+,)ĮSURWHLQOHYHOVLQQRUPR[LDDFXWHDQGFKURQLF
hypoxia. siRNA was used to deplete either endogenous LIMD1, PHD2, or both LIMD1 and
PHD2, alongside a scrambled control in U2OS cells. Cells were then exposed to hypoxia
for 0, 4, 16, 24, 48 or 72 hours, lysed in Passive Lysis Buffer (Promega) supplemented
with 10µM MG132 and resultant protein levels assayed by immunoblotting. Depletion of
/,0'DQG3+'SURWHLQVERWKLQGHSHQGHQWO\RUWRJHWKHUUHVXOWHGLQDQLQFUHDVHLQ+,)Į
protein levels at all time points assayed showing LIMD1 (and PHD2) are critical for
UHJXODWLRQ RI +,)Į LQGHSHQGHQW RI R[\JHQ WHQVLRQ
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In normoxia, following treatment with the control siRNA, only very low levels of
+,)ĮDUHSUHVHQWGXHWRLWVUDSLG3+'9+/PHGLDWHGGHJUDGDWLRQ7KHOHYHOV
RI +,)Į WKHQ LQFUHDVH WKURXJK H[SRVXUH WR  DQG  KRXUV K\SR[LD GXH WR
inactive PHD2), with no further increase seen after 24 hours. After 48 and 72
KRXUVWKHOHYHOVRI+,)ĮWKHQVLJQLILFDQWO\UHGXFH)LJXUHFRQWURO ODQHV
This trend follows the published and described level of expression through
normoxia, acute and chronic hypoxia (Stiehl et al., 2006).
:KHQ /,0' SURWHLQ LV GHSOHWHG DQ LQFUHDVH LQ +,)Į SURWHLQ LV VHHQ LQ
normoxia, as previously identified and described in the preliminary data (Figure
,QK\SR[LDWKHLQFUHDVHLQ+,)ĮSURWHLQOHYHOLVVLJQLILFDQWO\H[DJJHUDWHG
through to 24 hours when compared to the control siRNA. As cells enter chronic
K\SR[LD+,)ĮSURWHLQ OHYHOVGHFUHDVHEXW DUH VWLOO VLJQLILFDQWO\KLJKHU WKDQ LQ
WKHFRQWURO2YHUDOOORVVRI/,0'KDGDVWDELOLVLQJHIIHFWRQ+,)ĮDQGWKLVZDV
independent of oxygen tension; i.e. loss of LIMD1 inhibits the adaptive response
to hypoxia.
Depletion of PHD2 resulted in an even greater stabilisation and increase in levels
RI +,)Į WKDQ ZLWK /,0' GHSOHWLRQ 7KH LQFUHDVH LQ +,)Į IURP QRUPR[LD WR
16/24 hours hypoxia is seen in the same manner as with the control or LIMD1
knockdown. However no decrease is observed in chronic hypoxia. A possible
H[SODQDWLRQIRUWKLVFRXOGEHWKDWEHFDXVHWKHPDMRULW\RI+,)ĮGHJUDGDWLRQE\
WKHSURWHDVRPHLVGHSHQGHQWXSRQWKHLQLWLDOK\GUR[\ODWLRQRI+,)ĮDEODWLRQRI
this initial step (through siRNA depletion of PHD2) inhibits all the further
GRZQVWUHDPSURFHVVHV WKDWFXOPLQDWH LQGHJUDGDWLRQRI+,)ĮWKHUHIRUH3+'
ORVVKDVDPRUHSRWHQWVWDELOLVDWLRQHIIHFWRI+,)ĮWKDQ/,0'ORVVGRHV
8SRQFRPELQHGGHSOHWLRQRI /,0'DQG3+' WKHREVHUYHG LQFUHDVH LQ+,)Į
protein levels are between those seen with LIMD1 and PHD2 knockdown alone,
and still significantly higher than the protein levels in the scrambled control. The
OHYHOVRI+,)ĮGRQRWDSSHDUWREHFXPXODWLYHRI/,0'NQRFNGRZQFRPELQHG
with PHD2 knockdown, but neither was it as great an increase as with just PHD2
alone. The reason for this is unknown, but one possible explanation could be
that depletion of both proteins simultaneously could induce LIMD1 and PHD2
LQGHSHQGHQW+,)ĮGHJUDGDWLRQSDWKZD\V WREHFRPHDFWLYH DOORZLQJ IRU VRPH
GHJUDGDWLRQRI+,)ĮWRRFFXU
Overall these data show that LIMD1 loss, like loss of PHD2, causes an increase in
QRUPR[LFDQGK\SR[LF+,)ĮSURWHLQ OHYHOVDQG LQKLELWV WKHFHOOXODUDGDSWDWLRQ
WRFKURQLFK\SR[LDWKURXJKLQKLELWLRQRI+,)ĮGHJUDGDWLRQ
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5.5 +,)ĮLV3RVW7UDQVODWLRQDOO\0RGLILHGE\3KRVSKRU\ODWLRQ
After performing the siRNA depletion and time course experiment (Figure 5.14),
+,)ĮZDVREVHUYHGDVWZRGLIIHUHQWPRWLOLWLHVRQWKHJHORIWHQDSSHDULQJDVD
GRXEOHW HDVLO\REVHUYHG LQWKHVKRUWH[SRVXUHRI WKHDQWL+,)Į:HVWHUQEORW
indicated by arrows). Furthermore, in normoxia the predominant form was the
lower molecular weight band, whereas in hypoxia the predominant form was the
higher molecular weight form.
3XEOLVKHG LQYHVWLJDWLRQV LQWR +,)Į IXQFWLRQ LGHQWLILHG +,)Į EHFRPHV
phosphorylated and this directly effects its transcriptional activity.
8QSKRVSKRU\ODWHG +,)Į LV WUDQVFULSWLRQDOO\ LQDFWLYH KRZHYHU ZKHQ
SKRVSKRU\ODWHG LW LV DEOH WRGLPHULVHZLWK+,)ǃDQGEHFRPH WUDQVFULSWLRQDOO\
active (Wang and Semenza, 1993a; Berra et al., 2000). The different
SKRVSKRU\ODWHG IRUPV RI +,)Į ZHUH LGHQWLILHG DV UHVROYLQJ ZLWK GLIIHUHQW
motilities on a gel. It was therefore hypothesised that the differences observed
LQ+,)ĮPRWLOLW\)LJXUHZHUHDOVRGXH WRSKRVSKRU\ODWLRQ LQQRUPR[LD
+,)ĮLVWUDQVFULSWLRQDOO\LQDFWLYHVRLVWKHUHIRUHXQSKRVSKRU\ODWHGDQGUXQVDW
D ORZHUPROHFXODUZHLJKW+RZHYHU LQ K\SR[LDZKHUH +,)Į LV UHTXLUHG WR EH
active, it becomes phosphorylated and so runs at a higher molecular weight.
To investigate the differences in motilities and prove this may be due to
phosphorylation it was hypothesised that treatment of the higher motility form
RI +,)Į ZLWK D SKRVSKDWDVH VKRXOG UHVXOW LQ WKH DSSHDUDQFH RI WKH ORZHU
motility form. As the higher molecular weight form was only significantly
observed after cells had been exposed to hypoxia, with levels peaking by 16-24
hours, duplicate wells of U20S were exposed to hypoxia overnight prior to lysis
in RIPA buffer supplemented with protease inhibitors and MG132 to prevent
GHJUDGDWLRQRI+,)ĮIROORZLQJUHR[\JHQDWLRQRIWKHFHOOO\VDWHE\DWPRVSKHULF
oxygen). One of the duplicate wells was lysed with the lysis buffer also
supplemented with phosphatase inhibitors as a control. 50 Units of shrimp
alkaline phosphatase were added to the lysates, and incubated for 60 minutes at
37o&+,)ĮSURWHLQZDVWKHQDQDO\VHGE\:HVWHUQEORW)LJXUH
In agreement with the initial observation of the different molecular weights of
+,)Į LQ QRUPR[LD DQG K\SR[LD )LJXUH  LQ QRUPR[LF 826 FHOO O\VDWHV
+,)ĮZDVREVHUYHGDVDVLQJOHORZHUPROHFXODUZHLJKWEDQG$IWHUH[SRVXUHWR
KRXUVK\SR[LD+,)ĮZDVREVHUYHGDVDGRXEOHWZLWK WKHKLJKHUPROHFXODU
weight form appearing slightly more prominent (Figure 5.15, indicated by arrow
heads). Following SAP treatment however, there was no change in motility of
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+,)Į FRPSDUHG WR WKH XQWUHDWHG O\VDWH LQ HLWKHU QRUPR[LF RU K\SR[LF FHOO
lysates. This result did not correspond to the hypothesis that the molecular
weight differences were due to phosphorylation, as SAP treatment should have
UHVXOWHGLQGHSKRVSKRU\ODWLRQZLWKRQO\WKHORZHUPROHFXODUZHLJKW+,)ĮEHLQJ
observed on a Western blot.
It was reasoned, however, that this could be a false negative result for two
reasons. Firstly the amount of phosphorylated proteins in total cell lysate would
have been huge, and so as such the amount of SAP could have been rate
limiting in order to dephosphorylate all the phospho-proteins. Secondly, SAP is
not a specific protein phosphatase; it is a generic phosphatase that is most
commonly used to dephosphorylate the 5 base of a DNA vector or insert during
routine cloning and as such may not be the optimal phosphatase to use against
proteins.
Figure 5.15: Treatment of normoxic or hypoxic cell lysates with shrimp alkaline
SKRVSKDWDVHGRHVQRWDIIHFWPRWLOLW\RI+,)Į U2OS cells were exposed to hypoxia
for 24 hours prior to lysis in RIPA buffer supplemented with protease inhibitors and the
26S proteasome inhibitor MG132. 50 units of shrimp alkaline phosphatase (SAP) were
added and lysates incubated for 60 minutes at 37o&$QDO\VLVRIUHVXOWDQW+,)ĮSURWHLQ
OHYHOV E\ :HVWHUQ EORW VKRZHG WKH ORZHU PROHFXODU ZHLJKW +,)Į LQ QRUPR[LD DQG WKH
higher molecular weight in hypoxia. SAP treatment did not affect the molecular weight of
+,)ĮLQHLWKHUR[\JHQWHQVLRQ
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7R RYHUFRPH WKHVH SUREOHPV +,)Į ZDV SXULILHG IURP WRWDO FHOOXODU O\VDWH E\
LPPXQRSUHFLSLWDWLRQ ZLWK DQWL+,)Į DQWLERG\ 7KH LPPXQRSUHFLSLWDWLRQ ZDV
carried out in the presence of protease, phosphatase inhibitors and MG132 to
SUHVHUYHWKHDPRXQWDQGSKRVSKRU\ODWLRQVWDWHRIDQ\+,)Į7KHSKRVSKDWDVH
inhibitors were then removed from the IP by extensive washing with
unsupplemented RIPA, and successful immunoprecipitation confirmed by
Western blot. Immunoprecipitations were carried out using hypoxic U2OS, HEK
293T and HeLa cell lysates. This was for continuity with the endogenous IPs
(Figure 5.10 and Figure 5.11) and to assess if any possible phosphorylation was
cell type specific. Lambda protein phosphatase, which is a specific protein
SKRVSKDWDVH ZDV LQFXEDWHG ZLWK WKH SXULILHG +,)Į DQG LQFXEDWHG IRU 
minutes at 30o&DQGVXEVHTXHQW+,)ĮSURWHLQDQDO\VHGE\:HVWHUQEORW)LJXUH
5.16).
+,)Į ZDV H[SUHVVHG LQ WKH K\SR[LF H[WUDFWV RI DOO  FHOO OLQHV WHVWHG )LJXUH
5.16 Input lane). Upon close inspection of the input blot a doublet band is visible
in all the cell lines, albeit slightly obscured by the more prominent higher
motility form. As a control for specificity of the immunoprecipitation, an isotype
FRQWURO DQWLERG\ ZDV XVHG ,PPXQRSUHFLSLWDWLRQ RI +,)Į ZLWKRXW VXEVHTXHQW
lambda phosphatase treatment from HeLa and U2OS cells resulted in
immunoprecipitation of both the higher and lower molecular weight forms,
whereas 293T cells solely gave the higher form (Figure 5.16). Following
phosphatase treatment, the higher motility band disappeared from all three cell
lines, leaving the lower molecular weight form (Figure 5.16, indicated by arrow
heads).
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Figure 5.16: +,)Į LV SUHGRPLQDQWO\ SKRVSKRU\ODWHG LQ K\SR[LD DQG
unphosphorylated in normoxia. Hypoxic (16hours) cell extracts from U2OS, HEK 293T
DQG+H/DFHOOVZHUHLPPXQRSUHFLSLWDWHGZLWKDQDQWL+,)ĮDQWLERG\LQWKHSUHVHQFHRI
MG132, protease and phosphatase inhibitors so as to maintain phosphorylation status
and quantity of protein under normoxic immunoprecipitation conditions.
Immunoprecipitations were extensively washed with unsupplemented wash buffer before
LQFXEDWLRQZLWKODPEGDSURWHLQSKRVSKDWDVHDQG+,)ĮSURWHLQOHYHOVDVVD\HGE\:HVWHUQ
blot.
5.5.1 3KRVSKRU\ODWLRQRI+,)Į$IIHFWV7UDQVFULSWLRQRI+5(&RQWDLQLQJ
Genes
The phosphatase assay data indicated the difference in the two molecular weight
IRUPVRI+,)ĮZHUHGXHWRSKRVSKRU\ODWLRQDVSKRVSKDWDVHWUHDWPHQWLVDEOH
WRFRQYHUWWKHKLJKHUIRUPWRWKHORZHUIRUP,QQRUPR[LDWKHPDMRULW\RI+,)Į
that is present is of the lower molecular weight, meaning it is unphosphorylated
and so transcriptionally inactive (Figure 5.14). It was therefore hypothesised
that the increase in stability caused by depletion of LIMD1 and/or PHD2 would
not have any significant effects upon transcription of hypoxic responsive genes
in normoxia. However, in hypoxia where the stabilisation is of the predominantly
higher molecular weight phosphorylated form, it would be predicted that loss of
LIMD1 and or PHD2 would have the most significant increase on downstream
hypoxic gene transcription.
ʄ ƉƌŽƚĞŝŶ
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To test the hypothesis, siRNA mediated depletion of LIMD1 was performed in
HEK293T cells and resultant mRNA levels of HIF1 driven hypoxic responsive
genes assayed. These comprised of BNIP3 (a mitochondrial stress sensor),
JMJD1A (transcriptional regulator), WSB1 (protein degradation pathway), ALDOC
(glucose metabolism), Endoglin (endothelium glycoprotein), ERO1L (oxidative
protein folding), HK1 (glucose metabolism) and MXI1 (transcriptional repressor).
As controls, scrambled or PHD2 siRNA was also included. Following knockdown,
cells were exposed to 24 hours hypoxia and RNA levels of a selection of HIF
responsive genes were quantified (Figure 5.17). qRT-PCR analysis was kindly
performed by Dr. Victoria James.
Figure 5.17: mRNA levels of HIF-1 responsive genes following LIMD1, PHD2 or
control scrambled siRNA depletion. HEK293 cells were depleted of LIMD1 or PHD2 by
siRNA, prior to exposure to 24 hours normoxia (20%) or hypoxia (1%). RNA was then
extracted and mRNA levels of a selection of HIF-1 responsive genes quantified. Data are
mean ± SEM, n=3 independent experiments *P<0.005, **P<0.05. BNIP3,
BCL2/adenovirus E1B 19kDa interacting protein 3; VEGF, vascular endothelial growth
factor A; WSB1, WD repeat and SOCS box containing 1; ALDOC, aldolase C, fructose-
bisphosphate; ERO1L, Endoplasmic reticulum oxidoreductin-1-like; HK1, hexokinase 1;
MXI1, MAX-interacting protein 1. qRT-PCR analysis was kindly performed by Dr. Victoria
James.
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As hypothesised, following LIMD1 depletion, increases in mRNA transcription
were only observed in hypoxia and not normoxia for WSB1, HK1 and MXI1.
Similar observations were also observed following PHD2 depletion for BNIP3,
JMJD1A and WSB1 LPSOLFDWLQJ WKH LPSRUWDQFH RI +,)Į SKRVSKRU\ODWLRQ IRU
transcriptional activation, regardless of increased protein levels caused by LIMD1
or PHD2 depletion in normoxia.
Differences were also observed between the responsiveness of the same gene
following depletion of LIMD1 or PHD2. In normoxia, HK1 mRNA was not
significantly affected by LIMD1 depletion; however PHD2 depletion increased
HK1 mRNA levels three fold. In hypoxia, where LIMD1 depletion caused an
increase in mRNA levels compared to normoxia, PHD2 depletion caused an
increase compared to the scrambled control, but was not significantly more than
observed in normoxia. The converse result was observed with JMJD1A; LIMD1
depletion caused an increase in mRNA levels in both oxygen tensions, whereas
PHD2 depletion only caused an increase in hypoxia. These data therefore
suggest that the responsiveness of some genes may be cell type specific, with
the interactions with other endogenous proteins and pathways also possibly
affecting mRNA levels.
5.6 Summary
Under low oxygen tensions, LIMD1 promoter driven transcription (Figure 5.1)
DQG /,0' SURWHLQ )LJXUH  DUH ERWK XSUHJXODWHG E\ +,)Į GXH WR WKH
presence of a functional HRE within IR3 of the CpG Island (Figure 5.3). At a
molecular level, LIMD1 directly binds to the major oxygen sensor PHD2 (Figure
5.7), and forms an endogenous in vivo complex with PHD2, VHL, cul2 and
elongin B (Figure 5.10, Figure 5.11 and Figure 5.12) that was hypothesised to
SDUWLFLSDWHLQGHJUDGDWLRQRI+,)Į'HSOHWLRQRI/,0'ZKLFKZRXOGGLVUXSWWKH
GHJUDGDWLRQ FRPSOH[ FDXVHG D VWDELOLVDWLRQ RI +,)Į XQGHU QRUPR[LF DFXWH
hypoxic and chronic hypoxic conditions (Figure 5.14) showing that LIMD1 is
FULWLFDOIRUUHJXODWLRQRI+,)ĮDQGDGDSWDWLRQWRFKURQLFK\SR[LD,QQRUPR[LD
WKH VWDELOLVDWLRQ RI +,)Į LV RI WKH XQSKRVSKRU\ODWHG WUDQVFULSWLRQDOO\ LQDFWLYH
form, whereas in hypoxia it is predominantly of the phosphorylated,
transcriptionally active form (Figure 5.16), and this is implicated through qRT-
PCR analysis of HIF1 responsive genes following LIMD1 depletion in normoxia
and hypoxia (Figure 5.17).
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6.1 LIMD1 Gene Transcription and Promoter Methylation
To date, LIMD1 protein and gene loss has been demonstrated in lung, breast
and head and neck squamous cell carcinomas (HNSCC) and has been correlated
with poor prognosis and a decrease in survival from time of diagnosis (Sharp et
al., 2004; Sharp et al., 2008; Spendlove et al., 2008; Ghosh et al., 2008).
Specifically in lung cancer, LIMD1 protein loss has been identified in up to 79%
of tumours, however the reasons for loss of expression had not been fully
elucidated. Gene deletion and loss of heterozygosity has been identified as a
cause of loss of LIMD1 protein expression in 44% of lung tumours (Sharp et al.,
2008), leaving 30% of tumours with unexplained mechanisms of LIMD1 loss.
This therefore implicated other mechanisms must account for LIMD1 gene
silencing. Lung cancer is the second most common form of cancer in developed
countries; in the USA in 2010 it accounted for 15% of all new cancer cases, and
it has the highest mortality rate (30%) of all cancers (Jemal et al., 2010).
Therefore, identification of any other factors that result in LIMD1 loss could have
significant clinical implications and initial investigations performed in this thesis
focused upon identification of these mechanisms.
6.1.1 The LIMD1 Promoter is Methylated in the Non-LIMD1 expressing
MDA-MB435 Cell Line
As many characterised TSG have been shown to undergo epigenetic silencing
through promoter CpG Island hypermethylation, it was postulated that this could
also be a cause of LIMD1 silencing. Using the Ensembl Genome Browser a single
860bp CpG Island was identified within the promoter spanning -1250 to -390
relative to the predicted transcription start site (TSS) (Figure 3.1).
In an independent preliminary study, Huggins et al also analysed the promoter
for the presence of any CpG Islands (Huggins and Andrulis, 2008). They took a
region of the LIMD1 promoter spanning 10kb upstream from the translation
initiation codon and performed analysis using the European Bioinformatics
Institute CpG Island finder. They reported the identification of 3 small CpG
Islands very close together that spanned a 1.2kb region of the promoter that
ended at -400 relative to the TSS. Although using the Ensembl Genome Browser
only one CpG Island was identified, both programmes identified the CpG Islands
in the same promoter region (-1250 to -390 and -1600 to -400), thus the
findings of Huggins et al corroborate the results of this investigation. The single
large CpG Island identified in this study, compared to being split into three
smaller islands by Huggins et al can most likely be explained due to the different
algorithms used by both software programmes; however both results abide by
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the Gardiner-Garden and Takai CpG Island definitions (Gardiner-Garden and
Frommer, 1987; Takai and Jones, 2002).
Analysis of the LIMD1 promoter using mutational analysis identified IR5 as being
critically important for transcriptional activity as deletion of this region decreased
transcription by 90% (Figure 3.2). For initial investigations, the osteosarcoma
U2OS and breast epithelial MDA-MB435 cell lines, which had previously been
characterised as LIMD1 mRNA and protein expressing and non-expressing
respectively were used. The LIMD1 promoter and gene (including intron/exon
boundaries) were present in both lines as confirmed by PCR (Sharp et al,
unpublished data), however DNA sequencing of bisulphite treated genomic DNA
from both cell lines revealed that genomic DNA from U2OS was unmethylated,
whilst genomic DNA from MDA-MB435 cells was methylated (Figure 3.4).
Concurrent experimentation using methylation specific restriction analysis also
identified methylation within the LIMD1 promoter, mapped to within the region
spanning -885 to -373 (Huggins and Andrulis, 2008). IR5 is within this large
region, and corresponds to bases -678 to -658. The sequence of IR5
(CTCACTTCCGCGTCCCGCCGC) does not contain any endonuclease restriction
sites for pairs of methylation sensitive and insensitive isochizomers. Therefore,
similar methylation specific restriction analysis could not be performed
specifically on this region.
6.1.2 The LIMD1 Promoter is Methylated in Primary Lung Tumours
To assess the relevance of methylation within IR5 identified in the cultured cell
lines and correlate it to primary tumours, a cohort of 48 matched normal and
tumour lung tissues were used. Following bisulphite treatment of genomic DNA,
the region surrounding IR5 was analysed using methylation specific PCR (MSP).
MSP was initially chosen as after the initial bisulphite treatment, samples could
be quickly and easily analysed using standard PCR. Furthermore, as genomic
DNA from U2OS and MDA-MB435 cells had previously been characterised as
being unmethylated and methylated respectively, they were able to serve as
ideal internal controls. Analysis of the LIMD1 and Rassf1a promoters by MSP
gave the unexpected result of some tumours becoming hypomethylated
compared to the matched normal tissue (Figure 3.7). Mixed methylation status
and tumour hypomethylation has been reported at the Rassf1a promoter in
prostate carcinomas (Florl et al., 2004), however in lung tumours the Rassf1a
gene promoter is accepted as becoming hypermethylated when compared to
matched normal tissue (Burbee et al., 2001; Dammann et al., 2005; Pfeifer and
Dammann, 2005). Furthermore, the primers used for the Rassf1a MSP had been
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previously published where hypomethylation of tumour samples was not
observed. Therefore consideration had to be given to the results obtained.
More recent investigations into promoter methylation within non small cell lung
cancers have shown that some TSG are methylated even in normal tissues,
including LSAMP and OPCML that were methylated in 55-88% of normal and
cancer tissues as well as BRCA1 and p14ARF which were methylated in less than
8% of samples. Rassf1a was included in the analysis and showed methylation in
8% of normal and 40% of tumour samples (Zhang et al., 2011b). Therefore it
may be possible that the observations obtained with the MSP could be correct
with respect to normal methylation of Rassf1a or LIMD1, however weaknesses in
MSP methodology also need to be considered.
MSP is considered a simple qualitative method of methylation analysis, which
due to the presence of different intensity bands, with some barely detectable,
can be subjective, especially when only low level methylation is present.
Furthermore, altering the number of PCR cycles can change the intensity or
cause the appearance/disappearance of amplicons, again introducing a very
subjective method of analysis. The annealing of the methylation specific primer
is dependent upon the uniformed hypo or hyper methylation within the primer
annealing region, and so if there is a variation in methylation within this region,
factors such as mis-match base pairing within the primer can result in false
positive results. Furthermore, any variation of the methylation status within the
amplified region between the forward and reverse primers is not assayed unless
subsequent sequencing analysis is performed.
The mixed results obtained with the MSP could also originate from the biopsy
samples. LIMD1 expression within the blood associated cell lineages has not
been investigated, so any infiltrating lymphocytes or other cells would introduce
non-lung tissue derived genomic DNA that may be normally methylated or
unmethylated. Unpublished observations from immuohistochemical studies have
identified lymphocytes as expressing high levels of LIMD1 (Dr T.V. Sharp
unpublished data). As the tissue samples were obtained by biopsy, it is possible
that infiltrating lymphocytes, or indeed contamination of tumour samples with
adjacent normal tissue, could produce artefactal results. Assuming that normal
tissue/lymphocytes express LIMD1 and contain hypomethylated promoters,
contamination of potentially hypermethylated tumour cells with these could
produce a false observation of hypomethylation. Furthermore, it has been
reported in some renal carcinoma cell lines and renal cell carcinoma somatic
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hybrids, which contain up to 5-6 copies of chromosome 3 per cell, differentially
methylated alleles of Rassf1a were present inside the same cell (Dreijerink et
al., 2001). As such, this could also be the case for a proportion of the lung
tissue/tumour samples. Chromosome number analysis was not performed on the
cohort used within this thesis. Therefore, the possibility of aberrant chromosome
number increases could also contribute to the unexpected MSP result. Epigenetic
silencing of genes within normal tissue has been demonstrated (Shen et al.,
2007; Futscher et al., 2002), and so any blood lineages that have LIMD1
silenced, could achieve this through promoter methylation and thus introduce a
false hypermethylated tissue genotype.
To avoid any possible artefactal results that may be introduced through
experimental procedure, technique or analysis, the LIMD1 promoter was re-
analysed using bisulphite sequencing, which allows for methylation analysis at
the single base pair level (Figure 3.10) and omits any weaknesses in the
methodology associated with MSP. In contrast to the MSP results, no tumour
hypomethylation was observed. Mixed chromatogram peaks (referred to as
partially methylated within Chapter 3) were observed in some of the samples.
However, as the included U2OS/MDA-MB435 homogeneous cell population
controls did not produced any mixed peaks, this confirmed the biopsy samples
as harbouring heterogeneously methylated cell populations, and that the mixed
peaks were not introduced through experimental procedure.
26% of matched sample pairs showed aberrant tumour methylation at the
penultimate CpG dinucleotide within IR5, with one of these tumour samples also
having partial methylation at another CpG dinucleotide. The reason for why
predominantly only one CpG became methylated in the tumour samples is
unclear, however due to the specificity of the methylation a common, unknown,
mechanism may be responsible for this.
6.1.3 LIMD1 mRNA Expression is Down-Regulated in Lung Tumours
LIMD1 mRNA expression was down-regulated in 70% of the tumours analysed
(Figure 3.11); this corroborates well with immunohistochemical studies where
75-79% of lung tumours showed decreased expression of LIMD1 protein (Sharp
et al., 2008) and in the first study of LIMD1 mRNA expression in lung tumours
where 100% of the small cohort of samples showed mRNA down-regulation
(Sharp et al., 2004).
In the analysis presented in this study (Figure 3.11), 12.5% of the samples
failed to generate Ct values for LIMD1 mRNA in the tumour samples, implying
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that 3p LIMD1 gene deletion could have occurred; in total 4 out of 48 samples
did not express either LIMD1 or Rassf1a mRNA, which implies larger scale gene
deletion could have occurred that caused the silencing of a cluster of 3p21.3
tumour suppressor genes. Out of the samples that exhibited methylation, as 2 of
these showed no change in mRNA expression levels in the tumour compared to
the normal tissue, no definitive correlation between methylation and mRNA
expression could be drawn. This is the same conclusion obtained by Huggins et
al from primary breast tumours (Huggins and Andrulis, 2008).
6.1.4 LIMD1 is Epigenetically Silenced in MDA-MB435 Cells
The re-expression of LIMD1 protein in MDA-MB435 cells following treatment with
5-Aza-2deoxycytidine showed that LIMD1 was epigenetically silenced. This was
confirmed through sequencing of the promoter, which identified that following
treatment, the promoter became hypomethylated (Figure 3.13).
Increased methylation was observed within IR5 within the human lung tumour
samples assayed, however it may not be concluded if this alone causes silencing
of the LIMD1 gene. Firstly, as described, only one of the CpG dinucleotides
within IR5 became methylated in the tumour samples and secondly only a small,
yet transcriptionally critical, region of the promoter was analysed by sequencing.
It is therefore not known if this is sufficient to instigate silencing of LIMD1
expression and it cannot be ruled out that other regions of the promoter (within
the CpG) Island may have also been hypermethylated in the tumours and
contribute to silencing of LIMD1. As the MB435 cell line is of breast epithelial
origin, it is possible that epigenetic silencing of LIMD1 may be more applicable in
breast cancers, and this may be a future area of investigation.
5-Aza-2-deoxycytidine is a cytosine analogue that is incorporated into DNA
during replication and is resistant to methylation. Experimentally it has been
shown to cause the re-expression of multiple tumour suppressor genes including
Rassf1a (Shen et al., 2008) and BRCA1 (Magdinier et al., 2000). Clinically, 5-
Aza-2-deoxycytidine is administered to patients suffering from myelodysplastic
syndrome, acute myeloid leukaemia and chronic myelogenous leukaemia
(Kantarjian et al., 2003; Kantarjian et al., 2006). Furthermore, 5-Aza-2-
deoxycytidine treatment both with and without the HDAC inhibitor depsipeptide,
exerted anti-neoplastic effects on the MDA-MB435 and MB-231 breast cancer cell
lines (Primeau et al., 2003; Gagnon et al., 2003). In these investigations it has
been demonstrated that LIMD1 is re-expressed in MB435 cells following 5-Aza-
2-deoxycytidine treatment, and through LIMD1s associated tumour suppressive
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properties, may be a factor that contributes to the anti-neoplastic properties
observed. LIMD1 expression is reduced in breast cancer, where reduced
expression correlates with decreased survival (Spendlove et al., 2008) as well as
in lung and HNSCC (Sharp et al., 2008; Spendlove et al., 2008). Therefore,
there could be a clinical interest in expanding this research to assess if re-
expression of LIMD1 could be achieved in patients.
Epigenetic silencing of LIMD1 is evident as a possible cause of silencing within
tumours. However, from the results in the primary lung tumours, it is unlikely
that this could account for the 30% shortfall in unexplained mechanisms of
LIMD1 protein loss that have been reported. Therefore, further investigations
were performed on the promoter to address how transcription of LIMD1 is
controlled. Uncovering the mechanistic detail of this regulation could provide
further insights to gene silencing, as deregulation of a controlling transcription
factor would also result in deregulation of LIMD1 transcription.
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6.2 Identification of PU.1 as a Major Transcriptional Activator of
LIMD1
The IR5 region was identified as being critical for transcriptional activity of the
LIMD1 promoter, however the reasons for why this region was so critical were
XQNQRZQ 7KH GHFUHDVH LQ WUDQVFULSWLRQ IURP WKH ,ƩPXWDQW FRXOG KDYH EHHQ
due to stearic interference between transcriptional regulator proteins as a result
of the deletion of the 21bp of DNA. However, this was thought to be unlikely as
when the set of ten internal deletion mutants were examined together, a range
of increases, decreases and no changes in transcriptional activities were
observed, suggesting that the individual deletions were specific in abrogating
protein-DNA interactions. As deletion of IR5 resulted in the greatest (90%)
decrease in transcription, it was hypothesised that the region probably contained
a binding site for a critical transcription factor. Furthermore, CpG methylation
within this region also supported this hypothesis.
6.2.1 IR5 is Perfectly Conserved between LIMD1 Expressing Species
and Harbours an Ets Family Member/PU.1 Binding Motif
Comparative genomic analysis identified that the IR5 region was perfectly
conserved between 13 LIMD1 expressing mammals (Figure 4.1), which was
indicative of it containing a binding motif critical for survival of a species (Boffelli
et al., 2004; Pennacchio and Rubin, 2001). In silico screening of the promoter
for transcription factor binding motifs identified a putative Ets transcription
factor family member binding motif within IR5 (Figure 4.2), that through ChIP,
EMSA and siRNA depletion experiments was confirmed as being PU.1 (Figure
4.7, Figure 4.8, Figure 4.10).
PU.1 was initially identified as binding to the core sequence 5-GAGGAA (Klemsz
et al., 1990), however variations within the preceding and following bases
around the GGAA motif have since been identified; recent ChIP-Seq analysis of
PU.1 binding in macrophages and B-cells revealed the core binding motif for
PU.1 (GGAA) is commonly preceded by G/C then A/C, and followed by, in the
majority of sequenced motifs, GTG (Heinz et al., 2010). This gives rise to a
generalised consensus G/C-A/C-GGAA-GTG, which matches the IR5 sequence of
GCGGAAGTG. Other genes under PU.1 control have homology to the IR5
sequence, including secretory interleukin-1 receptor antagonist (IL-1Ra) which
has the consensus GCGGAAATA (Smith, Jr. et al., 1998), and Toll-like receptor 4
(TLR4) has the consensus GAGGAAGTG (Rehli et al., 2000). These additional
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experimentally verified PU.1 binding motifs therefore corroborate the
identification of PU.1 binding the LIMD1 promoter and activating its
transcription.
The initial internal promoter deletion experiments were performed in U2OS cells,
a cell line which by Western blot does not express PU.1 (Brown et al., 2011).
Furthermore, the same experiments were also performed in MDA-MB435 breast
HSLWKHOLDODQG$OXQJHSLWKHOLDOFHOOOLQHVGDWDQRWSUHVHQWHGZKHUHWKH,Ʃ
deletion also resulted in similar significant decreases in transcriptional activity.
These cells are also considered PU.1 negative, and so consequently it is believed
another transcription factor must also activate transcription from the same
region of the promoter. Point mutagenesis of the core Ets binding motif GGAA in
U2OS cells alone (Figure 4.3) resulted in the same significant decrease in
WUDQVFULSWLRQ DV REVHUYHG ZLWK WKH ZKROH ,Ʃ GHOHWLRQ 7KHUHIRUH LW LV KLJKO\
probable that in non-haematopoietic derived lineages, another Ets factor may
replace PU.1 as an activator of LIMD1 expression. From the Ets family member
controls used throughout Chapter 4, the family members Elk-1 and Ets-1 do not
appear to affect LIMD1 promoter transcription or associate with the promoter
both in vitro and in vivo.
As little as one flanking DNA base, or amino acid residue surrounding the protein
Ets domain is enough to provide specificity for Ets protein binding and gene
activation (Verger and Duterque-Coquillaud, 2002), with multiple factors also
being known to bind to the same single motif within a promoter. For example,
the platelet factor 4 (PF4) gene contains multiple Ets factor binding motifs; Ets1
binds to one motif to activate transcription, whilst three different Ets factors,
FLI-1, ELF-1, and GABP, compete for binding to another site during
megakaryocytic differentiation to regulate stage specific gene expression (Okada
et al., 2011). It is still not fully understood how different factors can bind to the
same motif, yet are also able to distinguish between almost identical sequences.
The similarity in sequence specificity of the Ets family proteins is illustrated in
Figure 6.1 (Hollenhorst et al., 2007). Expression profiles of 27 human Ets genes
in 16 tissue samples and 7 cell lines revealed that in each sample at least 16 Ets
members were expressed, with 14 showing ubiquitous expression (which was
defined as being expressed in a least 22/23 samples) (Hollenhorst et al., 2004).
It is thought however that stage/tissue specific changes in Ets family expression,
interaction with other Ets factors and transcriptional co-activator/repressor
proteins help facilitate the binding specificity (Hollenhorst et al., 2007). Genetic
redundancy of an Ets factor is unlikely to be a contributing factor, as deletion of
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each Ets member results in unique phenotypic consequences, summarised in
(Hollenhorst et al., 2004). Therefore with respect to LIMD1 expression, it may
be that several other Ets factors activate (or repress) its transcription.
Figure 6.1: The ETS transcription factor family bind to very similar DNA
sequences. Binding consensus sequences for the indicated Ets proteins were analysed
through in vitro screening (the SELEX method), with the height of each base directly
proportional to the frequency of which it is found. The Ets proteins bind to highly
homologous sequences, and the precise mechanisms for site discrimination are not fully
understood given that over half of Ets factors appear to be ubiquitously expressed
(Hollenhorst et al., 2007).
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6.2.2 The LIMD1 Promoter Contains a putative Second PU.1 Binding
Site
As well as being a transcriptional activator, PU.1 has also been associated with
gene silencing. Over-expression of PU.1 causes silencing of the tumour
suppressor c-myc in murine erythroleukaemia (MEL) cells through formation of a
transcriptional repressor complex that includes the proteins mSin3A and HDAC1
(Kihara-Negishi et al., 2001). In undifferentiated MEL cells, PU.1 is associated
with the MeCP2 co-repressor and mSin3A/HDAC1 at both a synthetic PU.1 motif
FRQWDLQLQJUHSRUWHUYHFWRUDQGDWWKHǃJORELQJHQHDQGUHSUHVVHGWUDQVFULSWLRQ
+RZHYHU IROORZLQJGLIIHUHQWLDWLRQ WKHFRPSOH[ZDV UHPRYHG IURP WKHǃJORELQ
gene and the gene expressed (Suzuki et al., 2003). PU.1 also associates with
the DNA methyl transferases 3a and b (Dnmt3a/b) and over-expression induced
methylation within, and subsequent silencing of the p16INK4A tumour
suppressor gene (Suzuki et al., 2006).
LIMD1 itself is epigenetically silenced through promoter methylation in the MDA-
MB435 breast cancer cell line, with promoter methylation also evident in 26% of
human lung tumours when compared to normal matched lung tissue (Sharp et
al., 2008; Huggins and Andrulis, 2008). In light of the possible dual function of
PU.1, the role of PU.1 during LIMD1-loss associated transformation remains to
be elucidated. In silico screening of the promoter identified a second putative Ets
domain/PU.1 binding site at -120 relative to the TSS. As point mutation of the
PU.1 motif within IR5 (Fig. 2B) resulted in a 90% decrease in transcription, it is
likely that the second PU.1 site is not involved in transcriptional activation.
However, during transformation it could act as a site for PU.1 binding,
subsequent Dnmt3a/b mediated CpG promoter methylation and ultimately loss
of LIMD1 expression through epigenetic silencing (Figure 6.2). It would be
interesting to assess, if under specific stimuli, PU.1 does indeed associate with
the second putative binding site, and if so does it induce methylation and
epigenetic silencing of LIMD1.
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Figure 6.2: Schematic representation of the possible role of PU.1 as a
transcriptional repressor of LIMD1 expression. (A) In this thesis PU.1 has been
identified as a major transcriptional activator of LIMD1 expression, and LIMD1 is not
expressed when the promoter is methylated. (B) However PU.1 has been observed to
associate with the transcriptional repressors MeCP2, HDAC1 and Dnmt3a/b, and repress
transcription through CpG methylation and the formation of a heterochromatin structure.
The LIMD1 promoter contains a second PU.1 binding motif that is not required for
transcriptional activation, however during transformation it could act as a functional
binding site for PU.1, leading to promoter CpG methylation and histone deacetylation,
causing a repression of LIMD1 transcription.
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6.3 Additional (Unconfirmed) Features of the LIMD1 Promoter
The in silico analysis of the LIMD1 promoter also identified other common
promoter related features that could be directly related to transcriptional control
of the LIMD1 gene. As this was not within the scope of this thesis, these sites
were not examined experimentally; however their identification and possible
implications will still be discussed.
6.3.1.1 SP1 Binding Sites
The transcription factor Sp1 binds to GC boxes and can activate transcription
(Briggs et al., 1986). Sp1 binding can be abrogated by methylation (Clark et al.,
1997), specifically exemplified within the extracellular superoxide dismutase and
p21 gene promoters in lung cancer cell lines (Zelko et al., 2008; Zhu et al.,
2003). 17 potential Sp1/GC boxes were identified within the LIMD1 promoter,
with all but three located within the CpG Island. It has not been determined if
Sp1 contributes to LIMD1 expression, however if so then LIMD1 promoter
methylation could prevent Sp1 binding and reduce gene expression accordingly.
6.3.1.2 TFIIB Recognition Element
A BRE (TFIIB recognition element) was also identified with a perfect match score
of 1.0 within IR1 of the CpG Island. The function of BRE elements is not fully
understood, however these elements can have both positive (Lagrange et al.,
1998) and negative (Evans et al., 2001) effects upon transcription.
6.3.1.3 Initiator Elements/TATA Boxes
Two Inrs (initiator elements) were identified, both 5 proximal to the CpG Island
as were two putative TATA boxes 305bp and 155bp upstream of the NCBI
predicted transcriptional start site. Experimentally, as these have not been
confirmed, it is not possible to ascertain if the LIMD1 promoter is a TATA
containing or TATA-less promoter. The TSS used within these investigations was
the unconfirmed NCBI assigned start site; as CpG Island containing genes often
do not possess just a single discreet start site but multiple sites spread over up
to 100bp (Stamatoyannopoulos, 2010), it is plausible that one or both or the
predicted TATA boxes could be functional and may indeed give rise a undefined
small range of transcriptional start sites.
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So far within the investigations discussed, the main focus has been upon LIMD1
transcriptional control specifically surrounding IR5, and how this regulates LIMD1
gene expression. The results obtained identified LIMD1 expression becoming
down-regulated through epigenetic silencing, as well as PU.1, and potentially one
or more other Ets factors as activators of LIMD1 gene expression. The
concluding part of the discussion will now switch focus from gene expression
control to a novel tumour suppressive function of LIMD1; as a negative regulator
of the hypoxic response.
6.4 LIMD1 is a Regulator of the Hypoxic Response
6.4.1 LIMD1 driven Transcription and Protein Levels are increased in
Hypoxia
Protein levels of PHD2, VHL and the SAG component of the VBC E3 ubiquitin
ligase complex are increased in hypoxia due to the presence of a HRE within
their promoters (Marxsen et al., 2004; Tan et al., 2008; Liu et al., 2011) and
WKLV IDFLOLWDWHV +,)Į GHJUDGDWLRQ LQ K\SR[LD ,QYHVWLJDWLRQV LGHQWLILHG WKDW
transcription from the LIMD1 promoter is also upregulated in hypoxia (Figure
5.1), reaching a maximal level after 24 hours and that this was dependent upon
+,)Į)LJXUH7KHELQGLQJVLWHIRU+,)ĮZDVPDSSHGWRZLWKLQ,5RIWKH
CpG Island (Figure 5.3), which corroborated with the HIF1 binding site identified
in the in silico screen for transcription factor binding motifs.
LIMD1 protein levels also modestly increased in hypoxia (Figure 5.2), with
GHSOHWLRQ RI +,)Į LQ K\SR[LD FDXVLQJ D VLJQLILFDQW GHFUHDVH LQ /,0' SURWHLQ
OHYHOV)LJXUH ,QWHUHVWLQJO\GHSOHWLRQRI+,)Į LQQRUPR[LDDOVRFDXVHGD
decrease in LIMD1 protein. This was surprising, as in normoxia, due to the rapid
3+'PHGLDWHGGHJUDGDWLRQRI+,)ĮDQGDFWLYH),+ZKLFKK\GUR[\ODWHV$VQ
preventing association with the p300/CBP transcriptional co-activator, there is
UHODWLYHO\ YHU\ OLWWOH DFWLYH +,)Į DEOH WR IRUP WKH DFWLYH +,) WUDQVFULSWLRQ
factor. However, studies with a HIF1 inducible reporter vector in association with
GHSOHWLRQRIHQGRJHQRXV+,)ĮKDYHLGHQWLILHGWKHUHLVDEDVDOOHYHORIQRUPR[LF
+,)GULYHQWUDQVFULSWLRQLQFHOOV'D\DQHWDOWKHUHIRUHLQGLFDWLQJ+,)Į
expression is critical for both normoxic and hypoxic LIMD1 expression.
,QYHVWLJDWLRQVLQWR+,)ĮELQGLQJVLWHVLQWKHKXPDQJHQRPHXVLQJ&K,3VHTDQG
ChIP-chip analysis identified that outside the core RCGTG binding motif, no
extended sequence preferences for HIF1 binding were identified, except at the R
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position, adenine was observed at a 3:1 preference over guanine (Xia et al.,
2009; Schodel et al., 2011). Over 50% of observed HRE elements were
identified as within gene promoter regions, with over 90% of HIF-1 binding in
hypoxia associated with genes that were actively expressed under normoxic
conditions (as determined by RNA PolII binding or the presence of tri-methylated
H3K4) (Xia and Kung, 2009). This data corroborates with the HRE identified
within the promoter (consensus ggaCGTGcag) and normoxic transcription of
LIMD1.
There are a reported 2.5 x 106 occurrences of the RCGTG motif within the human
genome (Xia et al., 2009). Only a minority of these (<1%) were identified by
HLWKHU &K,3VHTFKLS VWXG\ DV EHLQJ ERXQG E\ +,)Į WKHUHIRUH VKRZLQJ D
large redundancy in motifs; however this could be due to differing chromatin
accessibility as assayed through DNAse1 hypersensitivity experiments (Schodel
et al., 2011). The initial in silico identification of 3 putative HIF binding sites
within the promoter, of which only one proved to be functionally active (Figure
5.4) therefore demonstrates the importance of wet laboratory experimental
confirmation of transcription factor binding so as to avoid any false positive
results. This was also demonstrated with the identification of two PU.1 binding
sites within the LIMD1 promoter.
6.4.2 +,)Į 0RGXODWHV LIMD1 Transcription but is not a Major
Transcriptional Activator
The basal level of transcription from the LIMD1 promoter is only modulated by
HIF1, as the basal level of transcription is controlled by PU.1/other Ets factor,
and this is illustrated by the IR5 deletion. In hypoxia, HIF1 up-regulates LIMD1
transcription 2-3 fold (Figure 5.1). Following deletion of IR5, which abrogates
PU.1 binding, in normoxia transcription was repressed by ~90%. However, in
hypoxia with the same deletion there was a slight de-repression in the reduction
in transcription observed in normoxia (Figure 5.3), even though PU.1 was still
unable to bind. Compared to the wild type promoter in hypoxia, this equated to
DQUHGXFWLRQLQWUDQVFULSWLRQ$VWKH,ƩPXWDQWVWLOOFRQWDLQHGDIXQFWLRQDO
HRE, this de-repression can be explained by the binding of HIF1 to the reporter
plasmid, which provided a 2-fold enhancement in promoter driven transcription.
This therefore demonstrates that HIF1 solely acts to enhance LIMD1
transcription, whereas the major transcriptional activation from the promoter is
still provided by PU.1, even under hypoxic conditions.
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6.4.3 Promoter Methylation may Prevent Transcription Factor Binding to
the LIMD1 Promoter
It has been demonstrated that methylation of transcription factor DNA binding
motifs, including those for Sp1 and ETS transcription factors, prevents
transcription factor binding (Rozenberg et al., 2008). It has yet to be fully
proven if methylation of the Ets motif prevents PU.1 binding and thus a
reduction in LIMD1 transcription. Within the cohort of lung tissue and tumour
samples there was no evidence of methylation within the PU.1 motif. However,
in the epigenetically silenced MDA-MB435 cell line the entire IR5 was
methylated, and following 5-azacytidine treatment, became unmethylated and
LIMD1 re-expressed. This could therefore support the hypothesis of methylation
blocking transcription factor binding. Methylation of one or more residues could
also cause the association of methyl CpG binding domain (MBD) proteins, which
in turn would recruit HDACs and other chromatin structure modifying proteins to
enhance the formation of a transcriptionally inactive heterochromatin
conformation, thus indirectly blocking transcription (Dillon and Festenstein,
2002).
More recently it has been demonstrated that the PHD3 promoter is methylated in
a selection of transformed cells, including MB435 cells, and that this methylation
abrogates the normal hypoxic up-regulation of the protein (Place et al., 2011).
)XUWKHUPRUH QRQPHWK\ODWHG +5(V DUH FULWLFDO IRU K\SR[LF +,)Į PHGLDWHG
XSUHJXODWLRQRIHU\WKURSRLHWLQDQG+,)Į LWVHOI:HQJHUHWDO.RVORZVNL
et al., 2011). It could therefore be postulated that if the LIMD1 promoter, which
encompasses the HRE within IR3 was methylated, then this could also abrogate
the hypoxic up-regulation of LIMD1 and loss of the adaptive response in chronic
hypoxia.
6.4.4 LIMD1 Forms an Endogenous Complex with PHD2 and VHL/VCB
Complex Proteins
Preliminary data obtained in the Sharp laboratory using protein over-expression
studies identified LIMD1 as binding to both the proline hydroxylase (PHD) and
the von Hippel-Lindau (VHL) proteins, both of which are required for degradation
RI+,)ĮSUHGRPLQDQWO\XQGHUKLJKR[\JHQWHQVLRQV7RHQVXUH WKDW WKHRYHU
expression binding data between LIMD1/PHD2/VHL was a true reflection of an
interaction in vivo, extensive endogenous immunoprecipitation studies were
performed (Figure 5.10, Figure 5.11 and Figure 5.12). These investigations
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revealed that within the 3 distinct cell lines investigated (HEK 293T, HeLa and
U2OS), endogenous LIMD1 interacted with endogenous PHD2 and VHL, along
with elonginB and cullin2 that form part of the VCB E3 ubiquitin ligase complex.
This data therefore demonstrated that the formation of the complex was
physiologically true and occurs endogenously in vivo. Furthermore it was not cell
type specific and thus these results help present a new fundamental mechanism
RI+,)ĮUHJXODWLRQWKDWFRXOGKDYHPDMRUFOLQLFDOLPSOLFDWLRQV
6.4.5 /,0' /RVV 5HGXFHV WKH (IILFLHQF\ RI +,)Į 'HJUDGDWLRQ DQG
Inhibits Adaptation to Chronic Hypoxia
/HYHOV RI +,)Į SURWHLQ KDYH EHHQ ZLGHO\ UHSRUWHG WR GHFUHDVH IROORZLQJ
prolonged (chronic) exposure to hypoxia, and as in normoxia, are surprisingly
dependent upon the PHDs and VHL (Ginouves et al., 2008). This has been
attributed primarily to a hypoxic increase in PHD2 protein levels, which
compensates for its decreased (oxygen dependent) activity (Stiehl et al., 2006;
Ginouves et al., 2008). Furthermore, hypoxic upregulation of pyruvate
dehydrogenase 1 kinase, which phosphorylates and causes inactivation of
pyruvate dehydrogenase, inhibits the mitochondrial TCA cycle. This reduces
mitochondrial oxygen consumption and allows for redistribution of molecular
oxygen within the cell, thus causing a relative increase in intracellular oxygen
tension and allowing for increased PHD activity (Kim et al., 2006; Papandreou et
al., 2006). In addition, nitric oxide (NO) or other inhibitors of mitochondrial
UHVSLUDWLRQDOVRSUHYHQW VWDELOLVDWLRQRI+,)Į LQK\SR[LD +DJHQHW DO
7KHUHIRUH WKLV DOORZV IRU K\GUR[\ODWLRQ RI +,)Į IROORZHG E\ VXEVHTXHQW 9+/
mediated ubiquitylation/degradation.
LIMD1 was identified as forming an endogenous complex with VHL and PHD2, as
well as being up-regulated in hypoxia. Therefore the effect of LIMD1 depletion in
hypoxia was investigated. In normoxia, preliminary data identified that LIMD1
ORVV FDXVHG DQ LQFUHDVHV LQ +,)Į SURWHLQ VWDELOLW\ SUHVXPDEO\ WKURXJK
abrogation of the LIMD1/VHL/PHD2 complex. siRNA mediated depletion of LIMD1
LQKLELWHGGHJUDGDWLRQRI+,)ĮLQXSWRKRXUVK\SR[LDZKLFKZDVWKHORQJHVW
WLPHSRLQW DVVD\HG ,Q WKH FRQWURO VDPSOHV WKH OHYHOV RI+,)Į SHDNHG E\ 
hours, and then proceeded to decline after 24 hours and were expressed at
almost normoxic levels after 72 hours, which corroborated with other published
REVHUYDWLRQVRI+,)ĮLQFKURQLFK\SR[LD$VDSRVLWLYHFRQWURO3+'GHSOHWLRQ
was performed alongside, and as reported by Stiehl et alDOVR LQKLELWHG+,)Į
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degradation (Stiehl et al., 2006). This therefore demonstrated that loss of LIMD1
VLJQLILFDQWO\UHGXFHVGHJUDGDWLRQRI+,)ĮLQK\SR[LDDQGXOWLPDWHO\LQKLELWVWKH
intracellular adaptation to hypoxia.
+,)Į RYHUH[SUHVVLRQ LV FRPPRQO\ IRXQG LQ PDQ\ FDQFHUV DQG LV RIWHQ
associated with increased proliferation and metasteses. Therefore appropriate
FRQWURORI+,)ĮH[SUHVVLRQLVUHTXLUHGWRDOORZIRUSURSHUFRQWURORIFHOOJURZWK
DQG SUROLIHUDWLRQ ,Q D ZLGHVSUHDG VWXG\ RI +,)Į H[SUHVVLRQ LQ QRUPDO DQG
SULPDU\FDQFHUVRISULPDU\PDOLJQDQWWXPRXUVKDG+,)ĮRYHU
expression; this included prostate, breast, lung, colon, pancreas, brain, gastric,
ovarian, and renal cell carcinomas, mesothelioma, and melanoma (Zhong et al.,
1999). In the lung adenocarcinoma cell line CL1 and the gastric cancer cell line
6&0RYHUH[SUHVVLRQRI+,)ĮUHVXOWHGLQLQFUHDVHGLQYDVLYHQHVVRIFHOOVLQDQ
in vitro invasiveness assay (Shyu et al., 2007). In a cohort of breast tumours,
RIEUHDVWPHWDVWDVHVKDG+,)ĮRYHUH[SUHVVHGFRPSDUHGWRRQO\RI
primary breast cancers (Zhong et al., 1999). Furthermore, in human prostate
FDQFHUFHOO OLQHVHOHYDWHG+,)ĮSURWHLQZDVREVHUYHGZKLFKLVDVVRFLDWHGZLWK
increased cell growth and metastatic potential (Zhong et al., 1998). LIMD1 loss
has been demonstrated in lung, breast and HNSCC (Sharp et al., 2008;
Spendlove et al., 2008; Ghosh et al., 2010). Therefore it could be postulated
WKDW LQ FDQFHUV ZKHUH /,0' LV ORVW +,)Į SURWHLQ OHYHOV ZRXOG EH LQFUHDVHG
leading to the aforementioned increases in cellular proliferation and metastasis.
It is likely that this therefore represents one mechanism of LIMD1 mediated
tumour suppressive activity, and a future line of investigation.
6.4.6 /,0'([SUHVVLRQGRHVQRW(IIHFW+,)Į3KRVSKRU\ODWLRQ
,Q K\SR[LD +,)Į EHFRPHV SKRVSKRU\ODWHG ZKLFK IDFLOLWDWHV GLPHULVDWLRQ ZLWK
+,)ǃWRIRUPWKHDFWLYH+,)WUDQVFULSWLRQIDFWRUWKDWFDQHQKDQFHWUDQVFULSWLRQ
of HRE containing genes (Zagorska and Dulak, 2004; Semenza, 2003). Whilst
performing the described investigations within this thesis, it was observed on
:HVWHUQEORWVWKDWXQGHUQRUPR[LDDQGK\SR[LD+,)ĮDSSHDUHGWRPLJUDWHDW
WZR GLIIHUHQW PROHFXODU ZHLJKWV ,Q QRUPR[LD +,)Į ZDV DW D ORZHU PROHFXODU
weight than in hypoxia, where an additional, more prominent higher molecular
weight band was observed. Therefore further analyses were performed to assess
LI WKH GLIIHUHQW IRUPV RI +,)Į REVHUYHG FRUUHODWHG ZLWK LWV GLIIHUHQW
SKRVSKRU\ODWLRQ VWDWH 7UHDWPHQW RI SXULILHG K\SR[LF +,)Į ZLWK ODPEGD
phosphatase confirmed the different molecular weight observed was due to
phosphorylation (Figure 5.16).
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/,0' RU 3+' GHSOHWLRQ LQKLELWHG +,)Į GHJUDGDWLRQ DQG WKHUHIRUH LQFUHDVHG
WKH VWDELOLW\ DQG OHYHOV RI +,)Į SURWHLQ ,Q QRUPR[LD WKH VWDELOLVDWLRQ
predominantly resulted in an increase in the lower molecular weight form of
+,)Į ZKHUHDV LQ K\SR[LD LW ZDV SUHGRPLQDQWO\ WKH KLJKHU PROHFXODU ZHLJKW
phosphorylated form that was observed (Figure 5.14). This therefore indicated
WKDW ORVV RI /,0' RU 3+' GLG QRW DIIHFW WKH DELOLW\ RI +,)Į WR EHFRPH
SKRVSKRU\ODWHGLQGLFDWLQJWKDW/,0'VSHFLILFDOO\WDUJHWV+,)ĮIRUGHJUDGDWLRQ
rather than regulating any pathways that converge on its phosphorylation and
activity. Furthermore, as the dephosphorylation experiments were also
performed in three different cell lines (U2OS, HEK293 and HeLa), this further
validated the findings as not being cell type specific, thus corroborating a new
XQLYHUVDOUROHRI/,0'LQUHJXODWLRQRI+,)ĮSURWHLQH[SUHVVLRQ
6.4.7 Loss of LIMD1 Expression Affects HIF-1 Driven Gene Expression
qRT-PCR analysis of a panel of HIF1 responsive genes following hypoxic
exposure with and without LIMD1 depletion identified differences between
normoxic and hypoxic mRNA levels (Figure 5.17). LIMD1 depletion, which
UHVXOWHGLQDQLQFUHDVH LQ+,)ĮSURWHLQOHYHOVJDYHLQFUHDVHGJHQHH[SUHVVLRQ
of BNIP3, WSB1, HK1 and MXI1 in hypoxia, but not in normoxia, presumably due
WR +,)Į EHLQJ SKRVSKRU\ODWHG WUDQVFULSWLRQDOO\ DFWLYH SUHGRPLQDQWO\ LQ
hypoxia, despite the significant increase in normoxic protein levels following
LIMD1 depletion. Similar results were also observed with PHD2 depletion as a
control.
Some hypoxic responsive genes, however, showed a variation in response to 24
hours hypoxia, including Endoglin, which showed no hypoxic induction, and
ERO1L, which was up-regulated in both normoxia and hypoxia following LIMD1
or PHD2 depletion. Hypoxic induction of these genes have been previously been
reported; 24 hours hypoxia resulted in an 8-fold increase in Endoglin expression
in the monocytic U937 cell line, but only 1.3-fold in the endothelial HMEC-1 cell
line (Sanchez-Elsner et al., 2002). In MEF cells, ERO1L expression was increased
equally by either hypoxia, or the PHD2 inhibitor DFO in normoxia (Saletta et al.,
2010). An independent micro-array analysis of 6 cell lines identified large
variations in the number of genes up-regulated by hypoxic exposure; 486 genes
in monocytes compared to 2119 in HeLa cells (Benita et al., 2009). The
unresponsiveness of some HIF1 responsive genes despite increased levels of
+,)Į SURWHLQ KDYH DOVR EHHQ REVHUYHG LQ VWXGLHV RQ WKH PLQLFKURPRVRPH
PDLQWHQDQFH0&0SURWHLQVZKLFKDUH'1$KHOLFDVHSURWHLQVWKDWELQGWR+,)Į
and enhance its proline hydroxylation/degradation and inhibition of its
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transactivation domain (Hubbi et al., 2011; Semenza, 2011). shRNA mediated
knockdown of MCM3 resulted in an increase in synthetic HRE driven luciferase
transcription in normoxia in 293 cells, however under the same oxygen tension
in the same cell line, mRNA levels of the endogenous VEGF or Glut3 HRE
containing genes were not affected following MCM3 depletion (Hubbi et al.,
2011).
Therefore, there are strong implications that some genes may exhibit hypoxic
responses that are cell type specific, and may be dependent upon interactions
with endogenous cell specific proteins. With respect to LIMD1 depletion, these
variations will only be fully elucidated as the role of LIMD1 and the hypoxic
response in a range of cell types is investigated.
6.4.8 /,0' IRUPV D 1HJDWLYH 5HJXODWRU\ 3DWKZD\ RI +,)Į
Degradation
Data within this thesis has demonstrated LIMD1 is a critical component of an
endogenous complex containing PHD2 and VHL that is required for degradation
RI+,)ĮXQGHUERWKKLJKDQGORZR[\JHQWHQVLRQV)XUWKHUPRUHOLNH3+'DQG
SAG within the VHL complex, LIMD1 transcription and protein expression is up-
regulated in hypoxia through the presence of a HRE within its promoter.
7KLV GDWD FDQ WKHUHIRUH EH LQWHJUDWHG LQWR D SURSRVHG UHYLVHG PRGHO RI +,)Į
degradation. In normoxia, LIMD1 forms a complex with PHD2 and VHL/VCB
proteins, which facilitates the oxygen dependent hydroxylation of Pro402/564,
XELTXLWLQDWLRQ DQG VXEVHTXHQW GHJUDGDWLRQ RI +,)Į E\ WKH 6 SURWHDVRPH
&RQFXUUHQWWRWKLVGHJUDGDWLRQRI+,)ĮFDQDOVRRFFXULQWKHDEVHQFHRI/,0'
as well as also in the absence of PHD2, however these LIMD1 independent
mechanisms are not fully understood and are thought to provide a less efficient
SDWKZD\ IRU +,)Į GHJUDGDWLRQ <HH HW DO  )XUWKHUPRUH ),+
K\GUR[\ODWHV $VQ ZLWKLQ +,)Į SUHYHQWLQJ DVVRFLDWLRQ ZLWK WKH
WUDQVFULSWLRQDO DFWLYDWRU S&%3 +RZHYHU DV +,)Į UHJXODWLRQ H[LVWV LQ
equilibrium, there is still a low basal level of un-degraded, transcriptionally active
+,)Į LQ QRUPR[LD ZKLFK FRQWULEXWHV WR WKH WUDQVFULSWLRQ RI VRPH +5(
containing genes (Dayan et al., 2006), and this now includes LIMD1.
In hypoxic conditions, low oxygen concentrations means PHD2 activity is
significantly reduced. This therefore ablates PHD2 mediated hydroxylation of
+,)Į DQG LV WKXV XQDEOH WR EH UHFRJQLVHG E\ 9+/ DQG HVFDSHV GHJUDGDWLRQ
Similarly, FIH activity is also significantly reduced, and so Asn802 remains un-
K\GUR[\ODWHG ZKLFK DORQJ ZLWK SKRVSKRU\ODWLRQ RI VWDELOLVHG +,)Į SURWHLQ
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IDFLOLWDWHVGLPHULVDWLRQZLWK+,)ǃWR IRUPWKHDFWLYH+,)WUDQVFULSWLRQIDFWRU
HIF1 then binds to HREs, where association with the p300/CBP transcriptional
co-activator enhances transcription of these genes to allow adaptation to hypoxic
conditions.
However, PHD2, SAG and LIMD1 all contain HRE elements within their
promoters, which cause an upregulation of their expression in hypoxia. This
allows for formation of the same complex identified in normoxia. Increased PHD2
protein levels coupled with increased oxygen availability from inhibition of
PLWRFKRQGULDO UHVSLUDWLRQ DOORZV IRU 3+' K\GUR[\ODWLRQ RI +,)Į IROORZHG E\
VHL recognition and proteasomal degradation. Thus, a negative feedback loop is
formed. Again, LIMD1 and PHD2 independent mechanisms of degradation also
exist, however as described for normoxia, these are not fully elucidated but
DSSHDU WR EH OHVV HIILFLHQW 7KH QHW UHVXOW LV +,)Į GHJUDGDWLRQ LQFUHDVHV WKH
longer cells are exposed to hypoxia, giving rise to the characterised down-
UHJXODWLRQRI+,)ĮSURWHLQOHYHOVLQFKURQLFK\SR[LD
Chapter 6: Discussion
203
Figure 6.3: 3URSRVHG XSGDWHG PHFKDQLVP RI +,)Į GHJUDGDWLRQ. LIMD1 forms a
FRPSOH[ ZLWK 3+' DQG 9+/ WR IDFLOLWDWH GHJUDGDWLRQ RI +,)Į ,Q QRUPR[LD WKH KLJK
oxygen tension facilitates high PHD2 activity, causing hydroxylation of Pro402/564 that
DOORZV IRU 9+/ UHFRJQLWLRQXELTXLWLQDWLRQ DQG GHJUDGDWLRQ RI +,)Į +,)Į LV DOVR
degraded when LIMD1 is lost, however this process is less efficient, resulting in an
DFFXPXODWLRQ RI D VPDOO SRRO RI XQGHJUDGHG +,)Į WKDW LV DEOH WR IRUP WKH
transcriptionally active HIF-1 to provide a low basal level of HIF driven transcription. In
hypoxia, low oxygen tensions significantly inhibit PHD2 activity, causing the stabilisation
RI +,)Į DQG WUDQVFULSWLRQ RI +5( FRQWDLQLQJ JHQHV WR DOORZ FHOOXODU DGDSWDWLRQ WR
hypoxia. Hypoxic up-regulation of LIMD1 facilitates the formation of an active PHD2 and
9+/ FRPSOH[ UHVXOWLQJ LQ GHJUDGDWLRQ DQG D GHFUHDVH LQ +,)Į OHYHOV :KHQ /,0' LV
GHSOHWHGGHJUDGDWLRQRI+,)Į LV LQKLELWHGUHVXOWLQJ LQDQH[DJJHUDWHGDFFXPXODWLRQRI
+,)ĮSURWHLQWKDWJLYHVDIXUWKHULQFUHDVHLQ+5(JHQHWUDQVFULSWLRQ
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7.1 Future Work
This chapter will put a future perspective onto the novel findings presented
within this thesis, highlighting areas of particular significance and interest to
future work within the group.
7.1.1 Methylation Analysis of the Full LIMD1 Promoter and Gene
Within this thesis only a relatively small, but yet transcriptionally critical, region
of the LIMD1 promoter was assayed for CpG methylation. It would, however, be
of interest to analyse the whole of the CpG Island within the promoter. From the
initial promoter mapping using the deletion mutants (Figure 3.2), other regions
within the CpG Island are also critical for transcription; IR1, 8 and 9 all gave
reductions in transcription of over 50% when deleted. Therefore it is possible
that methylation of these regions may also reduce LIMD1 promoter driven
transcription. Furthermore, different experimental techniques could be used to
provide a quantitative rather than qualitative analysis of methylation.
Following PCR of bisulphite treated DNA, the subsequent amplicon could be sub-
cloned into a vector, transformed into competent bacteria and individual colonies
sequenced. As each colony would have originated from a single dsDNA fragment
within the amplicon, only single peaks would have been observed. From
sequencing large numbers of colonies, the proportion of methylated to
unmethylated individual residues could be quantified. In a similar manner,
pyrosequencing, which indirectly detects pyrophosphate release from
incorporated nucleotides through a parallel luciferase/luminescence assay, would
allow for quantification of methylated to unmethylated cytosines. Compared to
MSP, pyrosequencing is more sensitive and accurate with single base pair
resolution, as confirmed through comparative studies (Lee et al., 2008) and
allows for exact quantification of methylation.
There has in the past few years been increasing interest towards methylation
within intragenic regions of genes (i.e. within regions 3 to the ATG translation
initiation codon). Methylation of intragenic DNA does not prevent transcription of
genes; for example the intronic imprinting centre on the maternal allele for the
imprinted murine Igf2r gene is methylated as are the p16INK4A and p14ARF genes
and these are all expressed regardless of intragenic methylation (Lorincz et al.,
2004). Early studies using stably expressed plasmids with differential
methylation patterns (introduced in vitro) identified that promoter methylation
alone only reduced transcription by 50%, however methylati
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coding region alone or of the whole plasmid reduced transcription by up to ten
and two hundred fold respectively (Hsieh, 1997). Lorincz et al utilised a Cre/loxP
based recombinase mediated cassette exchange (RMCE) system to integrate an
in vitro methylated or unmethylated GFP gene into mouse erythroleukaemic cells
(Lorincz et al., 2004). This analysis revealed that intragenic methylation reduced
GFP expression by ~40% but did not affect RNA Pol II binding to the 5 promoter
region. Binding of Pol II to the intragenic methylated region however was
reduced by half, which correlated with the same reduction in mRNA levels when
compared to the unmethylated control (Lorincz et al., 2004). In the
unmethylated GFP region higher levels of covalently modified di- and tri-
methylated Lys4 and acetylated Lys 4 and 9 on histone H3 (modifications
associated with active promoters/genes) were observed when compared to the
methylated gene, overall suggesting intragenic methylation reduces the
efficiency of elongation but not initiation (Lorincz et al., 2004; Appanah et al.,
2007). A more recent genome wide analysis revealed that methylation that
extends into the first exon of a gene correlates highly with reduced expression,
even more significantly than promoter methylation, whilst further downstream
methylation towards the 3 end of a gene had little effect on expression (Brenet
et al., 2011). Therefore, with the increasing evidence of more than promoter
methylation being critical for gene silencing, it would be of importance to assess
the entire LIMD1 gene.
Point mutation of the PU.1/Ets consensus reduced LIMD1 promoter driven
transcription by 90% (Figure 4.3). Therefore, in a clinical setting, sequencing of
this motif would be indicative of LIMD1 expression, even if the remaining LIMD1
gene appeared non-mutated. As already discussed, this would also be indicative
RIGRZQVWUHDP+,)ĮSURWHLQOHYHOVDQGPL51$VLOHQFLQJHIILFDF\
7.1.2 The Identification of PU.1 as an Activator of LIMD1 Transcription
May Imply a Hematopoietic Lineage Related Function of LIMD1
PU.1 expression is associated almost exclusively to the haematopoietic lineages,
and it was for this reason endogenous protein studies were performed in the
U937 human leukemic monocyte lymphoma cell line. To date, LIMD1 protein
expression or function has not been studied in hematopoietic derived cell
lineages. The only exception being in this study, where LIMD1 has been
demonstrated to be expressed in U937 cells, in a PU.1 dependent manner. It
would therefore be of future interest to examine expression of LIMD1 in
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hematopoietic derived lineages. From the evidence presented, it could be
postulated that LIMD1 expression would mirror PU.1 expression, and as such it
may be expected that expression would be high in early myeloid lineages and
low/absent from the lymphoid lineages (Gallant and Gilkeson, 2006). However,
the interplay of other Ets factors could alter this prediction.
PU.1 loss is a characteristic occurrence in acute myeloid leukaemia, with as little
as a 20% loss in expression causing an increase in pre-leukaemic cells (Metcalf
et al., 2006; Stirewalt, 2004). This would therefore raise the possibility that if
LIMD1 is expressed in early myeloid lineages, PU.1 loss would also cause LIMD1
loss. This could result in a double hit for the cell; PU.1 loss would block
differentiation of cells through decreased myeloid cell maturation (Dahl and
Simon, 2003) and LIMD1 loss would contribute to transformation through its
elucidated mechanisms, namely loss of repression of E2F driven transcription,
UHGXFHGPLFUR51$VLOHQFLQJDQG LQFUHDVHG+,)ĮSURWHLQH[SUHVVLRQ 6KDUSHW
al., 2004; James et al., 2010).
3p deletions are rare in haematological malignancies, with deletions reported in
only 2.9% of AML, 1% of chronic myeloid leukaemias, 1.5% of acute
lymphoblastic leukaemias and 1.1% of non-Hodgkins lymphomas, with most
deletions happening in association with other genetic alterations, e.g. t(9;22)
translocations and deletions (Angeloni, 2007). Therefore, LIMD1 loss, if
applicable in these malignancies, is likely to be indirect, potentially through PU.1
loss. This is in contrast to lung cancers, where almost half of tumours that
exhibit loss of LIMD1 expression can be accounted for by chromosomal
alterations (Sharp et al., 2008).
Several components of the micro RNA silencing machinery are frequently
deregulated in cancers. TRBP is down-regulated due to genetic frame shift
mutations in sporadic and hereditary colorectal carcinomas and cell lines with
microsatellite instability, which also causes decreased levels of Dicer and mature
miRNAs. Re-introduction of TRBP into these cell lines re-establishes miRNA
processing and inhibits tumour growth (Melo et al., 2009). In a cohort of
hepatocellular carcinomas, Dicer was found to be down-regulated in tumour
tissue when compared to normal tissue (Wu et al., 2010). In NSCLC, patients
with lower expression levels of Dicer had a significantly reduced 5 year survival
rate when compared to tumours with higher levels of expression (~30%
compared to ~80% respectively) (Karube et al., 2005). In ovarian cancer
reduced expression of Dicer and Drosha mRNA correlated with reduced patient
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survival rates (~2.5 years compared to 7-9 years for low and high expression
respectively) (Merritt et al., 2008). In colorectal cancer, over expression of Dicer
correlates with a decreased patient survival and progression free survival (Faber
et al., 2011) and Dicer is also overexpressed atypical adenomatous hyperplasias,
bronchioloalveolar carcinomas and subsequent adenocarcinomas (Chiosea et al.,
2007). In gastric and colorectal cancers, AGO2 and GW182 are susceptible to
mutations that cause loss of expression in cancers with high microsatellite
instability that reduce their expression (Kim et al., 2010b).
The loss of functional microRNA mediated silencing components is also observed
in hematopoietic derived malignancies. In a proportion of multiple myelomas,
AGO2 is over expressed, and shRNA mediated knockdown of AGO2 is able to
induce apoptosis in H929, OCI-My5 and HL-60 myeloma cell lines as well as
reduce the expression of genes involved in myeloid leukaemia development
(Naoghare et al., 2011; Zhou et al., 2010). DGCR8 is observed to be down-
regulated in T-cell lines and along with TRBP up-regulated in B cell malignancies
(Lawrie et al., 2009). Drosha is upregulated approximately 10 fold in B cell lines
when compared to normal B cells, PACT is upregulated in T cell lines and Dicer
down-regulated in both B and T cell lines (Lawrie et al., 2009). In a cohort of
patients suffering from primary T cell lymphomas, patients with no Dicer
expression (60%) had a higher mean survival time than patients that expressed
Dicer (Valencak et al., 2011). As previously described, PU.1 loss is associated
with leukaemic transformation; therefore, any resultant loss of LIMD1 protein
expression would also reduce miRNA mediated gene silencing, and could mimic
the observations of loss of expression of other miRNA effector proteins.
Using ChIPseq, expression of miR-146a, 342, 338 and 155 that are all involved
in myeloid progenitor maturation, were found to be dependent on PU.1 (Ghani et
al., 2011). PU.1 also activates expression of the miR23a cluster (encoding
miR23a, 27a and 24-2) that promotes myeloid over lymphoid lineage
development from hematopoietic progenitor cells (Kong et al., 2010). In vivo it
has been demonstrated that over-expression of LIMD1 enhances miRNA silencing
(James et al., 2010). Thus, as PU.1 activates transcription of LIMD1 as well as
multiple microRNAs, it could be postulated that PU.1 may have a two-pronged
effect with regards to facilitating miRNA induced silencing. PU.1 induces specific
miRNA expression, and the efficacy of the silencing dictated by these miRNAs is
then also increased through increased PU.1 mediated expression of LIMD1.
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7.1.3 PU.1 and LIMD1 are Both Critical Regulators of Osteoclast
Differentiation
A functional miRNA mediated gene silencing pathway is also required for
osteoclastogenesis; loss of the miRNA-silencing associated proteins DGCR8,
Dicer1 and Ago2 impairs osteoclast differentiation and function (Sugatani and
Hruska, 2009). LIMD1 is an important component of miRNA mediated silencing
(James et al., 2010) and as previously described, during RANK-L mediated
osteoclast differentiation, Limd1 protein levels are up-regulated, and positively
regulate osteoclast differentiation (Feng and Longmore, 2005; Feng et al.,
2007). Therefore, loss of LIMD1 expression may impair osteoclast differentiation
through both reduced miRNA silencing efficacy and reduced sequestosome/AP-1
activation, and this will now be elaborated upon.
PU.1 is an essential transcription factor in osteoclastogenesis, with PU.1-/- mice
lacking osteoclasts and suffering from osteopetrosis (Tondravi et al., 1997). miR-
223 is a critical PU.1 driven miRNA for osteoclast differentiation; siRNA mediated
knockdown of miR-223 allows for osteoclast development, whereas over-
expression of precursor miR-223 blocked development (Sugatani and Hruska,
2007; Fukao et al., 2007). M-CSFR is expressed in osteoclast precursors, again
controlled by PU.1, and is essential for osteoclast differentiation (Karsenty and
Wagner, 2002). Nuclear factor 1-A (NF1-A) negatively controls expression of M-
CSFR, and is not detectable in osteoclast precursors that have a functional
miRNA silencing pathway; conversely in AGO2, DGCR8 or Dicer siRNA mediated
knockout cells, levels of NFI-A were elevated (Sugatani and Hruska, 2009).
Elevated NFI-A levels reduce M-CSFR and PU.1 protein expression and suppress
osteoclast formation/bone resorption. Therefore, for osteoclast development,
down-expression of NFI-A protein through a functional miRNA silencing pathway
is required (Sugatani and Hruska, 2009).
From the published literature and findings within this thesis, a PU.1/LIMD1
mediated mechanism of osteoclast differentiation may be postulated. Following
binding of RANK-L to RANK on the osteoclast precursor, trimerisation of the
receptor leads to activation of TRAF6, which through the sequestosome causes
DFWLYDWLRQ RI WKH WUDQVFULSWLRQ IDFWRUV 1)Ŧ% DQG $3 OHDGLQJ WR LQFUHDVHG
transcription of PU.1. The increased level of PU.1 protein then leads to increased
transcription of LIMD1 (Foxler et al., 2011) and pri-miR-223 (Fukao et al.,
2007). Increased LIMD1 protein expression then facilitates the formation of the
sequestosome and activation of AP-1 (Feng and Longmore, 2005; Feng et al.,
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2007). Furthermore, it also enhances miRNA mediated silencing (James et al.,
2010), which increases the efficacy of silencing of NFI-A through the PU.1 driven
miR-223. This decreases the amount of NFI-A protein, leading to increased
amounts of M-CSFR and PU.1, further driving a feed forward mechanism to
enhance osteoclast differentiation (Figure 7.1). This postulated model may be a
direction for future investigations that expands upon the initial investigations
into the role of Limd1 in osteoclastogenesis (Feng et al., 2007).
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Figure 7.1: Proposed model of PU.1 and LIMD1 co-operation to enhance
osteoclast differentiation. Trimerisation and activation of the RANK receptor is
facilitated through binding of RANK-L on the surface of the osteoclast precursor. This
leads to TRAF6 association with the sequestosome complex of proteins, which ultimately
OHDGV WR 1)Ŧ% DQG $3 WUDQVFULSWLRQ IDFWRU DFWLYDWLRQ DQG WKH H[SUHVVLRQ RI JHQHV WR
promote osteoclast differentiation. Furthermore, PU.1 transcription and protein levels are
also up-regulated; this leads to up-regulation of PU.1 specific miRNAs, including miR-223,
as well as LIMD1. Increased LIMD1 expression enhances sequestosome formation and
activation of AP1, positively influencing osteoclast differentiation. Furthermore, LIMD1
would also enhance the efficacy of PU.1 specific driven miRNA silencing. Specifically this
would lead to decreased translation and expression of NFIa, a negative regulator of
osteoclast differentiation. This would further increase PU.1 expression and M-CSFR, which
upon M-CSF binding would further promoter osteoclast differentiation.
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7.1.4 Loss of LIMD1 Expression May Initiate Cell Transformation and
Growth through Pathways Involving PU.1 or HIF1ɲ
+,)Į FRQWULEXWHV WR WKH GLIIHUHQWLDWLRQ RI DFXWH P\HORLG OHXNHPLD FHOOV
,QGXFWLRQ RI +,)Į LQ P\HORLG OHXNHPLF 8 FHOOV HLWKHU WKURXJK K\SR[LD RU
chemically induced hypoxia, resulted in leukemic cell growth arrest and
JUDQXORF\WLF GLIIHUHQWLDWLRQ 7KLV RFFXUV YLD +,)Į WUDQVFULSWLRQDO DFWLYLW\
LQGHSHQGHQW PHFKDQLVPV DV GHSOHWLRQ RI HQGRJHQRXV +,)ǃ ZKLFK ZRXOG
disrupt HIF1 activity) did not abrogate differentiation (Song et al., 2008). Again,
from the findings presented, de-regulation of LIMD1 protein expression, either
GLUHFWO\ RU LQGLUHFWO\ WKURXJK 38 SURWHLQ GHUHJXODWLRQ ZRXOG GLVUXSW +,)Į
protein expression and could thus contribute to AML.
Cancer stem cells (CSC) are a subset of cells found within cancers that are able
to self-renew and differentiate and are responsible for initiating and maintaining
tumour growth and metastases (Gao, 2008; Gupta et al., 2009). The first
identification of the existence of these cells was in acute myeloid leukaemia
(Lapidot et al., 1994), and since then CSCs have been identified in brain, breast,
ovarian, prostate and pancreatic cancers as well as melanomas and multiple
myelomas.
+,)Į VLJQDOOLQJ ZDV REVHUYHG WR EH DFWLYDWHG LQ KXPDQ $0/ DQG PRXVH
lymphoma stem cells under normoxic conditions (Wang et al., 2011). In colony
IRUPLQJ XQLW FIX H[SHULPHQWV GHSOHWLRQ RI HQGRJHQRXV +,)Į RU LQKLELWLRQ
with its inhibitor echinomycin within the stem cells, abrogated the ability of CSCs
to form colonies and in mice eradicated transplanted human AML or lymphoma.
Similarly, reduced VHL protein levels were also required for CSC function, thus
IXUWKHU LPSOLFDWLQJ WKH LPSRUWDQFH RI +,)Į IRU &6& LQ KDHPDWRORJLFDO
malignancies (Wang et al., 2011). PU.1 loss is characteristic of leukemic
transformation (Metcalf et al., 2006; Stirewalt, 2004), and as already discussed
could lead to a decrease in LIMD1 expression. The PU.1-LIMD1 mechanics could
WKHQ EH DSSOLFDEOH WR WKH IXQFWLRQ RI +,)Į ZLWKLQ &6&V ORVV RI /,0'
H[SUHVVLRQ ZRXOG OHDG WR D VWDELOLVDWLRQ DQG LQFUHDVHG DFWLYLW\ RI +,)Į WKXV
allowing for CSC function and tumour growth. This is an exciting possibility that
adds an extra level of complexity to the formation of haematological
malignancies, with the question raised of PU.1 loss as an initiating or
contributing factor in the activation of CSCs.
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7.2 Final Conclusions
In conclusion, the data presented in this thesis identifies LIMD1 as being
epigenetically silenced, with evidence of aberrant promoter methylation
demonstrated in primary human lung tumours, providing a possible further
explanation for LIMD1 protein loss in cancer distinct from that of large genomic
GHOHWLRQV RU /2+ )XUWKHUPRUH 38 DQG +,)Į ZHUH LGHQWLILHG DV EHLQJ WZR
activating transcription factors of LIMD1 transcription, with the former giving rise
WR WKH SRVVLELOLW\ RI XQGLVFRYHUHG KDHPDWRORJLFDO IXQFWLRQV RI /,0' +,)Į
enhances LIMD1 transcription and protein expression in hypoxia, contributing to
D QHJDWLYH UHJXODWRU\ SDWKZD\ IRU +,)Į UHJXODWLRQ DQG DOORZLQJ FHOOXODU
DGDSWDWLRQWRFKURQLFK\SR[LD38DQG+,)ĮDUHERWKGHUHJXODWHGLQDUDQJH
of cancers, and as such this work forms a platform for further investigations to
elucidate novel tumour suppressive properties of LIMD1 as a potential clinical
target for novel drug design/treatment.
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8.1.1 Nucleic Acid Sequence of the LIMD1 Promoter
Figure 8.1: Nucleic acid sequence of the LIMD1 Promoter. The nucleic acid
sequence of the cloned LIMD1 promoter used in investigations within this thesis. Also
indicated is the CpG Island (green) and the ten internal promoter regions that were used
for the initial promoter mapping experiments (green, IR1-IR10).
-199 0
CAGG CACTTGGCATACAGA TAT GGTCAAATGGAG TGG GAAACCTACCACCCA ACCAAACA
AAAA AAAACGCATGTTAAC CAA CAAATAAATAAT TAT AAATAGTTATCAGAA CTGAGCAG
GAAG TAAAGAGGGTGCTGA AAA AGAACAACAGGA ACC ACTCTGAGGAGGCCT CTAAGAGG
AGGT GACTTCAGCAGGGAT GGG AAAGATGAGCCA CTC AGTTTAGGGGCAAGC TCTGGGCA
GACA CCAGGAAGCTCCTGC AGC TAGAGTGCAGGG AGG GAGGGAAGATCCCTA GATCTGGC
CCAG AAGGCTGCGGCAAGG GGC CGATTTCAATTT AAT TCTGGGGTAAGCACT GAGGATTT
AGGT AGAGAAGTGTCTGTT CTA GTATTTGCCTTA GGA TCACGATGGCTGTAG TGTGGGAA
ATGA AACCTCTCCAGGATC GCC TGGGAACTGGTA TAG GGAGTCCCGGGCCAT GCGGGGGC
GCCA AGGAGTCAGGCCTGG TGT CCCTGCAGCCGC GCG GATCCACTTGCAGAT GGGTCCCT
CTAC GAATAACGAGCCTAC TAG GGCACGTGCTTT TAC TGCTGCACTGAGGAC GTGAAATG
CGCG CAGGCACAACGAGAC TTT CTTCTTTTTCGC TCT TTCAGAGGGCCCGGG CTCCCATC
TACG CTTTGCTGGTTACGT TGG CATGTTGGGCAT TTC CCCCTCTCTGCCTCA GTCTCCCG
ACCT GTCAAAGAGGACGGT GGGCCAGCCATGGGT GAC ACGCCCGTGCGC CTC TCCAATAG
TGCA CCTCGGGCAAGCCGG GCG GCGGGCACAGCC TGG ACGGTGCCGGCCTCG AGAGGCAC
AAAG GGCTGGCTTTCCACC GGG GAAACTGAGGCA GTG GAGCGAGGAGCGGCG TCCTCGAA
AGTC CTCGCAAACTCCCAG CGC CTGTGTTGGGCC CAT GCAGGCTACCCAGGC CGCCCGTC
TCCG AGCGGAGGACCCCGC CCA GCGCTGCCAGGG GCG GGGCCGGGCTGAGGA CCCGAGGC
TGGA AGGGAGGTCGGAGCA CCC AATTCGGTCCAG GAC TCGCAGGGGGCGGCA GTGGCGGC
GGCG AAGTCCCGTGCAGTC CCA GTGCTAGAGCGT GGG ACGGACTTGTGGGGC ACCCCTCG
GTGT TCTCCAGCCAGGCCT GGG GGCAGGAGGCCC AGC CACGCTGCCGGGTGC AGGCCTGC
CCCT GG
[IR1 ]GCGCCCGCCCGCGC GCC GTCCCCGCCCCT
[IR2 ]CGGCCGCCCCCTCC GCC CCGGCGCGGGCT CG
[IR3 ]GGACGTGCAGAGCC GGC GAGCGAGC
[IR4 ]AGCAGGGACTGCGC CTG GCGCA
[IR5 ]CTCACTTCCGCGTC CCG CCG
[IR6 ]CCCTCCGGCCCGCG CGC GCCGATCC
[IR7 ]GCCGCCGCCATCGG ACA ATGGGCCG
[IR8 ]CCAGCCCCAGCTGC CGT GAA
[IR9 ]CTTCCTGCCGCTGC TCG GCCGCCCGTGCG TCC C
[IR1 0]GGACGGCGTTCCT GCC AGGCGCCGGCCG GGA TC
GCAG CTCCGGGGAAGCAGC GGA GGACCCAGCGCC TGG AACGTACCTGCGCCT CAGCCGCC
GCGC GTTTGCTCCGGCCCG ACT CGCGGCCTCGGC GCC CTCCCGGCCGATTCA GCTTCACC
CGGC CCAGTCGGC TGCTGC CTT GCTGTGAGTTTC CGT GTTTGGTTGCCTAAG GAGGATGT
GATT TTACTTTTTTGCTGT TTT CTTTTTCCTTTT ATA ATTTGAAGAGGAGAA AAGAACTC
CGCT GAGCAGGCCCGGGAC GGC GAAGTGCCACCA GCT ACCCCAACAAGGACG TCTCCAGG
GGAA AGGGAGTTGGAAGCA AAC TTGGTCCAGCTG GCG TTGAGGTCTCAACTT CGGCTGGA
CTCT TAAATCCTGGGGTCA TGC CCTTCACGCTAG GCA GGTGGAAGTCTTTAC TTGTACTG
GGCC GGACTTGAGCCCCGA CCC TTCGCCAGCATC TCC CCGCTGCCCTCAACA CACACACA
CACA CACACACACACACAC ACA CACACACACACA CAC ACACA (+1) CACACA CACACACG
GCAC CTGGGCTAGGCCCGG ACA CCTGTCTGCAGC A TG GATAAGTATGACG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8.1.2 The LIMD1 Promoter Showing the Relative Positions of the
FRQILUPHG38DQG+,)Į%LQGLQJ6LWHV
Figure 8.2: The LIMD1 promoter annotated with the transcription factor binding
sites identified within this thesis. Shown is the sequence of the LIMD1 promoter with
the identified binding sites of the transcription factors PU.1 and HIF1Į7KH&S*,VODQG
is also identified in green, along with the unconfirmed transcriptional start site
and the translational start site.
CAGGCACTTG GCATACAGAT ATGGTCAAAT GGAGTGGGAA ACCTACCACC CAACCAAACA -1930
AAAAAAAACG CATGTTAACC AACAAATAAA TAATTATAAA TAGTTATCAG AACTGAGCAG -1870
GAAGTAAAGA GGGTGCTGAA AAAGAACAAC AGGAACCACT CTGAGGAGGC CTCTAAGAGG -1810
AGGTGACTTC AGCAGGGATG GGAAAGATGA GCCACTCAGT TTAGGGGCAA GCTCTGGGCA -1750
GACACCAGGA AGCTCCTGCA GCTAGAGTGC AGGGAGGGAG GGAAGATCCC TAGATCTGGC -1690
CCAGAAGGCT GCGGCAAGGG GCCGATTTCA ATTTAATTCT GGGGTAAGCA CTGAGGATTT -1630
AGGTAGAGAA GTGTCTGTTC TAGTATTTGC CTTAGGATCA CGATGGCTGT AGTGTGGGAA -1570
ATGAAACCTC TCCAGGATCG CCTGGGAACT GGTATAGGGA GTCCCGGGCC ATGCGGGGGC -1510
GCCAAGGAGT CAGGCCTGGT GTCCCTGCAG CCGCGCGGAT CCACTTGCAG ATGGGTCCCT -1450
CTACGAATAA CGAGCCTACT AGGGCACGTG CTTTTACTGC TGCACTGAGG ACGTGAAATG -1390
CGCGCAGGCA CAACGAGACT TTCTTCTTTT TCGCTCTTTC AGAGGGCCCG GGCTCCCATC -1330
TACGCTTTGC TGGTTACGTT GGCATGTTGG GCATTTCCCC CTCTCTGCCT CAGTCTCCCG -1270
ACCTGTCAAA GAGGACGGTG GGCCAGCCAT GGGTGACACG CCCGTGCGCC TCTCCAATAG -1210
ÃCpG Island start
TGCACCTCGG GCAAGCCGGG CGGCGGGCAC AGCCTGGACG GTGCCGGCCT CGAGAGGCAC -1150
AAAGGGCTGG CTTTCCACCG GGGAAACTGA GGCAGTGGAG CGAGGAGCGG CGTCCTCGAA -1090
AGTCCTCGCA AACTCCCAGC GCCTGTGTTG GGCCCATGCA GGCTACCCAG GCCGCCCGTC -1030
TCCGAGCGGA GGACCCCGCC CAGCGCTGCC AGGGGCGGGG CCGGGCTGAG GACCCGAGGC -970
TGGAAGGGAG GTCGGAGCAC CCAATTCGGT CCAGGACTCG CAGGGGGCGG CAGTGGCGGC -910
GGCGAAGTCC CGTGCAGTCC CAGTGCTAGA GCGTGGGACG GACTTGTGGG GCACCCCTCG -850
GTGTTCTCCA GCCAGGCCTG GGGGCAGGAG GCCCAGCCAC GCTGCCGGGT GCAGGCCTGC -790
CCCTGGGCGC CCGCCCGCGC GCCGTCCCCG CCCCTCGGCC GCCCCCTCCG CCCCGGCGCG -730
GGCTCGGGAC GTGCAGAGCC GGCGAGCGAG CAGCAGGGAC TGCGCCTGGC GCACTCACTT -670
ÃHIF1ɲ binding site
CCGCGTCCCG CCGCCCTCCG GCCCGCGCGC GCCGATCCGC CGCCGCCATC GGACAATGGG -610
ÃPU.1 binding site
CCGCCAGCCC CAGCTGCCGT GAACTTCCTG CCGCTGCTCG GCCGCCCGTG CGTCCCGGAC -550
GGCGTTCCTG CCAGGCGCCG GCCGGGATCG CAGCTCCGGG GAAGCAGCGG AGGACCCAGC -490
GCCTGGAACG TACCTGCGCC TCAGCCGCCG CGCGTTTGCT CCGGCCCGAC TCGCGGCCTC -430
GGCGCCCTCC CGGCCGATTC AGCTTCACCC GGCCCAGTCG GCTGCTGCCT TGCTGTGAGT -370
ÃCpG Island end
TTCCGTGTTT GGTTGCCTAA GGAGGATGTG ATTTTACTTT TTTGCTGTTT TCTTTTTCCT -310
TTTATAATTT GAAGAGGAGA AAAGAACTCC GCTGAGCAGG CCCGGGACGG CGAAGTGCCA -250
CCAGCTACCC CAACAAGGAC GTCTCCAGGG GAAAGGGAGT TGGAAGCAAA CTTGGTCCAG -190
CTGGCGTTGA GGTCTCAACT TCGGCTGGAC TCTTAAATCC TGGGGTCATG CCCTTCACGC -130
TAGGCAGGTG GAAGTCTTTA CTTGTACTGG GCCGGACTTG AGCCCCGACC CTTCGCCAGC -70
ATCTCCCCGC TGCCCTCAAC ACACACACAC ACACACACAC ACACACACAC ACACACACAC -10
ACACACACAC ACACACACAC ACACGGCACC TGGGCTAGGC CCGGACACCT GTCTGCAGCA +50
ÃTranscription start site
TGGATAAGTA TGACGACCTG GGCCTGGAGG CCAGTAAATT CATCGAGGAC CTGAACATG +110
ÃTranslation start site
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8.1.3 Sequencing Chromatagrams of Primary Lung Tumours that
Exhibited a Change in Methylation of IR5 Compared to Matched
Normal Lung Tissue
Figure 8.3 Sequencing chromatograms of primary lung tumour samples that
exhibited increased promoter hypermethylation when compared to matched
normal lung tissue. Genomic DNA was extracted from a cohort of primary lung tumours
and matched normal tissue and IR5 bisulphite sequenced. Displayed is the sequencing
chromatograms from the tumour samples that displayed hypermethylation compared to
the matched control tissue. The four CpG dinucleotides within IR5 are indicated, along
with the respective tumour sample number.
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8.1.4 Sequencing Chromatograms of Point Mutations Created Within
and Downstream of the PU.1 Binding Motif
CC-TT
A
TT-CC
B
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Figure 8.4: Sequencing chromatograms of the LIMD1 promoter following site
directed mutagenesis of the putative PU.1 binding motif and control downstream
base. In silico scrutinisation of the LIMD1 promoter for transcription factor binding motif
identified a putative binding motif for the transcription factor PU.1. Site directed
mutagenesis was used to mutate the motif from TTCC to TTTT along with a downstream
cytosine as a control. The mutations were then reverse-mutated back to the wild-type
sequence. The mutations were sequenced to confirm their identity using a reverse
downstream primer, resulting in a chromatogram of the anti-sense strand read 5 to 3.
Shown are the chromatograms with the mutations identified. (A) CC-TT mutation and (B)
TT-CC reversion back to wild type sequence of the PU.1 motif. (A) C-T mutation and (B)
T-C reversion back to wild type sequence of a downstream cytosine as a control.
C-T
C
T-C
D
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8.1.5 Sequencing chromatogram of PU.1 cDNA Sub-cloned into pcDNA4
His/Max TOPO Vector
Figure 8.5: Sequencing chromatogram of pcDNA4-PU.1. PU.1 cDNA was amplified
from cDNA kindly donated by A. Rizzino using primers to incorporate a 5 EcoR1 and a 3
BamH1 restriction endonuclease site. The PCR product was then ligated into a linear
pcDNA His/Max TOPO vector (Invitrogen) and the resultant plasmid sequenced with a T7
forward primer to ensure the PU.1 cDNA was of the correct sequence and was in-frame.
EcoR1 PU.1 InternalATG
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8.1.6 Sequencing Chromatograms of Point Mutations Created Within the
putative Hypoxic Response Elements within the LIMD1 Promoter
ȴ,Z ? ,Z ?
ȴ,Z ?
HRE1 HRE2
Wild type
,Z ? ȴ,Z ?
ȴ,Z ?
A
B
C
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Figure 8.6: Sequencing chromatograms of the LIMD1 promoter following site
directed mutagenesis of the three putative hypoxic response elements. In silico
scrutinisation of the LIMD1 promoter for transcription factor binding motifs identified
three putative HREs. The wild type promoter showed an increased activity in hypoxia
compared to normoxia, so to identify the HRE responsible, site directed mutagenesis was
used to sequentially mutate each HRE. (A) and (D) Sequencing of the wild type promoter
LGHQWLILHGWKH+5(HOHPHQWVZLWKHDFKVHTXHQWLDOO\PXWDWHG%Ʃ+5(&Ʃ+5(DQG
(Ʃ+5(
ȴ,Z ?
ȴ,Z ?
HRE3
Wild type
D
E
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